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Detecting genetic similarity between complex human traits by exploring 
their common molecular mechanism 
Jialiang Gu 
Abstract 
The rapid accumulation of Genome Wide Association Studies (GWAS) and association studies 
of intermediate molecular traits provides new opportunities for comparative analysis of the 
genetic basis of complex human phenotypes. Using a newly developed statistical framework 
called Sherlock-II that integrates GWAS with eQTL (expression Quantitative Trait Loci) and 
metabolite-QTL data, we systematically analyzed 445 GWAS datasets, and identified 2114 
significant gene-phenotype associations and 469 metabolites-phenotype associations (passing a 
Q-value cutoff of 1/3). This integrative analysis allows us to translate SNP-phenotype 
associations into functionally informative gene-phenotype association profiles. Genetic similarity 
analyses based on these profiles clustered phenotypes into sub-trees that reveal both expected 
and unexpected relationships. We employed a statistical approach to delineate sets of 
functionally related genes that contribute to the similarity between their association profiles. This 
approach suggested common molecular mechanisms that connect the phenotypes in a subtree. 
For example, we found that fasting insulin, fasting glucose, breast cancer, prostate cancer, and 
lung cancer clustered into a subtree, and identified cyclic AMP/GMP signaling that connects 
breast cancer and insulin, NAPDH oxidase/ROS generation that connects the three cancers, and 
apoptosis that connects all five phenotypes. Our approach can be used to assess genetic similarity 
and suggest mechanistic connections between phenotypes. It has the potential to improve the 
diagnosis and treatment of a disease by mapping mechanistic insights from one phenotype onto 
others based on common molecular underpinnings. 
 v 
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1. Introduction 
1.1. Importance of disease classification and the need for similarity study 
Disease classification is an indispensable component in the health-related system because it 
influences the curriculum of medical education, biomedical research publication, medical care 
delivery and reimburse rate. Current disease nomenclature is under periodical updates because it 
must provide consistent terminology to permit clear communication about diseases that are 
defined by agreed upon criteria and reflects the scientific advance in our understanding of 
molecular pathways and environmental factors that contribute to disease origin and pathology[1]. 
Similarity study is at the core of disease classification because it sets the boundary between 
disease categories. Traditionally, diseases are classified based on symptom similarity, followed 
by histology similarity. The recently available genomic data provides a new similarity criterion 
for disease classification. 
1.2. Current state of disease classification and the need for a new similarity 
metric 
Contemporary classification of human disease dates to the late 19th century, and derives from 
observational correlation between pathological analysis and clinical syndromes. Through the last 
century, this symptom-based classification has become more objective with the advancement of 
histology and definitive laboratory tests became an essential part of the overall diagnostic 
paradigm[2].  Today, International Statistical Classification of Diseases and Related Health 
Problems(ICD) version 10 has become a wide accepted taxonomy of diseases. Although this 
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taxonomy has served well for the delivery of medical care, there exist two types of mis-
classifications where 1) single phenotype with various symptoms are artificially separated as 
distinct diseases 2) multiple distinct diseases are classified under an umbrella disease class.  
Example for the first type of error include Emery-Dreyfus muscular dystrophy, Charcot-Marie-
Tooth axonal neuropathy, lipodystrophy, and premature aging disorders. These disorders can all 
be traced to mutations in the LMNA gene[1]. 
Example for the second type of error include hypertrophic cardiomyopathy which can be caused 
by several different sarcomeric proteins mutations including myosin heavy chain, myosin light 
chain, tropomyosin, and troponin C [3]. Clearly, searching for one therapy for such a bag of 
different phenotypes under the same name can hardly lead to success due to the distinct behavior 
of constituting components.  
Given these misclassifications based on symptom and histology, a new similarity metric is 
needed to capture the real characteristic of human diseases and thus redefine the current disease 
classification system. 
1.3. Example of new similarity metric in Precision Medicine Initiative 
Precision Medicine Initiative is a national effort launched in 2015 in the search for prevention 
and treatment strategies that take individual variability into account. The main driving force for 
this new wave of precision medicine is large-scale biologic databases (such as the human 
genome sequence), powerful methods for characterizing patients (such as proteomics, 
metabolomics, genomics, diverse cellular assays, and even mobile health technology), and 
computational tools for analyzing large sets of data[4]. Clearly, genomic data has been chosen as 
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the new evidence in this new trend. Target diseases includes diabetes and cancer where the new 
metric has proved its efficacy.  
For example, multiple lung cancers can be differentiated by their genomic characterization which 
is traditionally classified by tumor’s histological appearance as small-cell lung cancer and non-
small-cell lung cancer. Molecular understanding of lung cancer gave birth to two drugs Gefitinib 
and Erlotinib, which inhibited the function of certain receptor tyrosine kinases, including 
epidermal growth factor receptor (EGFR). These two drugs exert significant anti-tumor effect in 
early trials, but only in 10 percent of patients. These 10 percent of patients are found to carry 
mutations that activates EGFR in their cancer[5, 6]. 
In this example, lung cancer is classified by genomic mutation instead of histological appearance 
and lead to improved prediction of drug response. More cancers have been classified by genomic 
information including transcription profiling and proteomic analysis[7, 8].  
Similar to the cancer example, a new wave of association studies have been conducted in the 
search of genomic characterization of various diseases. Such Genome Wide Association Study 
provides new evidence for similarity study in the nucleotide resolution. 
1.4. Our approach 
Genome Wide Association Studies (GWAS) seek to identify the genetic basis of complex 
phenotypes by associating genetic variants (typically characterized by Single Nucleotide 
Polymorphisms, or SNPs) to particular traits across different individuals.  These studies have 
been applied to a wide range of phenotypes, including many complex diseases, and have led to 
the identification of a large number of informative SNPs [9, 10]. These disease associated SNPs 
brought significant insights into disease mechanisms and informed strategies for improved 
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intervention and prevention. GWASs have also been successfully implemented to define the 
relative influence of genotype and environment on phenotype prevalence, assisting in risk 
prediction[9]. 
Despite these successes, traditional GWAS analyses based on the association of individual SNPs 
have only limited power. Many potentially informative SNPs fall below the genome-wide 
significance threshold, which is set high due to the large number of loci typically tested. Also, 
for associations that do exceed the genome-wide significance threshold, the functional link 
between an individual SNP and the phenotype is often poorly understood. To circumvent these 
problems, integrative analysis methods have emerged that combine GWAS with other 
quantitative molecular data. These methods attempt to bridge the knowledge gap between 
GWAS SNPs and phenotypes by uncovering the genes and other intermediate molecular traits 
(IMTs) through which genetic polymorphisms generate phenotypic differences [11-15]. These 
approaches utilize the collective power of SNPs and generate mechanistic hypotheses that can be 
tested and can guide future therapeutic interventions.  
As GWAS have been applied to additional human traits, it has become increasingly apparent that 
seemingly unrelated complex traits may share common genetic origins[16-19]. Phenotypic 
connections (often in the form of co-occurrence) have long been observed based on 
epidemiological studies [20]. Recent comparative GWAS analyses have lent genetic support to 
these earlier observations by searching for pleiotropic SNPs implicated across multiple 
phenotypes[21-23] . However, genetic similarity between different phenotypes can be obscured 
at the SNP level.  Phenotypes sharing a set of IMTs may not necessarily associate with the same 
SNPs, since multiple SNPs can converge on the same IMT, and only a small subset of these 
SNPs will be identified in a particular GWAS. Furthermore, it is quite difficult to infer common 
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mechanisms based on the shared SNPs, as they often fall into non-coding regions with no 
obvious functional implication.  
We developed an integrative analysis framework in which GWAS-IMT analysis is combined 
with comparative analysis of multiple phenotypes (Figure 1.1). Such analysis not only enables us 
to translate SNP-phenotype association to IMT-phenotype association (which yields improved 
statistical power and mechanistic insight), but also to generate hypotheses regarding common 
physiological processes underlying different (and sometimes seemingly unrelated) phenotypes 
based on the similarity of their IMT association profiles. 
The first step in this integrative analysis is to associate the IMTs with phenotypes using all the 
SNPs present in GWAS results. We developed a new computational algorithm called Sherlock-II 
to integrate GWAS data with eQTL and metabolite-QTL data, translating SNP-phenotype 
associations into gene/metabolite-phenotype associations. This produces a gene-phenotype 
association matrix and a metabolite-phenotype association matrix and defines a gene association 
profile for each phenotype (one column of the gene-phenotype association matrix).   
We then analyze the relation between phenotypes and infer possible common underlying 
physiological processes (PP) by two different approaches. In the first approach, we group the 
phenotypes based on the similarity between their gene association profiles and then identify 
groups of functionally related genes (such as those defined by gene ontology (GO) terms or 
pathways) that contribute to the similarity. This generate hypotheses on PPs (green boxes in 
Figure 1.1) that connect multiple phenotypes (orange boxes in Figure 1.1).  
In the second approach, we apply two-way bi-clustering to the gene-phenotype association 
matrix to identified sub-clusters in which a group of genes are associated with a subset of 
 6 
phenotypes. We hypothesize that such a group of genes participate in the same PPs that influence 
the subset of phenotypes. We conducted literature searches on each group of genes to identify 
similar mechanisms through which they may affect the phenotypes, such as common pathways. 
This often leads to important clues into the PPs involved.  
Our analysis predicts new connections between PPs and phenotypes (Figure 1.1) supported by 
multiple genes and thus generates etiological hypotheses with genetic support. Identifying 
different diseases associated with common PPs also provide an opportunity to transfer existing 
intervention from one disease to another.  
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Figure 1. 1 A schematic of the integrative analysis framework.  
The underlying model is that SNPs (red triangles) influence phenotypes (orange boxes) by influencing intermediate 
molecular traits (IMTs, blue squares) which in turn contribute to various physiological processes (green boxes), and 
each phenotype is controlled by a combination of physiological processes.  In the first step of the analysis, data from 
GWASs and association studies of IMTs (such as eQTL and metabolite-QTL) are integrated to infer IMT-phenotype 
associations. A comparative analysis of the IMT association profiles for different phenotypes then identifies genetic 
similarity between phenotypes, supported by shared IMTs. These IMTs may point to a set of common physiological 
processes (blue arrows pointing to the same green boxes), suggesting shared physiological processes underlying 
different phenotypes (green arrows initiating from the same green box). 
 
 
 
 
SNP
Intermediate Molecular Trait
  (proteins, metabolites,...)
Phenotype
immune
response
  insulin 
secretion
diabetes asthma
breast 
cancer
ulcerative 
    colitis
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... ... ......
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2. Aims and Strategy 
In this work, an attempt is made to demystify genetic mechanism of complex phenotypes. We 
approach this in three steps. 
First, IMT-phenotype associations are identified as genetic evidence to detect phenotypic 
similarity. Multiple GWAS SNPs are assembled together if they are identified by omics dataset 
to influence the same IMT. For example, multiple GWAS SNPs influencing the same gene’s 
expression level are assembled together, indicating such gene’s association with target 
phenotype. Association strength is characterized by combining the GWAS SNP’s summary 
statistics in a way similar to Fisher’s combined probability test. 
Second, PP-phenotype association are identified by grouping IMTs based on existing knowledge. 
Multiple IMTs are integrate together if they are classified into the same functional group based 
on existing knowledge. For example, multiple genes belonging to the same GO pathway are 
integrated together, indicating this GO pathway is contributing to the genetic underpinning of 
target phenotype. PP-phenotype association strength is characterized by an approach previously 
developed to identify a subset of functionally related genes that drive the similarity between two 
gene expression profiles[24] 
Finally, we expand the PP-phenotype association by removing the involvement of existing IMT-
interaction knowledge. Specifically, IMTs are not integrated based on knowledge such as GO 
terms but are integrated in an unsupervised manner. We employ algorithm previously built for 
the analysis of large-scale gene expression data to cluster phenotypes and IMTs at the same time. 
As a result, similarity between multiple phenotypes are captured by a subset of IMT where the 
IMT-phenotype association are statistically significant.  
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3. Result 
3.1. Sherlock-II: a new computational algorithm to infer IMT-phenotype 
association  
In order to investigate the underlying biology of multiple phenotypes simultaneously, we built a 
computational tool called Sherlock-II (a new generation of our previous published tool 
Sherlock[13]) to infer IMT-phenotype associations from GWAS and functional datasets in a 
statistically robust manner. Similar to Sherlock, Sherlock-II detects gene-phenotype association 
by comparing the GWAS SNP with the eQTL SNP of a gene, with the assumption that if the 
gene is causal to the phenotype, SNPs that influence the expression of the gene should also 
influence the phenotype, thus the eQTL profile of the gene should have significant overlap with 
the GWAS profile of the phenotype. The statistical framework used by Sherlock-II is also 
directly applicable to metabolite-QTL data [25], allowing us to infer associations between 
metabolite levels and phenotypes. 
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3.1.1. Metabolite phenotype associations  
Table 3. 1  metabolite-phenotype association passing Q-value cutoff 0.05.  
 
Application of Sherlock-II to integrate GWAS with metabolite-QTL data leads to the 
identification of 469significant metabolites-phenotype associations. For example, we have 
replicated the association between methionine-sulfone and chronic kidney disease found in a 
previous study[25] with more supporting SNPs.  Interestingly, metabolite-phenotype associations 
seem to be enriched for neuropsychiatric/neurodegenerative diseases when a stringent statistical 
threshold is applied (Q-value<0.05, Fisher’s exact test p-value= 0.0264, see Table 3.1). For 
examples, we have identified a strong association between gamma-glutamylglutamate and 
schizophrenia (p-value=3.97E-07, Q-value=2.46E-04); this metabolite was observed to decrease 
phenotype metabolite p-value Q-value
ALZHEIMER palmitoyldihydrosphingomyelin(d18:0/16:0) 7.38E-05 0.0445
AUTISM pregnenolonesulfate 7.04E-05 0.0454
X-15503 5.51E-05 0.0355
homocitrulline 1.47E-06 0.000932
alpha-glutamylglycine 0.000134 0.0426
16a-hydroxyDHEA3-sulfate 0.000131 0.028
X-11308 1.80E-05 0.0104
dehydroisoandrosteronesulfate(DHEA-S) 5.25E-05 0.0169
1-palmitoyl-2-linoleoyl-GPC(16:0/18:2) 5.11E-05 0.0169
X-11850 7.55E-05 0.0427
BIPOLAR	DISORDER ergothioneine 8.01E-05 0.0484
BIPOLAR	DISORDER	AND	SCHIZOPHRENIA X-11441 4.34E-05 0.0223
CHRONIC	KIDNEY	DISEASE methioninesulfone 1.50E-05 0.00609
homocitrulline 4.26E-05 0.00915
guanidinoacetate 1.89E-05 0.00609
xanthine 0.000178 0.041
homoarginine 0.000135 0.041
HIGH-DENSITY	LIPOPROTEIN	CHOLESTEROL 2-arachidonoyl-GPE(20:4) 8.41E-05 0.0498
PANCREATIC	CANCER X-17299 8.33E-05 0.0468
SCHIZOPHRENIA methioninesulfone 2.15E-06 0.00139
gamma-glutamylglutamate 3.97E-07 0.000246
WEIGHT trigonelline(N'-methylnicotinate) 9.26E-05 0.045
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in schizophrenic patients and is one of five best discriminators between the schizophrenic 
patients and the controls[26]. We have identified palmitoyl-dihydrosphingomyelin as the most 
significantly associated metabolite with Alzheimer’s disease (p-value=7.38E-05, Q-
value=4.45E-02). Palmitoyl-dihydrosphingomyelin is a particular type of sphingomyelin and it 
has been reported that a significant increase of sphingomyelin levels have been observed in the 
cerebrospinal fluid from individuals with prodromal Alzheimer’s Phenotype compared to 
cognitively normal controls [27]. For Autism, the most significantly associated metabolite is 
homocitrulline, and decreased homocitrulline concentration has been detected in Autistic 
patients[28]. In all the cases except methionine sulfone, the metabolite was implicated by 
multiple weak metabolite-QTL SNPs aligned to moderate GWAS SNPs, thus cannot be 
identified by genome-wide significant metabolite-QTL SNPs and GWAS SNPs alone (Figure 
1.2). 
 12 
 
Figure 1. 2 Four examples of metabolite-phenotype associations  
QQ plot for metabolite p-value distribution (left panel), QQ plot of original GWAS study (inserts in the left panel), 
and alignment between the metabolite-QTL and GWAS profiles (right panel) are presented. (A) Methionine sulfone 
is associated with chronic kidney disease. (B) Palmitoyl-dihydrosphingomyelin is associated with Alzheimer’s 
disease. (C) Gamma-glutamylglutamate is associated with schizophrenia. (D) Homocitrulline is associated with 
Autism.  
GWAS SNPs of Chronic Kidney Disease
mQTL SNPs of methionine sulfone
(A)
GWAS SNPs of Alzheimer
mQTL SNPs of palmitoyl-dihydrosphingomyelin
GWAS SNPs of Schizophrenia
mQTL SNPs of gamma-glutamylglutamate
(B)
(D)
GWAS SNPs of Autism
mQTL SNPs of homocitrulline
(C)
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3.1.2. Gene phenotype associations 
we have identified thousands of genes significantly associated with various phenotypes with 
Sherlock-II. Literature supporting these identified gene phenotype associations provides 
molecular detail that inspires mechanistic analysis. Take rheumatoid arthritis (RA) as an 
example. Three out of five most significant RA associated genes are from human leukocyte 
antigen family (HLA-DRB5, HLA-DPA1, HLA-DPB2), consistent with the established immune 
origin of RA [29]. The third most significant gene ITPR3(inositol 1,4,5-Trisphosphate Receptor 
Type 3) mediates the release of intracellular calcium, and has been identified as RA associated 
gene through a pathway based analysis [30]. The involvement of  intracellular calcium signaling 
in the RA pathology is  supported by single cell imaging showing abnormal intracellular calcium 
signaling in RA patients[29]. We also identified CACNB1(Calcium Voltage-Gated Channel 
Auxiliary Subunit Beta 1), further supporting the role of abnormal calcium signaling in RA.  In 
addition, two other genes involved in regulating apoptosis (BAK1 and GSDMB) are significantly 
associated with RA, and cytokine induced cell apoptosis were observed in RA synovium[31]. 
3.1.3. Summary of gene/metabolite phenotype associations  
Overall, we have identified 2114 gene-phenotype associations (with Q-value <1/3) covering 
1421 genes and 70 phenotypes, and 469 metabolite-phenotype associations (Q<1/3) covering 308 
metabolites and 51 phenotypes. To facilitate the analysis by the community we have provided a 
full list of the gene/metabolite-phenotype associations in appendix.  
 
 
 14 
Using Sherlock-II, we have systematically analyzed the published GWAS data, using a set of 
eQTL and metabolite-QTL data we curated. The analyses include 445 GWAS datasets covering 
88 phenotypes, 8 individual eQTL covering 6 unique tissues[32-39] , GTEx (version 7) 
data[40] , and 1 metabolite-QTL dataset [22]. To include the possibility that the expression of a 
gene can influence the phenotype through multiple tissues, we combined eQTL data across 
different tissues: when a SNP appears in multiple eQTL datasets, we assign the most significant 
p-value to it in order to capture the best eQTL signal across tissues. This merged version 
includes the eQTL profiles of 21,892 genes. For each GWAS dataset, Sherlock-II calculates a p-
value for every gene measuring the statistical significance of the overlap between the merged 
eQTL profile of the gene and the GWAS profile. In many cases, although only weak individual 
associations are present in the GWAS data, Sherlock-II detects strong gene/metabolite-
phenotype association signals as many GWAS SNPs are considering in aggregate during the 
transformation. By combining across multiple SNPs with weak associations, information present 
in GWAS associations at levels below traditional gnome-wide significance thresholds can be 
extracted. Our global analysis uncovers many gene/metabolite-phenotype associations that shed 
light on the genetic determinants of complex human traits, including disease risks.  
The above results suggest that the significant gene/metabolite associations with other phenotypes 
identified by Sherlock-II are also likely to be biologically meaningful and detailed analysis can 
lead to new insight into the disease etiology.  
3.2. Global analysis of the genetic similarity between phenotypes 
3.2.1. Hierarchical clustering of phenotypes based on gene phenotype association profile 
The global gene-phenotype association matrix not only allows us to identify genes associated 
with a specific phenotype but also enables the analysis of the genetic similarity between different 
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phenotypes at the gene level. Previous analyses of genetic similarity at the SNP level revealed 
certain overlapping SNPs between statistically associated phenotypes, lending genetic support to 
the observed co-occurence [41-43]. Genetic similarity at the gene level may yield stronger signal 
as multiple SNPs may converge at the same gene (e.g., influencing the expression of the same 
gene through different eQTL SNPs (eSNPs), thus one gene may be implicated in multiple 
phenotypes that do not necessarily share SNPs in the original GWAS data.  Indeed, we have 
observed many instances where a gene’s eQTL profile aligned to the GWAS profiles of two 
different phenotypes through different SNPs (see Figure 3.1 for an example). More importantly, 
genetic similarity analysis at the gene level also allows us to delineate the common 
cell/molecular mechanisms underlying different phenotypes, which we describe in more detail in 
the next section.  
 16 
 
Figure 3. 1 example alignment 
 (A) Genetic similarity between schizophrenia and height supported by co-association with multiple genes. (B) the 
gene RPL23 is co-associated with both phenotypes, supported by eSNPs that aligned to non-overlapping GWAS 
peaks (highlighted with red circles) in two different phenotypes.  
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Figure 3. 2 global hierarchical clustering of phenotypes based on gene association profiles.  
Highlighted branches discussed in the text: 1) GWASs of the same phenotypes (green); 2) phenotypes that are 
closely related and analyzed in the same GWAS (orange); 3) phenotypes that are known to share genetic etiology 
(blue); and 4) phenotypes with no obvious relations but co-occurences were observed based on previous 
epidemiological studies (red).  
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Alzheimer[pubmed:24162737]
Neuroticism[pubmed:27089181]
Depressive
Breast Cancer[pubmed:17903305]
Fasting insulin
Fasting glucose
Lung Cancer
Prostate Cancer
Diabetes[pubmed:22885922]
Diabetes[pubmed:18372903]
Age Related Macular Degeneration
Breast Cancer[pubmed:29059683]
Head Circumference
Parkinson
Education Attainment − College
Alzheimer[pubmed:17998437]
Acute Lymphoblastoid Leukemia
Agreeableness
Neuroticism[pubmed:21173776]
Upper Gastrointestinal Cancer
Early Growth
Smoking Age Onset
Childhood Intelligence
Neuroblastoma
Coronary Artery Disease
Smoking Ever Smoke
Smoking Former Smoker
Pancreatic Cancer
Asthma
Juvenile Arthritis
Attention Deficit Hyperactivity Disorder
Schizophrenia[dbgap:pha002859]
Glaucoma
Metformin
Glioma
Alcoholism
Longevity[pubmed:22279548]
Birth Weight
Longevity[pubmed:24688116]
Extraversion
Anorexia Nervosa
Smoking Cigar per Day
Waist−Hip Ratio adjusted for BMI
Chronic Kidney Disease[pubmed:21355061]
Chronic Kidney Disease[pubmed:20383146]
Diastolic Blood Pressure
Systolic Blood Pressure
Autism[pubmed:23453885]
Autism[pubmed:28540026]
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We first seek to identify the global similarity between two different phenotypes by comparing 
the gene-phenotype association vector (-log10(p-value) for each gene, with a dimension of the 
number of genes = 21892) for the two phenotypes.  Intuitively, similar gene p-value vectors 
imply that the phenotypes respond similarly to the expression changes of individual genes. We 
applied hierarchical clustering to cluster all the phenotypes, using Euclidean distance between 
gene-phenotype vectors.  The result of this global clustering analysis is a tree in which 
phenotypes with similar p-value vector are placed next to each other in a subtree (Figure 3.2). 
We find similar/related phenotypes were clustered together as expected.  However, more 
interestingly we find phenotypes that are not obviously related are also clustered together, 
suggesting that they share similar genetic mechanisms. 
The expected phenotype sub-clusters are formed by 1) GWASs of the same phenotype (e.g., 
osteoporosis, Alzheimer, diabetes, chronic kidney disease, and autism), indicating that at the 
global level the association was replicated; 2) phenotypes that are closely related and were 
studied in the same GWASs (e.g., LDL cholesterol, HDL cholesterol, total cholesterol, and 
Triglyceride; diastolic and systolic blood pressure); 3) phenotypes that are known to share 
genetic etiology in previous studies (e.g., bipolar disorder (BP),  schizophrenia (SZ), the 
combination of the BP and SZ, and five psychiatric disorders including BP and SZ [44], and  
phenotypes with strong evidence supporting their shared mechanisms (e.g.,  rheumatoid arthritis, 
Crohn’s disease, and ulcerative colitis, due to their common inflammatory/autoimmune nature). 
The fact that these different groups of related phenotypes were clustered together suggests that 
the gene-phenotype vector captured the major genetic information of the phenotype.  
The global similarity analysis based on the gene-phenotype vector revealed a number of sub-
trees in which phenotypes with no obvious relations are linked together (Figure 3.2, red 
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subtrees). Here we discuss a few examples: 1) a subtree that contains age at menarche, childhood 
obesity, body mass index; 2) a subtree with 5 phenotypes: breast cancer, fasting insulin, fasting 
glucose, lung cancer, and prostate cancer; 3) head circumference, Parkinson, and education 
attainment; 4) childhood intelligence with neuroblastoma; 5) longevity with birth weight. Upon 
literature search, we found that for each of the groups, there were previous epidemiologic studies 
that found the co-occurrence of the phenotypes: 1) a previous study found that girls experience 
early menarche are significantly often overweight/obese [45]; 2) hyperinsulinemia with insulin 
resistance is a significant risk factor for breast cancer independent of adiposity or body fat 
distribution [46];  3) higher educational attainment significantly lower the risk for Parkinson’s 
disease [47]; 4) children with neuroblastoma score a significantly higher IQ than the control [48] 
5) mouse experiment  showed that low birth weight correlates with increased longevity [49].  
These were the observed correlations of the phenotypes, and the fact that they are clustered by 
the gene -phenotype association matrix indicates that they are linked by the associations with a 
set of genes that should shed light on the common underlying genetic mechanisms. 
Delineating common genetic mechanisms underlying seemingly unrelated phenotypes 
To identify potential common mechanisms that underlie two seemingly unrelated phenotypes, we 
search for genes that drive the similarity between the two gene-phenotype vectors. One 
straightforward approach is to analyze the most significantly associated genes with each of the 
phenotypes and test for significant overlap. This approach yielded insight for some of the 
phenotype subtrees. One example is the age-at-menarche/body-mass-index/childhood-obesity 
subtree. We found overlapping genes in each of the three pairwise comparisons (Figure 3.3). 
Multiple genes are associated with age-at-menarche and body-mass-index with a theme on cell 
growth and proliferation. For example, SMAD3 is significantly associated with both age-at-
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menarche and body-mass-index and is a pivotal intracellular nuclear effector of the TGF-beta 
(transforming growth factor beta) signaling which play a critical role in regulating cell grow, 
differentiation and development[50]. MAP2K5 (Mitogen-Activated Protein Kinase Kinase 5) is 
also significantly associated with both the phenotypes and the signaling cascade mediated by this 
kinase is involved in growth factor stimulated cell growth and muscle differentiation [51]. Genes 
simultaneously associated with both childhood-obesity and body-mass-index include TFAP2B 
and CENPO. TFAP2B is a transcription factor of AP-2 family which stimulate cell proliferation 
and suppress terminal differentiation of specific cell types during embryonic development [52]. 
CENPO encodes a component of the interphase centromere complex which is required for 
bipolar spindle assembly, chromosome segregation and checkpoint signaling during mitosis thus 
is critical to cell division[53]. Thus examination of the shared significant gene associations 
suggests a common theme on cell growth and development underlying all three phenotypes. 
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Figure 3. 3 overlapping genes between phenotype pairs 
Overlapping genes in the three pair-wise comparisons of the phenotypes in the subtree (age-at-menarche/body-mass-
index/childhood-obesity) from the hierarchical clustering of the phenotypes.  
While comparing the top associated genes between phenotypes yields clues about the common 
mechanisms for some of the phenotype subtrees, its power of detection is limited. For many 
phenotype pairs that are similar based on their gene association p-value vector and thus clustered 
together, the top associated genes for the two phenotypes do not overlap (an example is the 
subtree with 5 phenotypes including fasting-insulin and breast-cancer).  This suggests that the 
similarity is driven by more diffused signal distributed to a set of genes with weak associations. 
To identify such set of genes, we employ an approach previously developed to identify a subset 
of functionally related genes that drive the similarity between two gene expression profiles[24] . 
This approach assesses the contribution of a subset of genes defined by a GO category (or a 
pathway) to the Pearson correlation and assigns a z-score to the subset (see Method). This allows 
the ranking of the significance of different subsets of genes based on their z-score; we call it  
-log10(P-value)
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3.2.2. Gene Ontology terms reveal common mechanism connecting phenotypes  
Using the Partial-Pearson-Zscore, we analyze the pairs of phenotypes in a subtree and found 
many significant GO categories that contribute to the similarity, suggestive of common 
underlying mechanisms for these phenotype pairs. As expected, for the subtree with rheumatoid-
arthritis/Crohn’s-disease/ulcerative-colitis, we found that the top GO categories that contribute to 
the similarity between RA and CD are “antigen processing and presentation of peptide or 
polysaccharide antigen via. MHC class II” (ranked 1st, z-score = 18.6) and similar GO categories 
(“MHC class II protein complex” ranked 2nd, and “peptide antigen binding” ranked 3rd),  and 
pyroptosis (an inflammatory form of cell death) (ranked 6th, z-score= 14.8). Similarly, GO 
categories contributing to the similarity between RA and UC include pyroptosis (ranked 1st z-
score = 20.7). These results suggest that at least part of the common underlying mechanisms for 
these diseases are immune in nature and involve inflammation induced cell death.  
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Table 3. 2 Summary of the top GO categories connecting 5 phenotypes  
(A): Top 5 non-redundant GO categories with highest Partial-Pearson-Zscore for each pair of the phenotypes. 
Recurrent GO terms across different pairwise comparisons were highlight with different colors. Also highlighted is 
the “cgmp catabolic process” that support the relation between breast cancer and fasting insulin. (B) to (D):  
proposed models with causal relations to explain the observed co-associations between the expression of the genes 
in the GO term and multiple phenotypes. Alternative models were considered in the discussion section.  
 
For the subtrees with phenotypes not obviously related, Partial-Pearson-Zscore analysis also 
revealed significant GO categories suggestive of the genetic mechanisms that connect these 
phenotypes together. An example is the subtree with 5 phenotypes including fast insulin and 
breast cancer (Figure 3.2). Significant GO categories were found for all 10 pair-wise 
comparisons (Figure 3.2). For example, we found that the “cgmap catabolic process” is the most 
significant GO category for the fast-insulin/breast-cancer pair. This category includes several 
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nucleotides phosphodiesterase, such as PDE4A and PDE2A. These are dual specificity cAMP 
and cGMP phosphodiesterase, which degrade cAMP and cGMP, and thus suppress cAMP/cGMP 
signaling. Inhibitors of these enzymes have been used as anti-cancer drugs[54], as the activation 
of cyclic nucleotide signaling is sufficient to inhibit proliferation and activate apoptosis in many 
type of cancer cells[54, 55]. cAMP signaling pathway is also strongly connected to insulin 
secretion. Among the various intracellular signals involved, cAMP is particularly important for 
amplifying insulin secretion[56]. Thus altered cAMP/cGMP signaling seems to connect with 
both breast cancer and fast-insulin.  
Among the most significant GO terms from the pair-wise comparisons, “NAD(P)H oxidase 
activity” occurred multiple times and connects all three cancer types (breast cancer, prostate 
cancer, lung cancer). NAD(P)H oxidases are known to express at high level and produce ROS in 
cancer cells. Over-expression of these enzymes (possibly induced by inflammatory signal) has 
been linked to tissue injury and DNA damage from ROS that accompany pre-malignant 
conditions, contributing to the initiation and progression of a wide range of solid and 
hematopoietic malignances[57]. 
One of the most frequently appeared GO terms is related to apoptosis (Figure 3.2, colored red). 
This theme occurred in 6 out of 10 phenotype pairs and connects all 5 phenotypes. Defect in the 
normal programmed cell death mechanisms play a major role in the pathogenesis of tumor [58].  
Apoptosis is also known to play an important role in the pathophysiology of both type I and type 
II diabetes and excess apoptosis is the underlying cause for beta-cell loss [59]. Thus altered 
apoptosis might be the common mechanism connecting the  three cancer phenotypes and 
changed fasting-insulin/fasting-glucose level in normal people. 
 25 
Another GO term that connect all the phenotypes is “tail-anchored membrane protein insertion 
into ER”. This GO term includes several genes (such as SGTA and BAG6) involved in the post-
translational pathway through which tail-anchored membrane proteins are recognized and 
targeted to ER membrane[60] . This pathway is important in many cellular processes including 
the regulation of cell cycle. SGTA over-expression was involved in the pathogenesis of breast 
cancer [61] and BAG6 is involved in the control of apoptosis and is required for the acetylation 
of P53 upon DNA damage, linking them to cancer risk [53]. ER membrane targeting is also 
important for insulin secretion, potentially connecting these genes to the fasting insulin/glucose 
phenotype.  
We propose models with causal relations to explain the observed co-associations between the 
expression of a set of functionally related genes and multiple phenotypes (Figure 3.2). These 
models are not unique, as there exists alternative and possibly less parsimonious models that can 
also explain the observed co-associations (see Discussion). 
3.2.3. Two way bi-clustering detects genes associated with multiple phenotypes  
The Partial-Pearson-Zscore approach can detect the co-association of a subset of gene defined by 
a GO term or pathway with a pair of phenotypes, and examination of all the pairwise 
comparisons can reveal common GO terms/pathways associated with multiple phenotypes 
clustered in a sub-tree. With the complex relations between physiological processes and 
phenotypes (Figure 1.1), it is possible that multiple genes not necessarily belonging to a 
predefined functional category can co-associate with multiple phenotypes not necessarily in the 
same sub-tree. 
To detect the co-association of a subset of genes with multiple phenotypes, we applied a two-
way bi-clustering algorithm – the Iterative Signature Algorithm (ISA) [62]  to the global gene-
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phenotype association matrix.  This algorithm was developed previously to analyze gene 
expression data in order to detect a subset of genes with similar expression patterns across a 
subset of experimental conditions. The ISA algorithm starts with a seed of a sub-matrix and 
iterates through phenotypes and genes to recruit/drop members till the set of phenotypes and 
genes converge to a stable submatrix.  Statistical significance of detected phenotype-gene sub-
clusters are calculated by random permutation of the input p-value matrix within each phenotype 
(see Method). 
 
Figure 3. 4 Subclustering of phenotype-gene association matrix 
Subclustering analysis revealed a set of genes co-associated with multiple phenotypes. (A) the global gene-
phenotype association matrix, filtered to enrich the signal and reduce the dimension. The rows and the columns of 
the filter matrix were reordered by the hierarchical clustering algorithm. Certain subclusters are already visible. (B) 
One of the sub-clusters identified by the ISA algorithm. This subcluster consists of 18 genes and 7 phenotypes 
including a few neuro-psychiatric diseases, osteoporosis, breast cancer and physiological traits such as insulin level 
and blood pressure. (C) gene-phenotype associations in the subcluster supported by literature (check marks). 
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Starting from a filtered global gene-phenotype association matrix to improve the signal and 
reduce the search space for the ISA algorithm (see Figure 3.4 and Method), we have identified a 
number of significant sub-clusters that connect multiple genes with multiple phenotypes.  In 
general, these sub-clusters involve phenotypes that are expected to be together as well as 
phenotypes that are seemingly unrelated, and genes with a range of different functional 
categories, suggesting a complex web of connections between physiological processes and 
phenotypes (Figure 1.1).  Here we discuss the most significant sub-cluster and provide a list of 
sub-clusters discovered by the bi-clustering algorithm in Figure 3.5.  
 
Figure 3. 5 all sub-clustering from phenotype-gene association matrix 
Other examples of the sub-clusters discovered by applying the ISA bi-clustering algorithm to the gene-phenotype 
association matrix.  
The most significant sub-cluster contains 7 diverse phenotypes and 18 genes with a broad range 
of biological functions (p-value = 1E-6 Figure 3.4). According to gene annotations [53], this set 
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of genes seems to be enriched for regulatory function: ARHGAP27 is a Rho GTPase activating 
protein, CRHR1 encodes a corticotropin-releasing-hormone-receptor, BPTF is a transcription 
factor highly expressed in the brain of Alzheimer’s patients, DND1 is an inhibitor of miRNA 
mediated repression, FAM215B is a non-coding RNA, KANSL1 is a component of histone 
acetylation complexes, and PLEKHM1 is an adaptor protein that regulates  Rab7 dependent 
fusion events in the endolysosomal system. Some of the gene-phenotype associations predicted 
by this sub-cluster are supported by literature (Figure 3.4 and table 3.3), and several genes 
associate with multiple phenotypes across the sub-cluster. For examples, MAPT (microtubule 
associated protein tau, known to be associated with multiple neurodegenerative and 
neuropsychiatric diseases [63] ) is associated with Parkinson[64], Autism[65],  and Systolic 
blood pressure [66]. Consistently we found MAPT antisense transcript with similar association 
patterns, as the expression of MAPT antisense is negatively correlated with MAPT expression 
[65, 67-70].  PLEKHM1 is known to be associated with breast cancer, Parkinson, and 
osteoporosis, and mutations in this gene are associated with autosomal recessive osteopetrosis 
type 6 [71-74]. These examples suggest that other gene-phenotype associations in this submatrix 
may also be true and biological meaningful associations. A comprehensive summary of literature 
support for gene-phenotype association is shown in table 3.3.  
Among the seven phenotypes in this sub-cluster, several were known to be correlated based on 
previous epidemiological studies. For example, in addition to the connection between fasting 
insulin and breast cancer discussed above, insulin was linked to several phenotypes in this 
cluster:  1) there is a high prevalence of insulin resistance in non-diabetic Parkinson’s disease 
patients [75] ;  2) it was suggested that abnormal insulin signaling underlies increased autism risk 
based on the evidence that mutations that hyperactivate PI3K pathway cause autism [76]; 3) 
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insulin resistance co-occurs with hypertension[77]; 4) insulin may work to stimulate osteoblast 
differentiation, and diabetes have a higher risk of bone fracture[78]. These evidences suggest that 
insulin signaling may be one of the physiological processes that connect these phenotypes 
together.  
Functional analysis of genes in the sub-cluster added further support that regulation of insulin 
signaling is a common mechanism, with three of the genes in the cluster having strong 
connection with insulin. The first gene CRHR1 encodes a corticotropin-releasing-hormone-
receptor. Administration of corticotropin, the downstream functional hormone of CRHR1, results 
in a 5- to 10-fold rise in plasma insulin levels in mice [79]. In ER positive breast cancer which 
constitutes about 80% of all breast cancers, estrogen alters the splicing of CRHR1 and disrupts 
CRH-mediated signaling, which contributes to the cancer growth driven by estrogen[80].  Thus 
CRHR1 may connect insulin and breast cancer through the downstream insulin signaling. The 
second gene is NMT1(N-myristoyltransferase). Its association with insulin is supported by mice 
experiment that liver particulate N-myristoyltransferase activity appears to be inversely 
proportional to the level of plasma insulin [81]. The third gene is PLEKHM1 which is an adaptor 
protein that regulates Rab7 dependent fusion events in the endolysosomal system[53]. 
PLEKHM1 participates in the degradation of insulin granule by the fusion of secretory granule 
with lysosomal, which is highly up-regulated upon starvation [82]. Thus loss of function 
mutations in this gene may lead to high insulin level that drives osteopetrosis.   
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Table 3. 3 literature search for the most significant sub-cluster. Number indicates pubmed ID 
 
4. Discussion 
4.1. Advantage of similarity study on gene/metabolite level than on SNP level 
We have developed a computational framework to study the genetic similarity between different 
phenotypes and to delineate the potential mechanisms underlying the similarity by integrating 
GWASs of multiple phenotypes with association studies of IMT.   We demonstrated the 
approach by a global analysis of 445 GWASs covering 88 complex human phenotypes. Our 
analysis revealed expected as well as unexpected relationships between phenotypes, and 
suggested specific mechanisms that connect these phenotypes together. Our analysis also 
revealed many specific gene-phenotype and metabolite-phenotype associations that should 
motivate more detailed mechanistic studies in the future. 
Comparing with genetic similarity analysis using GWAS data at the SNP level, our analysis 
framework has several advantages.  First, comparing the genetic profiles at the gene level can 
yield stronger signal, as multiple SNPs can converge on the same gene.  Even if the GWAS 
peaks of two different phenotypes do not align by proximity, they can be “aligned” through a 
gene, i.e., they may influence the expression of the same gene. We provided one example in 
/ Breast Cancer Parkinson Autism Neuroticism Fasting Insulin Systolic Blood Pressure osteoporosis
ARHGAP27 / 25370933 / / / / /
ARL17B / 25370933 / / / / /
BPTF / / / / / / /
CRHR1 17097220/24526122 25370933 / / 14301515 / 19801982
DCAKD 23227362 / / / / / /
DND1 28191469 / / / / / /
DND1P1 / / / / / / /
FAM215B / / / / / / /
KANSL1.AS1 / 25370933 26777411 / / / /
LRRC37A / / / / / / /
LRRC37A17P / / / / / / /
LRRC37A2 / 25370933 / / / / /
MAPT 20579400 20070850/21292315 26479762 / / 23969178 /
MAPT.AS1 29441192 / / / / / /
NMT1 30446635 / / / 8240341 / /
PLEKHM1 28229117 25370933/21292315 / / / / 17404618
RDM1 22016618 / / / / / /
RPS26P8 / / / / / / /
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which the gene RPL23 is co-associated with both schizophrenia and height (Figure 3.1);  the 
correlation of the two phenotypes has been observed in epidemiological studies [21] . The co-
association is supported by two GWAS SNPs associated with the two phenotypes respectively.  
These two SNPs do not align by proximity; they align to two different eSNPs for the same gene. 
Secondly, genetic similarity analysis at the gene level readily suggests potential mechanisms 
connecting different phenotypes. We have presented two different approaches to delineate 
genes/pathways that contribute to the genetic similarity: Partial-Pearson-Zscore analysis to 
identify a group of functionally related genes that contribute to the similarity between a pair of 
phenotypes, and a sub-clustering analysis of the global gene-phenotype association matrix that 
identifies a set of genes co-associated with multiple phenotypes. Analyses using these 
approaches led to specific hypotheses regarding the mechanisms that connect expected as well as 
unexpected relationships between phenotypes, and we expect that the power of detection will 
grow as more GWAS and IMT data accumulate.  
4.2. Alternative mechanisms supported by the same genetic evidence 
It is important to note that the data we obtained using this analysis framework are co-associations 
between genes and phenotypes supported by multiple GWAS and eQTL SNPs, not causal 
relations.  In suggesting mechanistic models, we proposed specific causal relationships that are 
consistent with the data (Figure 3.2). However, there are often alternative (and perhaps less 
parsimonious) models that are consistent with the observed data. For example, we proposed that 
SNPs influence genes involved in apoptosis which can independently influence fasting 
insulin/glucose levels and cancer risks (Figure 3.2). However, there exists alternative models that 
are also consistent with the data. For example, SNPs can influence fasting insulin level which in 
turn influences apoptosis associated genes’ expression which in turn influences cancer risk. A 
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variation of this model is that insulin can influence apoptosis associated genes’ expression and 
cancer risk independently (Figure 4.1). These alternative models are also consistent with the co-
associations between SNPs and all the phenotypes (including the gene expression phenotype), 
but less parsimonious in that there is a missing molecular trait in between SNPs and fasting 
insulin/glucose. However, the true mechanistic model is not necessarily the most parsimonious. 
Clearly more experiments/analyses are needed in order to discriminate between different models.  
 
Figure 4. 1 Alternative mechanisms 
Alternative models explaining the co-associations among the expression of apoptosis related genes, fasting 
insulin/glucose, and cancers. (A) the model we proposed in Figure 3.2. (B)-(C): alternative models that also explain 
the observed co-associations.  
5. Method 
5.1. Sherlock-II algorithm 
Sherlock-II detects IMT-phenotype association by comparing the GWAS SNPs with the QTL 
SNPs of the IMT (eQTL or metabolite-QTL), with the assumption that if an IMT is causal to the 
phenotype, SNPs that influence the IMT should also influence the phenotype, thus the QTL 
profile of the IMT should have significant overlap with the GWAS profile of the phenotype.  To 
test the significance of the overlap, Sherlock-II first selects the QTL SNPs of an IMT that pass a 
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threshold, aligns these SNPs to the corresponding SNPs in the GWAS, and test whether the 
aligned GWAS SNPs have p-values significantly better than those picked at random.  
When testing the significance of a selected set of loci in a given GWAS, Sherlock-II uses a 
simple scheme to compute a score for the n p-values of the GWAS SNPs that best tag these loci. 
It then uses a convolution-based approach to construct an empirical null distribution for scores 
involving n p-values drawn randomly from the full set of GWAS p-values. In certain instances, 
particularly with eQTL for many genes, this test will be performed repeatedly for all 
intermediate molecular traits in a study. If dependence between the sets of IMTs is detected — 
for example, due to pleiotropic loci that regulate many genes — a provision of adjusting the null 
distribution is included. Through extensive testing and simulation, we show that our empirical 
strategy produces p-values that are highly resistant to inflation. In this section, we describe the 
individual components of the Sherlock-II method in detail in the order in which they occur.  
Identifying Tag SNPs for Independent Blocks  
Sherlock-II statistics is based on the assumption that the collection of SNPs tested are tagging 
independently segregating haplotype blocks in both the GWAS and eQTL cohorts. 
Understanding the true block structure of the cohorts is critical to accurately estimating gene 
significance. The inadvertent inclusion of dependent blocks can inflate the significance of genes 
by over-counting true associations; conversely, a conservative approach that enforces wide 
separation between tagging SNPs may miss many independent loci. The preferred approach to 
identifying independent blocks requires genotypes for both the GWAS and functional data to 
define block boundaries based on regions of rapid decay in  linkage-disequilibrium (LD). 
However, since the difficulty of obtaining genotypes across a large number of GWAS studies 
makes this impractical, we constructed a database of LD using Caucasian cohorts from the 1000 
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Genomes Project. We use PLINK (v1.07) to compute r2 linkage between common SNPs for 379 
individuals in the CEPH, CEU, TSI, GBR, FIN, and IBS cohorts of 1000 Genomes release 
v3.20101123. This permits the alignment of associated loci in the functional data to 
corresponding SNPs in GWAS data, and it enables the identification of independently- 
segregating tag SNPs in the combined data for use in the statistical test.  
We first match the GWAS SNPs to all the loci present in a given functional data set that pass a 
specific threshold. For the eQTL data used here, the nominal threshold is typically eSNP p-
values < 10 -5.  If matching SNPs are not present in both data sets, we use the closest GWAS 
SNPs in r2 LD > 0.85, if available. We then use an agglomerative clustering approach to identify 
non-overlapping blocks of SNPs in r2 LD < 0.2. From each block, the functional SNP with the 
strongest association is selected as a tag, and its corresponding GWAS SNP is included in the set 
subjected to statistical test. Since discrepancies between the various cohorts — GWAS, 
functional, and linkage — are inevitable, a minimum 100 kb distance between tag SNPs is 
enforced. In addition, we exclude SNPs from the human leukocyte antigen (HLA) region 
between 6p22.1 to 6p21.3 due to its complex linkage structure.  
Core Statistical Method  
Once a set of SNPs related to a specific molecular trait is identified, we compute a score s by 
simply combining their GWAS log p-values:  
𝑠 = − 𝑙𝑜𝑔'((𝑝+)-+.'  
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This converts our collection of SNPs into a scalar quantity that, when referenced against the 
appropriate null distribution, indicates the statistical significance of selecting this subset from the 
pool of all independent GWAS loci. Our approach is analogous to Fisher’s combined probability 
test using the scoring function −2 𝑙𝑜𝑔0(𝑝+)-+.' which follows a c2 distribution with 2n degrees 
of freedom when p-values are drawn from a uniform distribution on (0,1). With our method, 
instead of assuming a particular form for the distribution of GWAS p-values, we use discrete 
convolution to compute an empirically-derived distribution of scores when combining n p-
values. Since s represents a specific score, we let S represent a random variable of all possible 
scores. We form the discrete probability distribution function (PDF) of S using bins of width b 
log units, where the probability of scores in the range 0 ≤	s < b is the first element, b ≤ s < 2b is 
the second element, and so forth. Thus, fn[s] = P(S = s) is the discrete PDF for a score 
comprising n independent GWAS p-values. For the simplest case of scores involving only a 
single SNP, the PDF f1[s] is essentially a normalized histogram of p-values for all independent 
(unlinked) SNPs in the GWAS that aligned to a eQTL SNP across all genes:  
𝑓'[𝑘] = 1𝑁 𝐼[𝑘𝑏	 ≤ −𝑙𝑜𝑔'((𝑝+) < (𝑘 + 1)𝑏]=+.'  
where I is the indicator function, N is the total number of SNPs, b is the bin width, and k = s/b is 
the array index. For computational efficiency, the minimum GWAS p-value is typically 
truncated at 10 -9, well below genome-wide significance, yielding 900 bins when spacing b = 
0.01 is used. This single-locus PDF forms the basis from which null distributions for any 
arbitrary number of functionally-related loci are formed. Since the sum of two independent 
random variables has a PDF equal to the convolution of their individual probability distributions, 
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scores involving two GWAS p-values have PDF f2 = f1 * f1. In the general case for any value of 
n > 1, the PDF fn[s] is formed from n-1 recursive convolutions of f1[s]:  
𝑓- 𝑘 = 𝑓' 𝑙 ⋅ 𝑓-?'[𝑘 − 𝑙]@A.(  
where again k = s/b is the array index. For the special case of a truly uniform p-value 
distribution, we have an exact continuous solution to the recursive convolution for n p-values 
(which can be obtained from the chi-square distribution) 
𝑓- 𝑠 = ln	(10)- 1𝑖 𝑠-?'10?F-?'+.(  
To motivate the use of our empirical approach, we compare this theoretical result to our 
empirical method for GWAS of differing power. For low-powered association studies with p-
value distributions close to uniform, the tail of the empirical distribution is similar to the tail of 
the theoretical distribution, leading to roughly identical estimates of significance for a given 
score. For well-powered meta analyses that appear to contain inflation from various sources, 
significant differences in the distribution tails can lead to an appreciable overestimation of 
significance for high scores when using the theoretical distribution. With the empirical 
distribution derived from the real GWAS data, Sherlock-II is insensitive to the input GWAS 
inflation. 
Correcting for Pleiotropic and Sampling Effect 
Another source of inflation stems from a lack of true independence between molecular traits 
across a given functional dataset. For example, pleiotropic loci may appear to regulate hundreds 
of genes in the eQTL data for a given tissue. In our simulations, these loci may inflate the output 
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test statistic due to chance alignment with significant GWAS SNPs; in our tests, this occurs at an 
appreciable level in perhaps five percent of the cases. Since our method permits the use of a 
unique distribution f1 for each p-value added to the score, it enables a simple scheme for 
reducing inflation by adjusting each distribution based on the number of molecular traits affected 
by the locus. For the eQTL example, this involves conditioning the GWAS distribution based on 
the number of genes influenced by a locus across the entire eQTL data set. When chance 
alignment of pleiotropic loci and significant GWAS SNPs occurs, the overrepresentation of 
small p-values is reflected in the null distribution for affected genes. Thus, in practice, the actual 
distribution incorporated into a Sherlock-II score with eQTL data is conditioned on the number 
of genes that are regulated by the same locus:  
𝑓'|H∈JKLMNOP 𝑘 = 𝐼[𝑘𝑏 ≤ −𝑙𝑜𝑔'((𝑝+) < (𝑘 + 1)𝑏] ∩ 𝐼[𝐶+ ∈ 𝐶STU+AV]=+.' 𝐼[𝐶+ ∈ 𝐶STU+AV]-+.'  
 
where I is the indicator function, N is the total number of SNPs, k is the index, b is the bin width, 
and the ith SNP is assigned gene count Ci while the locus in question has count c. 𝐶STU+AV is 
several non-overlapping sets, each including a range of gene count c. For example 𝐶STU+AVW 
includes all SNPs that regulate 6 to 10 genes. Now the distribution contains only the p-values of 
SNPs that belong to the same count family. With this change, instead of computing the 
significance of a set of SNPs drawn from GWAS, our method computes the significance of a set 
of SNPs drawn given their individual pleiotropies count family. In our simulations, this results in 
a minor change in the significance and rank order of output genes in most cases but prevents  
inflation whenever chance alignment of significant GWAS SNPs and pleiotropic loci occurs 
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(Figure 5.1).  Specifically, we penalize SNPs regulating the expression of a large number of 
genes.  
 
Figure5. 1 Sherlock-II is robust to inflation 
Using p-value distribution conditioned on the pleiotropic counts of the SNPs prevents the inflation of the gene-
phenotype association p-values. Top Row: QQ plots from case-control randomization GWASs show no signal. 
Middle Row: The chance overlap of pleiotropic loci in eQTL data and low p-value SNPs from the randomized 
GWAS can result in inflation of gene-phenotype association p-values. Bottom Row: the use of PDFs conditioned on 
SNP pleiotropy corrected the inflation. 
 
5.2. Global analysis to identify molecular similarity between phenotypes 
We first filtered the gene-phenotype association matrix to eliminate redundancies. For each 
phenotype with multiple GWAS dataset from overlapping cohorts, we chose a representative one 
with the strongest signal, defined as the one with the largest number of genes with p-value of 
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association smaller than 0.001. Note that the representative GWAS doesn’t have to be the one 
with the biggest sample size because some signal is only statistically significant in a sub-
population.  
For genetic similarity analysis, we transformed the p-values in the gene-phenotype association 
matrix to -log10(p-value), so that genes with small p-values can have a stronger weight in the 
distance calculation.  
5.2.1. Hierarchical clustering 
Hierarchical clustering is applied to the gene-phenotype association matrix to group phenotypes 
together based on their genetic similarity. We used R and its default distance measure, the 
Euclidean distance, to calculate distance between phenotype p-value vectors. We then use Ward's 
method to cluster the phenotypes [83]  
5.2.2. Partial-Pearson-Zscore analysis  
We employed a simple statistical approach to detect gene ontology terms that contribute 
significantly to the genetic similarity between two different phenotypes. Gene Ontology gene 
annotations were downloaded from Ensembl.  We removed the GO terms with less than 5 genes 
(not enough statistics) and more than 100 genes (too non-specific) from the analysis, after which 
6796 GO terms were used.  For a specific pair of phenotypes, we calculate a Partial-Pearson-
Zscore for each of the 6796 GO terms using the following formula (previously developed for 
analyzing similarity between two gene expression profiles [24])  
𝑧Y = (𝑥+ − 𝑢\)(𝑦+ − 𝑢V)/𝜎\𝜎V 𝑛Y+∈Y  
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where  xi and yi are -log10(p-value) for gene i associated with the two phenotypes, 	𝑢 	𝑎𝑛𝑑 𝜎  
are the mean and standard deviation for x and y respectively, J is the gene set defined by the GO 
term, and 𝑛Y is the number of genes in the GO term. This formula is similar to the one for 
calculating Pearson correlation (with a normalization -=c), except that the summation is partial – 
only for the genes in the subset. We argued that the null distribution for 𝑍e should be standard 
normal distribution, and verified that this is indeed the case by randomly sample all phenotypes 
pairs and generate 𝑍e for all the GO terms (Figure 5.2). 
 
Figure 5. 2 partial-pearson-zscore distribution 
Distribution of the Partial-Pearson-Zscore generated by analyzing GO terms for all the phenotype pairs. The 
distribution has a mean of 0.066 and a standard deviation of 1.06, which are very close to that from the standard 
normal distribution as expected from a z-score. 
 
5.2.3. Two-way bi-clustering algorithm 
In order to enhance signal and reduce the search space, we further filtered gene-phenotype p-
value matrix before sub-clustering algorithm is applied. We removed the columns and rows in 
histogram and normal curve of zscores of GO terms across all pheontype pairs   mean= 0.076  sd= 1.17
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which none of the gene-phenotype associations passed a Q-value cutoff of 1/3. Thus we only 
keep the phenotypes and genes with at least one significant association.  
We used the ISA algorithm (Iterative Signature Algorithm ) [62] to detect sub-clusters. This 
algorithm was developed to detect a subset of genes with similar expression patterns in a subset 
of conditions. The ISA algorithm starts with a seed of a sub-matrix and iterates through 
phenotypes and genes to recruit/drop members till the set of phenotypes and genes converge to a 
stable submatrix.  By default, ISA randomly choose columns/rows as seed to begin iteration with 
the assumption that a large number of random seeds will cover most starting conditions that 
converge to stable submatrices.  We went further by eliminating the randomness from seeding 
with an exhaustive set of seeds. More specifically we generated n(n-1)/2 number of seeds for n 
phenotypes to exhaust all possible combination of starting conditions. Standard post-processing 
steps with R ISA package [84]  are conducted to merge similar sub-clusters. 
Statistical significance of the discovered sub-cluster is calculated by permutation test. One 
permutation is defined by permuting the p-value vector of each phenotype in the gene-phenotype 
p-value matrix, keeping the p-value distribution within each phenotype invariant. Then ISA 
algorithm is applied with the same parameters used in the discovery phase to detect sub-clusters 
from the permutated matrix. A robustness score defined by ISA[62, 85, 86] is calculated for each 
sub-cluster discovered from the permutated matrix. The highest robustness of these sub-clusters 
is recorded for each permutation. Sub-cluster p-value is calculated by comparing its robustness 
score with the distribution of the robustness score generated from all the permutations. 
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6. Visualization 
With high throughput statistical framework Sherlock II, we have generated millions of IMT-
phenotype associations, each supported by dozens of SNPs. With this rich information comes the 
difficulty for data retrieval and inspection. By default, Sherlock-II outputs one txt file and one 
static html file for each GWAS-QTL pair. Although the html file provides a basic degree of 
visualization for individual Sherlock-II result file, it provides little help for the exploration of 
phenotype connections where multiple Sherlock-II result files are required to be analyzed 
together. 
we need an interactive tool to allow user to make selection of phenotype combination and 
generate figures accordingly because the total number of phenotype combination is too large. 
Theoretically, the number of all combination of phenotypes scales exponentially (2-) with 
respect to the number of individual Sherlock-II results. Given 445 GWAS datasets paired with 
several QTL datasets, the sheer number of Sherlock-II results is estimated to exceed 10f(  which 
makes it time-wise too expensive and storage-wise inefficient to prepare visualization for all 2- 
phenotype pairs.   
6.1. Interactive web-interface 
The interactive tool is called Sherlock-Vis and is implemented as a browser based visualization 
tool consist of three layers as shown in figure 6.1 flowing the MVC design pattern[87]. The top 
layer is a dynamic drawing layer where plots are drawn/updated right after user makes a 
selection. I implemented this layer using standard HTML and Javascript library called Data 
Driven Document(D3)[88] and rely on a third party server Flask to make the website public . 
The bottom layer can be thought of a warehouse storing all the Sherlock-II generated result 
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information. I base this layer on Oracle MySQL database. The middle layer that connects 
dynamic drawing layer and warehouse layer is called business logic layer. This layer is 
responsible first for communication that retrieve/store data from/to database and forward/receive 
data/command from browser. It is also responsible for all the data structure manipulation such as 
sorting and filtering. I implemented this layer from scratch using the general purpose 
programming language Python. 
 
Figure 6. 1 design pattern of web interface 
The MVC design pattern is implemented in three connected layers. Instruction is initiated from the browser, 
forwarded to database after data structure manipulation in the business logic layer with python. After data is 
retrieved from the database, they are feed back to the browser for display. 
6.1.1. Browse gene-phenotype associations 
In order to allow user selection, the web interface need basic input boxes including a way to 
select source GWAS, QTL. GWASs are not listed individually in a drop box because it can be 
more intuitive to allow users to select from 70 unique diseases rather than 445 GWAS datasets.  
This is partially feasible because there are rarely too many GWASs for the same disease. On the 
contrary, QTL datasets are listed individually due to the limited number of choices.  
database
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Another necessary input field is number of genes to display for each GWAS-QTL pair because 
firstly webpage cannot accommodate 20,000 genes at the same time and secondly genes with 
insignificant association statistics are excluded in most statistical analysis thus only genes with 
significant association statistics are frequently selected for display. To accommodate this use 
pattern, user can specify a number N (default 30) of genes to display which will be the top N 
genes with most significant association statistics. In this case multiple GWAS-QTL pairs are 
selected, top N genes for each pair will be joint together and the joint set are all displayed. In the 
case the joint set contains too many genes to display simultaneously, excess genes can be viewed 
by scroll the gene list to the right direction by mouse.  
Finally, there is a unique use pattern when user needs only transcription factor displayed for each 
GWAS-QTL pair. A separate check box is created to accommodate this use case.  
The browser interface is created as Figure 6.2.  
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Figure 6. 2 web-interface overview 
The web-interface. Part A: selection interface allows user to choose source disease and eQTL, specify the number of 
genes with most significant association to display, and choose whether only transcription factors be displayed. Part 
B: gene list generated for the selection.  
After user makes a selection, a list of genes will be displayed for each GWAS-QTL pair.  The 
GWAS_QTL pair is named in the format disease---tissue(GWAS---QTL) where disease 
corresponds to GWAS and tissue corresponds to QTL origin. By default, 30 genes with the most 
significant gene-phenotype p-value are displayed. The gene list is sorted in alphabetic order and 
color coded for gene-phenotype association p-value, more intensive color for more significant p-
value. The exact association statistics can be inspected once cursor is hovered over the gene-
disease association box.  
(A)
(B)
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Recall we need an Sherlock-Vis to accommodate phenotype combination rather than individual 
GWAS-QTL pair. To meet this need, Sherlock-Vis allows multiple GWAS-QTL pairs be 
displayed in the same plot as a response to multiple selection of source diseases as shown in 
Figure 6.3.  The set of genes to display are the union of top genes from all GWAS-QTL pairs. A 
black box indicates that the gene-disease association is not available. This way it is easy to 
compare a gene’s association with multiple phenotypes. For example, search for genes 
significantly associated with multiple phenotypes.  
One recurrent search pattern for multiple disease-QTL pairs is enrichment study. Specifically, 
test whether genes significantly associated with one disease also have significant association 
with another disease.  To address this need, Sherlock-Vis provides sorting function by clicking 
the target GWAS-QTL pair as shown in Figure 6.3. The gene list for all GWAS-QTL pairs will 
be reordered in the increasing order of gene-disease association p-value for target GWAS-QTL 
pair.  
Similarly, it is fair to look for enrichment of diseases given a target gene. Sherlock-Vis provides 
sorting function by clicking the target gene as shown in Figure 6.3. The GWAS-QTL pairs will 
be reordered in the increasing order of gene-disease association p-value for target gene.  
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Figure 6. 3 multiple phenotypes on web-interface and sorting 
 (A) Multiple phenotype-eQTL pairs are displayed, gene set are the union of top 30 for each phenotype-eQTL pair, 
genes not displayed in Figure6.3 can be viewed by scrolling to the right by mouse. (B) gene list can be sorted with 
respect to a chosen phenotype-eQTL pair by clicking on the pair name. In this example, gene list is sorted by the 
second phenotype-eQTL pair, ALZHEIMER[PUBMED:21460841]---Lymphoblastoid (ADGC_2011_adj_stage1---
Dixon_07) .  
6.1.2. Browse SNPs supporting gene-phenotype associations 
SNPs provides quantitative evidence supporting gene-disease association. Given Sherlock-II’s 
capability of integrating influence from trans-SNP and SNP with mediocre association strength, 
it will be helpful to visualize all supporting SNPs for a target gene-disease association.  
To meet this need, Sherlock-Vis provides separate plots to visualize GWAS SNPs, eQTL SNPs 
and their alignment relation. User can select a target gene to plot by right click the gene name in 
gene list of a GWAS-QTL pair (chosen gene will turn green to indicate selection). Clicking the 
“draw Manhattan plots” button will initiate a search for all SNPs supporting the gene-disease 
association.  
The Manhattan plots are drawn for GWAS and QTL separately but using the same x-axis scale to 
facilitate alignment inspection. For both case, x-axis are chromosomes. Y-axis indicates 
association strength on the log scale because otherwise the difference between significant 
association statistics will be hard to tell. For SNP-GWAS associations, the y-axis is capped at 
global significance level 1E-8 so that any SNP with a more significant p-value can be truncated 
Click to sort
(B)
(A)
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to 1E-8 without losing information for the purpose of inspecting SNP’s support for gene-disease 
association. Similarly, Y-axis is capped in a similar way. When Manhattan plot is drawn for only 
one gene, the GWAS SNPs are drawn as black dots while QTL SNPs are drawn as blue squares. 
Gene location on the genome is indicated by a blue vertical line.   
While inspecting supporting SNPs on a genome level gives a global idea of all SNPs, it is 
necessary to inspect SNPs on a local scale for more details. For example, Sherlock-II allows SNP 
alignment by LD so a GWAS SNP and eQTL SNP can be aligned and possess different locations 
on the same chromosome. Such detail can only be viewed within a small range of genome. To 
accommodate for this need, Sherlock-Vis support zooming function along the x-axis. User can 
use the mouse scroll wheel as shown in Figure 6.4. On a small scale, the vertical blue line 
indicating gene location transformed into a blue square with both ends indicating location of first 
nucleotide of first exome and last nucleotide of last exome of the target gene, as shown in Figure 
6.4.  
While inspecting supporting SNPs on global and local scale provides qualitative information, 
quantitative details are also embedded in Sherlock-Vis. Recall Sherlock-II identified genes does 
not have to be the closest gene to GWAS SNP. For the purpose of comparison, Sherlock-Vis 
calculates the closest gene for each SNP and display this information once cursor is hovered over 
the target SNP. Together displayed also include the exact SNP-GWAS or SNP-QTL p-value on 
log scale and aligned GWAS SNP when cursor is hovered over an eQTL SNP. 
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Figure 6. 4 Manhattan plot on web interface 
Manhattan plot showing aligned SNPs supporting gene ADAM15’s association with Alzheimer’s disease. (A) 
Target gene is colored green to indicate selection. (B) Target gene’s Manhattan plot consists of two halves, each 
having x-axis as chromosome. The top half has y-axis as GWAS p-value on log scale for each GWAS SNPs, 
indicated by black dots. The bottom half has y-axis as eQTL p-value on log scale for each eQTL SNP, indicated by 
blue squares. A color bar indicates gene location on the genome scale (in this example it is drawn on chromsome 1 
due to target gene ) (C-D) zoom-in view for the aligned SNPs can be achieved by the mouse wheel, SNP detail can 
be inspected by hovering over the SNP indicator(black dots for GWAS and blue square for eQTL). 
(A)
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Multiple genes, if simultaneously associated with the same phenotype, provide better evidence 
for the underlying mechanism. For example, existing knowledge such as gene ontology can be 
employed to explain the target phenotype. To provide genetic support for such multi-gene 
evidence, Sherlock-Vis allows the user to plot Manhattan plots for multiple genes at the same 
time as shown in Figure6.5. In the GWAS Manhattan plot panel, SNP sets supporting individual 
genes are united into one set. Multiple lines indicating gene location are plotted and color coded. 
In the eQTL Manhattan plot panel, SNPs supporting each gene are plotted separately with 
different color.  
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Figure 6. 5 Manhattan plot for multiple genes on web interface 
Manhattan plot showing aligned SNPs supporting gene ADAM15, BIN1 and BNC1. (A) Target genes are colored 
green to indicate selection. (B) GWAS SNPs supporting all genes are plotted in the same panel. (C) eQTL SNPs of 
gene ADAM15 is plotted in blue color. (D) eQTL SNPs of gene BIN1 is plotted in cyan color. (E) eQTL SNPs of 
gene BNC1 is plotted in orange color. 
Sherlock-II calculate gene-disease association statistics based on a subset of eQTL SNPs that 
align with GWAS SNP and are independent of each other. The independence here is defined by 
LD score of 0.2, specifically any two eQTL SNPs with LD score larger than 0.2 are considered 
(A)
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dependent and only one of them will be chose as tag SNP in subsequent calculation, the other 
SNPs are treated as untagged SNPs. The chosen one has the most significant influence on target 
gene expression.  
It can be interesting to look at not only tag eQTL SNps, but also untagged eQTL SNPs as an 
intuitive inspection of Sherlock-II workflow. Sherlock-Vis is capable to reproduce Sherlock-II’s 
entire alignment process as shown in Figure 6.6.  
By selecting the untagged checkbox, untagged eQTL SNPs will be drawn besides tag eQTL 
SNPs by unfilled squares just like tag eQTL SNPs. All the details such as association statistics 
and nearest gene are included as well. The only difference between untagged and tag eQTL 
SNPs are their shape, indicating untagged eQTL SNPs do not contribute to gene-disease 
association calculation. Their corresponding aligned GWAS SNPs will be drawn as unfilled 
circles as shown in Figure 6.6.  
Sherlock-II calculates gene-disease association first selecting a subset of GWAS SNPs that also 
influence target gene’s expression. It then compares this subset of GWAS SNPs’ p-values with 
all GWAS SNPs’ p-value.  A gene will have a significant association statistics if its subset of 
GWAS SNPs are highly enriched for significant GWAS p-values. Given this background, it 
could be straightforward if the comparison can be displayed. Sherlock-Vis satisfy this need by 
allowing all GWAS SNPs and eQTL SNPs for the target gene to be displayed at the same time. 
Similar to displaying untagged eQTL SNPs, target gene’s subset of GWAS SNPs are solid 
circles while the other are unfilled circles as shown in Figure 6.6. A GWAS p-value threshold is 
enforced to filter out too weak GWAS signal which can be noise. The default threshold is set as 
p-value 1E-3.  
 53 
 
Figure 6. 6 unaligned and untagged supporting SNPs on web interface 
(A)
(B)
(C)
(D)
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However, Sherlock-II do this in a step-wise manner and include all eQTL SNPs that in LD with 
other eQTL SNPs  
 
The Model part is supported by MySQL database storing SherlockII computed IMT-phenotype 
association and the supporting SNPs. Multiple schemas divide the whole logic into tables linked 
to each other through 
6.1.3. Database models 
The Model part is supported by MySQL database storing SherlockII computed IMT-phenotype 
association and the supporting SNPs. Multiple schemas divide the whole logic into tables linked 
to each other through foreign keys. The most important two tables are named gene_fields and 
metabolite_fields which stores IMT-phenotype association including the source GWAS, 
eQTL/metabolite-QTL and the association p-value and Q-value. The gene_fields table and its 
supporting tables are shown in figure 6.7. Metabolite_fields table has the same schema. 
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Figure6. 7 database schema 
Data base schema for gene-phenotype association. (A) The main table gene_fields stores source GWAS, eQTL 
information and the associated gene and association statistics. (B) Supporting SNPs are stored in table 
gene_SNP_fields, linked to table gene_fields through foreign key gene_fields_id (C) GWAS’s phenotype annotation 
and eQTL’s tissue origin is stored in separate tables.  
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7. Partially completed Attempts and future 
directions 
7.1. Allele direction 
Motivation 
Sherlock-II identifies IMT-disease association by summarizing the supporting SNPs’ p-values. It 
will also be interesting to inspect individual SNP’s direction. An example question to ask is 
whether minor allele of all SNPs supporting the same IMT are influencing its 
expression/concentration in the same direction? For example, if the minor allele of three SNPs 
supporting the same metabolite-disease association all reduces the metabolite’s concentration 
and increases disease risk, more confidence will we have to conclude that decreased metabolite 
concentration will increase disease risk. Inference like this will be useful in the design of clinical 
intervention and could also help refine our hypothesis of disease etiology.  
Current discovery 
In a pilot study, I have detected SNP consistency supporting guanidinoacetate’s association with 
chronic kidney disease. This association is supported by three SNPs rs7969761, rs10519022 and 
rs10519022. Specifically, A/T allele on rs7969761 reduces CKD risk and reduces 
guanidinoacetate concentration, A/T allele on GWAS SNP rs10519022 increases CKD risk and 
A/T allele on its aligned mQTL rs1153854 increases guanidinoacetate concentration, A/T allele 
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on GWAS SNP rs8101881 reduces CKD risk and A/T allele on its aligned mQTL rs10418164 
reduces guanidinoacetate concentration.  
 
Figure 7. 1 SNP direction 
three SNPs on three different chromosomes are modulating the gene expression level consistently and influencing 
disease risk at the same direction. 
Method in the pilot study 
The SNP consistency supporting guanidinoacetate’s association with chronic kidney disease is 
discovered by first applying statistical filtering on supporting SNPs. Sherlock-II integrates 
multiple aligned GWAS SNPs together to generate gene/metabolite score, the majority of which 
have weak p-values. Although meaningful in aggregate, GWAS SNPs with weak p-value are 
vulnerable to statistical noise when considered individually. Thus it is only safe to consider 
GWAS SNPs with mediocre to significant p-values. Following this logic, I first set a mediocre 
statistical threshold for GWAS SNP’s p-values (1E-3).  In the example shown in Figure 7.1, such 
a GWAS SNP threshold excludes most supporting SNPs but does not affect the few 
comparatively significant ones. Applying this filtering step on all significant gene/metabolite-
phenotype associations reduces the number of potentially interesting SNPs greatly which makes 
manual inspection a manageable task. 
 
GWAS SNPs of Chronic Kidney Disease
mQTL SNPs of guanidinoacetate
(A)
(T) (A)
(A)
(T)
(A)
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Points to improve 
A complete consistency like Figure 7.1 is rare. In most cases, a majority but not one hundred 
percent of supporting SNPs have the same allelic direction. A statistical interpretation is needed 
to explain and benefit from such incomplete consistency. Once designed, such statistical 
interpretation can also help inspecting individual SNP after the SNP-level filtering and replacing 
the still-time-consuming manual inspection on individual SNPs.  
7.2. eQTL Mechanism  
Motivation 
eQTL dataset provides the experimental observation of SNP-gene expression association, but 
does not provide the association mechanism, especially the eQTL SNPs that are far away from 
gene coding region. How can these variant influence a remote gene’s expression? Such 
mechanism, once known, will provide more detail about disease etiology and further our 
understand. It will also reduce the risk of eQTL SNP expression associations being statistical 
noises and make Sherlock-II prediction more reliable.  
Current discovery 
To elucidate the eQTL mechanism, I collaborate with Shen lab in UCSF where they conduct 
promoter capture HiC experiment. The basic idea is that a eQTL SNP influences remote gene 
expression by falling into an enhancer region and affect target gene expression through 
promoter-enhancer interactions, or from random polymer looping, where undirected physical 
motion of chromatin causes loci to collide.  
Using promoter capture data from Shen lab, I have detected triple alignment among GWAS, 
eQTL and promoter capture datasets. One such triple alignment contains a SNP that falls in a 
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promoter capture enhancer/promoter region, being itself a eQTL SNP and also influence disease 
risk. The triple alignment was done using 445 GWAS datasets, 8 eQTL datasets and 7 promoter 
 capture datasets including astrocyte, excitatory, hippocampal region and fetal interneuron, fetal 
inferior parietal lobule, fetal neuron, fetal Retinal ganglion cells. The triple alignment results 
cover all 88 diseases.  
We can try to explain disease etiology by combining eQTL-promoter capture mapping with 
Sherlock-II results. In the case when an eQTL SNP align influences disease risk and also gene 
expression through promoter capture, we can hypothesize the SNP influences disease risk by first 
influencing gene expression in the enhancer-promoter interaction fashion, then the altered gene 
expression increases/decreases disease risk.  
Method in the pilot study 
The promoter capture dataset from Shen lab consist of pairs of chromosome segments that 
interact with each other. Each end of the pair consists of chromosome, chromosome start and 
chromosome end. At least one half of a pair is a gene promoter region while the other end can be 
a remote enhancer region or another promoter region. 
One SNP-gene association provided by eQTL dataset is mapped to multiple promoter-capture 
associations because one gene can have multiple transcription start sites. For a given gene, I 
include all promoter capture pairs whose promoter region falls within a few kilo base pairs away 
from each of transcription start site as shown in Figure 7.2. 
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Figure 7. 2 promoter enhancer interaction 
 
Points to improve 
It will be interesting to investigate the proportion of eQTL SNPs explained by promoter capture 
data. We can also compare Sherlock-II results supported by eQTL SNPs explained by promoter 
capture data and the rest. For example, do Sherlock-II results supported by eQTL SNPs 
explained by promoter capture data have a less significant association statistic than the other? 
Answer to this question can be positive because the majority of eQTL SNPs explained by 
3kb from TSS 3kb from TSS
TSS 1 TSS 2 SNPgene
gene SNP SNP_bait TSS1 TSS1_promoter_1
gene SNP SNP_bait TSS1 TSS1_promoter_2
gene SNP SNP_bait TSS1 TSS1_promoter_3
gene SNP SNP_bait TSS2 TSS2_promoter_1
gene SNP SNP_bait TSS2 TSS2_promoter_1
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promoter capture data are expected to be trans-eQTL and harbor a less significant influence on 
gene expression level.  It will be equally interesting to look for disease enrichment in the result 
subset explained by promoter capture data. For example, enrichment of neural disease in the 
portion explained by promoter capture dataset, if identified, will provide detailed genetic 
evidence of both the underlying etiology and genetic similarity across multiple neural diseases. 
It will also be interesting to look for eQTL mechanism other than promoter capture. One 
promising type of functional dataset is methylation where methylation of the base altered the 
proximity of binding proteins and influence gene expression. One particular advantage of the 
methylation dataset is its classification of association by tissues which match eQTL well. For 
example, the roadmap epigenomics consortium have mapped more than 100 tissues and cells 
types[89]. Such a rich collection of source tissue will allow fine mapping between eQTL and 
methylation datasets. At the same time, it is worth mentioning epigenomics dataset’s caveat that 
methylation datasets do not provide high resolution on the genome scale. Biologically, multiple 
proximal nucleotides can be affected by the same methylation modification, making it hard to 
differentiate individual SNP when explaining eQTL datasets.   
7.3. Dimension reduction 
Motivation 
Comparing phenotype similarity using more than 20,000 genes is possible but less intuitive 
comparing with the alternative if we can extract the most important few features for each 
phenotype. In the extreme case where we can use two aggregate pseudo-gene to represent 20,000 
genes, the 88 phenotypes can be drawn on a two dimensional surface. This way phenotype 
similarity can be inspected visually. 
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Method in the pilot study 
Principle Component Analysis(PCA) is a widely used dimension reduction technique. The 
intuition is to project each phenotype vector in the input gene-phenotype association matrix onto 
its eigenvectors. By definition, such projection will decompose input onto multiple orthogonal 
dimensions with the first dimension capturing the most variance, the second dimension capturing 
the second most variance … One particular convenient feature of PCA is that the variance 
captured by each orthogonal dimension is the eigenvalue in the process of eigen-decomposition. 
In this way we can visualize the reducing trend of variance explained by each dimension and 
dimension reduction can be achieved when the first few dimensions explains the majority of toal 
variance. For example, if the first 2 dimensions explain 95% of the total variance in a four 
dimensional dataset, we can safely reduce each data point in the original data set from four 
dimension to 2 dimension. 
Our gene-phenotype association matrix is composed of 69 phenotypes and 21892 genes. 
Applying PCA on this association matrix gives 68 principle components because the number of 
principle components is bounded by the minimum of phenotypes and genes.  
Unfortunately, the first few dimensions do not represent the majority of input variances as shown 
in Figure 7.3. The first two principle components explain less than 7 percent of the total variance 
which makes it inappropriate to discard the other  dimensions because doing so will lose too 
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much information.
 
Figure 7. 3 PCA percentage variance 
percent of variance explained by PCA principle components. The x-axis is principle component 1 to principle 
component 68, y-axis is percentage of variance explained.   
Points to improve 
Because the first few principle components do not explain the majority of variance, dimension 
reduction in this case will lose much information. Further exploration of data preprocessing is 
needed in order to allow PCA to function well in dimension reduction. For example, Shelrock-II 
outputs gene/metabolite-phenotype association p-values and by far they are transformed into log 
scale for visual inspection of extreme small p-values. There may exist other p-value 
transformations that provides clear separation of extreme small p-values but at the same time 
offer a better dimension reduction potential.  
One transformation other than log scale transformation is called inverse normal transformation 
where p-value are assumed to be the complement of cumulative probability function of a hidden 
normal variable. In this way, a p-value 0.5 is mapped to z-score of 0, a p-value 0.001 is mapped 
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to 3.090232 because the probability for a standard normal variable to take value at least 
3.090232 is 0.001. 
Comparing with log scale transformation, the inverse normal transformation provides the same 
resolution for the region between 0.00051 and 0.30106 but provides better resolution for the less 
significant region 0.02742 to 0.30106 as shown in Figure 7.4. This will help differentiating 
significant versus non-significant p-values. Another difference lies for the region between 0.5 
and 1 which are all mapped to 0 in inverse normal transformation numerically. This mapping 
does not result in a loss of information for the purpose of clustering because nothing within this 
region is considered significant associations.   
 
Figure 7. 4 logarithm and inverse normal transformation 
Comparison between log scale transformation(green) and inverse normal transformation(red).  
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7.4. More phenotype connection supported by gene ontology terms 
Motivation 
Figure 3.2 gives the phenotype hierarchical clustering results and we investigate the gene 
ontology terms supporting subtrees. However, not all phenotype connections are captured by the 
hierarchical clustering algorithm, especially local similarity defined by a subset of genes (for 
example GO terms). For example, connection between schizophrenia and height has been 
reported in epidemiological study but they are not placed adjacent to each other in hierarchical 
clustering. A further investigation of this phenotype pair reveals GO terms supporting this 
connection. This proves that phenotype pairs not adjacent to each other in the hierarchical 
clustering result can have local similarities supported by GO terms. 
Current discovery 
The first three Go ontology terms supporting schizophrenia and height are positive regulation of 
myoblast proliferation (zscore 19.7) magnesium ion homeostasis (zscore 13.3) and negative 
regulation of megakaryocyte differentiation (zscore 13.2). Reduced level of magnesium level is 
observed in schizophrenia patients[90], thus directly link to schizophrenia. Meanwhile, 
magnesium ion influences height through muscle tissue that magnesium bind competitively to 
calcium ion binding sites and thus participates in the regulation of muscle contraction[91]. 
Similarly, literatures support megakaryocyte’s influence on both schizophrenia and height that 
megakaryocyte controls the biogenesis of platelet[92] and altered platelet physiology has been 
observed in schizophrenia[93].  Megakaryocyte is associated with height by serving as a 
regulator of bone marrow homeostasis and physiology[94]. 
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In order to detect more phenotype connections, I find the three most similar phenotypes for each 
phenotype by comparing their gene association profile. The three most similar phenotypes to 
height are as pubertal growth late adolescence, osteoporosis and fasting glucose.  The top GO 
terms supporting each phenotype pair are consistent with phenotypes that the first GO term 
connecting height with pubertal growth late adolescence is chondroblast differentiation which is, 
by definition, related to bone physiology. The first GO term connecting height with osteoporosis 
is glucose-6-phosphate transport, linking osteoporosis to the third most similar phenotype fasting 
glucose. The top first GO term linking height and fasting glucose, insulin receptor substrate 
binding, gives more mechanistic evidence on a finer granularity. 
In seek of more interesting GO terms linking seemingly unrelated phenotypes, I find one GO 
term, positive regulation of telomere maintenance via telomere lengthening, linking Alzheimer’s 
disease, bipolar disorder, glioma and longevity as shown in Figure 7.1. 
Table 7. 1 telomere maintenance connecting 5 phenotypes  
 
('Alzheimer[pubmed
:21460841]', 
'Alzheimer[pubmed:
25188341]')
('Alzheimer[pubmed
:21460841]', 
'Longevity[pubmed:
24688116]')
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lipoprotein particle 
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receptor-mediated 
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hormone receptor 
binding(8.5) rna transport(10.8)
receptor-mediated 
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host cell(13.5)
neurotransmitter 
transport(10.0)
regulation of brown 
fat cell 
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integral component 
of postsynaptic 
specialization 
membrane(9.3) dna protection(6.8)
positive regulation 
of telomere 
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telomere 
lengthening(12.7)
2th GO term
cdc73/paf1 
complex(10.1)
positive regulation 
of histone h4 
acetylation(14.2)
positive regulation 
of telomere 
maintenance via 
telomere 
lengthening(5.6)
nerve growth factor 
binding(9.3)
positive regulation 
of sensory 
perception of 
pain(10.3)
creatine kinase 
activity(7.6)
choline 
transmembrane 
transporter 
activity(5.5)
negative regulation 
of epidermal growth 
factor-activated 
receptor activity(8.0)
cardiac muscle cell 
development(5.2)
regulation of cellular 
response to 
stress(8.4)
3th GO term
positive regulation 
of telomere 
maintenance via 
telomere 
lengthening(9.5)
epsilon dna 
polymerase 
complex(10.6)
transmembrane 
receptor protein 
tyrosine phosphatase 
activity(5.6)
positive regulation 
of telomere 
maintenance via 
telomere 
lengthening(7.4)
dna repair 
complex(9.0)
replication fork 
protection 
complex(6.8)
t cell 
chemotaxis(4.9)
anterior commissure 
morphogenesis(6.5)
glycerolipid 
metabolic 
process(5.2) spectrin(6.4)
4th GO term dsrna transport(7.1) torc1 complex(6.5)
bitter taste receptor 
activity(5.4)
diacylglycerol 
kinase activity(6.7)
positive regulation 
of telomere 
maintenance via 
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sphingomyelin 
metabolic 
process(6.6)
trna splicing, via 
endonucleolytic 
cleavage and 
ligation(4.9)
macrophage 
activation involved 
in immune 
response(6.4)
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transmembrane 
transporting atpase 
activity(4.8)
positive regulation 
of transcription 
initiation from rna 
polymerase ii 
promoter(6.2)
5th GO term
cerebellar purkinje 
cell 
differentiation(7.1)
metanephric 
collecting duct 
development(6.5)
maintenance of cell 
polarity(5.2) fucose binding(6.5)
carbohydrate:proton 
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activity(8.8)
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natural killer cell 
mediated 
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of coagulation(6.3)
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Alzheimer                 [PMID: 27312549] Telomere Shortening in Alzheimer's Disease Patients
Telomere-phenotype literatures:
Longevity                 [PMID: 24350925] Telomeres and their role in aging and longevity
Glioma                       [PMID: 26014050] Telomere maintenance and the etiology of adult glioma
Bipolar Disorder     [PMID: 28621334] Telomere Length and Bipolar Disorder
(A)
(B)
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Telomeres are DNA-protein structures that form protective caps at the end of eukaryotic 
chromosomes. Accelerated rate of telomere shortening has been observed in Alzheimer’s disease 
patients[95]. Multiple evidences has linked telomere biology to aging and mechanism leading to 
longevity[96]. Telomere maintenance has been identified as an important role in glioma 
susceptibility, initiation, and prognosis[97] Shortened telomere length is associated with familial 
risk for bipolar disorder[98]. 
Method in the pilot study 
Computing the three most similar phenotypes for a chosen target phenotype is straightforward 
but there exist caveats. It is tempting to choose the three phenotypes from hierarchical clustering 
as three most similar ones. However, hierarchical clustering is history dependent, meaning the 
most similar phenotype to target can be joined earlier due to a smaller distance to a third 
phenotype. For this reason, the three most similar phenotypes to target phenotype need to be 
calculated separately.  
On the contrary, finding GO term linking multiple phenotypes involves multiple steps. This 
cannot be easily completed due to the large number (more than 7000) of GO terms for each 
phenotype pair and the exponential number of phenotype combinations ( it is the power set of all 
phenotypes which scale to 2Wg ) 
In order to find GO term linking multiple phenotypes in a feasible time scale, I divided the 
searching process in two steps. First search for any candidate GO terms that link target 
phenotype with the most other phenotypes. Second validate the candidate GO terms across 
phenotype combinations.  
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In the first step, I start seeking GO term candidate by choosing a target from the 69 phenotypes 
and a zscore threshold (set to zscore 4 by default). Then all GO terms associating the target 
phenotype with all other 68 phenotypes are sorted by number of phenotypes pairs passing the 
threshold. For example, the GO term connecting the most phenotypes with glioma passing zscore 
threshold is positive regulation of telomere maintenance via telomere lengthening. This GO 
terms connects glioma with 6 phentoypes (bipolar disorder, Crohn’s disease, ever smoked, 
depressive, ulcerative colitis and Alzheimer’s disease). The GO term connecting the second most 
phenotypes with glioma passing zscore threshold is flavonoid glucuronidation, associating 
glioma with 4 phenotypes (acute lymphoblastoid leukemia, cholesterol, systolic blood pressure 
and high density lipoprotein).  This process is repeated for all phenotypes by choosing each as 
target. At the end of the first step, I have a few GO terms for each phenotype connecting it with 
at least two other phenotypes where the GO terms pass zscore threshold.  
In the second step, I apply several criteria to the top few GO terms of each phenotype. The first 
criterion is the number of phenotypes GO term connecting with the target phenotype. Inspecting 
a GO term that links three phenotypes with target one makes it qualify to pass the first step but 
may not be very promising in linking multiple phenotype together. This criterion makes the 
search process a heuristic rather than algorithm but significantly accelerates the search process. 
The second criterion requires the GO terms to be specific than broad concept. This is necessary 
to ensure GO terms conveys specific physiological process connecting phenotypes. Otherwise, 
we may find a GO term linking multiple phenotypes but not convey information only because 
that GO term is protein binding and thus too broad to further our understanding. GO terms 
satisfying these two criteria is run against all phenotype combinations only the phenotype pairs 
passing the same zscore cutoff set in the first step is kept.  
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Points to improve 
When looking for the three most similar phenotypes for a chosen target phenotype, Euclidean 
distance was used to measure phenotype similarity. Although intuitive, Euclidean distance is 
sensitive to noise accumulated through the dimensions. In our case, weak dissimilarity across the 
twenty thousand genes can contribute to the similarity metric and bias the results. To resolve this 
problem, other distance metric can be attempted which are more robust to dimensionality 
difference. 
One particular solution for the above mentioned defect can be pearson’s correlation coefficient 
which is confined between -1 and 1. Shifting this domain to 0 to 2 gives a well-defined distance 
range and I expect this metric to be robust against small noised from high dimension. 
When looking for GO terms connecting multiple phenotypes together, I applied two criteria to 
reduce the number of candidate GO terms. This process can be biased to my knowledge base and 
susceptible to falsely exclude interesting connection. A parameter-free approach is expected to 
remove this bias and help the search to capture more phenotype connections.  
One particular solution for the above mentioned defect can be a background distribution of GO 
term zscores. Given first few GO terms from each target phenotype that connecting it with at 
least two other phenotypes, the GO terms’ zscore can be collected and used to build a global 
background distribution across all phenotypes. The significant few out of this background zscore 
distribution can be used to choose candidate GO terms for further inspections in a parameter free 
fashion. 
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Appendix 
Metabolite-phenotype associations with Q-value threshold 0.333 
phenotype metabolite p-value Q-value 
ACUTE MYELOID LEUKEMIA nicotinamide 0.00145 0.278 
ACUTE MYELOID LEUKEMIA 1-arachidoyl-GPC(20:0) 0.000417 0.2 
ACUTE MYELOID LEUKEMIA mannose 0.000692 0.2 
AGE RELATED MACULAR 
DEGENERATION 
1-(1-enyl-palmitoyl)-2-palmitoyl-GPC(P-16:0/16:0) 0.000148 0.091 
AGE RELATED MACULAR 
DEGENERATION 
2-arachidonoyl-GPE(20:4) 0.000658 0.141 
AGE RELATED MACULAR 
DEGENERATION 
1-stearoyl-2-linoleoyl-GPC(18:0/18:2) 0.000689 0.141 
AGREEABLENESS N-acetylmethionine 0.000717 0.214 
AGREEABLENESS 3-methylglutarylcarnitine(1) 0.000696 0.214 
ALZHEIMER X-12688 0.000355 0.137 
ALZHEIMER O-sulfo-L-tyrosine 0.000542 0.297 
ALZHEIMER sphingomyelin(d18:2/14:0_d18:1/14:1) 0.00219 0.281 
ALZHEIMER X-17167 0.00299 0.3 
ALZHEIMER N-acetyl-1-methylhistidine 0.00109 0.253 
ALZHEIMER X-24065 0.000661 0.137 
ALZHEIMER N6-carbamoylthreonyladenosine 0.00249 0.329 
ALZHEIMER trans-urocanate 0.00146 0.3 
ALZHEIMER alpha-glutamyltyrosine 0.00198 0.329 
ALZHEIMER 2-hydroxyglutarate 0.0015 0.281 
ALZHEIMER palmitoyldihydrosphingomyelin(d18:0/16:0) 7.38E-05 0.0445 
ALZHEIMER 1-palmitoyl-2-linoleoyl-GPC(16:0/18:2) 0.000963 0.297 
ALZHEIMER X-21628 0.000953 0.137 
ALZHEIMER X-11261 0.00113 0.253 
ALZHEIMER sphingomyelin(d18:1/15:0_d16:1/17:0) 0.00216 0.322 
ALZHEIMER behenoylsphingomyelin(d18:1/22:0) 0.00142 0.285 
ALZHEIMER N-acetylmethionine 0.00277 0.281 
ALZHEIMER 3-methylglutarylcarnitine(2) 0.002 0.308 
ALZHEIMER glycocholenatesulfate 0.00259 0.278 
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phenotype metabolite p-value Q-value 
ALZHEIMER X-24278 0.00268 0.281 
ALZHEIMER 4-androsten-3beta_17beta-diolmonosulfate(2) 0.00327 0.281 
ALZHEIMER sphingomyelin(d18:1/20:0_d16:1/22:0) 0.000812 0.273 
ALZHEIMER 1-arachidonoyl-GPC(20:4n6) 0.00205 0.294 
ALZHEIMER oleoyl-linoleoyl-glycerol(18:1/18:2)[2] 0.00307 0.329 
ALZHEIMER palmitoyl-linoleoyl-glycerol(16:0/18:2)[2] 0.00152 0.281 
ALZHEIMER tryptophanbetaine 0.00134 0.329 
ASTHMA sphingomyelin(d18:1/14:0_d16:1/16:0) 0.00206 0.319 
ASTHMA gulonicacid 0.00125 0.319 
ASTHMA 2-docosahexaenoyl-GPE(22:6) 0.00102 0.319 
ASTHMA 1-docosapentaenoyl-GPC(22:5n3) 0.00213 0.319 
ATTENTION DEFICIT 
HYPERACTIVITY DISORDER 
2-hydroxybutyrate/2-hydroxyisobutyrate 0.00084 0.293 
ATTENTION DEFICIT 
HYPERACTIVITY DISORDER 
pyroglutamylglycine 0.00141 0.293 
ATTENTION DEFICIT 
HYPERACTIVITY DISORDER 
gamma-glutamylglutamine 0.00114 0.293 
ATTENTION DEFICIT 
HYPERACTIVITY DISORDER 
dodecanedioate 0.00207 0.323 
AUTISM 1-adrenoyl-GPC(22:4) 0.00712 0.309 
AUTISM X-24061 0.00628 0.309 
AUTISM 1_2_3-benzenetriolsulfate(2) 0.000532 0.158 
AUTISM X-21892 0.00195 0.271 
AUTISM X-16071 0.00171 0.292 
AUTISM X-17189 0.000353 0.227 
AUTISM stearoylcarnitine 0.00151 0.249 
AUTISM 1-stearyl-GPC(O-18:0) 0.001 0.297 
AUTISM cholate 0.0012 0.318 
AUTISM 1-palmitoyl-2-meadoyl-GPC(16:0/20:3n9) 0.00355 0.286 
AUTISM X-22147 0.00237 0.305 
AUTISM X-12206 0.0029 0.292 
AUTISM theophylline 0.000235 0.117 
AUTISM 2-palmitoyl-GPC(16:0) 0.00097 0.312 
AUTISM trigonelline(N'-methylnicotinate) 0.00133 0.291 
AUTISM 5alpha-androstan-3beta_17beta-dioldisulfate 0.000694 0.0894 
AUTISM 1-stearoyl-GPE(18:0) 0.00286 0.307 
AUTISM alpha-hydroxyisocaproate 0.000211 0.136 
AUTISM 1-methylhistidine 0.000363 0.158 
AUTISM gamma-glutamylhistidine 0.00292 0.235 
AUTISM X-19141 0.00106 0.3 
AUTISM dehydroisoandrosteronesulfate(DHEA-S) 5.25E-05 0.0169 
AUTISM N-acetylputrescine 0.00159 0.302 
AUTISM pregnsteroidmonosulfate 0.00262 0.315 
AUTISM tiglylcarnitine 0.00277 0.261 
AUTISM margarate(17:0) 0.00271 0.305 
AUTISM 17-methylstearate 0.00154 0.188 
AUTISM X-11850 7.55E-05 0.0427 
AUTISM paraxanthine 0.000631 0.264 
AUTISM oleoylcarnitine 0.000502 0.151 
AUTISM caproate(6:0) 0.00196 0.307 
AUTISM dihydroorotate 0.00248 0.228 
AUTISM methylglucopyranoside(alpha+beta) 0.0019 0.332 
AUTISM X-11308 1.80E-05 0.0104 
AUTISM proline 0.00104 0.318 
AUTISM 5alpha-pregnan-3beta_20alpha-diolmonosulfate(2) 0.00134 0.258 
AUTISM 2-palmitoleoyl-GPC(16:1) 0.00119 0.127 
AUTISM citrate 0.0015 0.286 
AUTISM 1-stearoyl-2-arachidonoyl-GPI(18:0/20:4) 0.0011 0.249 
AUTISM arachidate(20:0) 0.00176 0.209 
AUTISM N1-methyladenosine 0.00296 0.272 
AUTISM X-24241 0.00671 0.309 
AUTISM androsteroidmonosulfate(1) 0.000454 0.073 
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AUTISM X-11540 0.00226 0.272 
AUTISM creatinine 0.000377 0.227 
AUTISM 4-acetylphenolsulfate 0.000661 0.195 
AUTISM X-11905 0.00201 0.292 
AUTISM pseudouridine 0.000416 0.261 
AUTISM taurodeoxycholate 0.000187 0.0602 
AUTISM X-15728 0.00181 0.286 
AUTISM X-24435 0.00159 0.209 
AUTISM kynurenine 0.00111 0.303 
AUTISM phosphatidylcholine(18:0/20:5_16:0/22:5n6) 0.00171 0.271 
AUTISM sphingomyelin(d18:1/20:0_d16:1/22:0) 0.000419 0.27 
AUTISM bilirubin(Z_Z) 0.00108 0.33 
AUTISM 4-androsten-3beta_17beta-diolmonosulfate(1) 0.00111 0.251 
AUTISM X-23782 0.00176 0.249 
AUTISM androsteronesulfate 0.000226 0.145 
AUTISM X-11787 0.00153 0.305 
AUTISM dimethylglycine 0.000335 0.216 
AUTISM 2-methylcitrate/homocitrate 0.00159 0.249 
AUTISM N-acetylglutamine 0.000352 0.0833 
AUTISM palmitoyl-linoleoyl-glycerol(16:0/18:2)[1] 0.000111 0.0672 
AUTISM succinylcarnitine 0.00112 0.307 
AUTISM 1-palmitoyl-2-arachidonoyl-GPE(16:0/20:4) 0.00062 0.302 
AUTISM propionylglycine 0.00313 0.286 
AUTISM X-12822 0.0016 0.297 
AUTISM homocitrulline 1.47E-06 0.000932 
AUTISM X-14056 0.00164 0.242 
AUTISM DSGEGDFXAEGGGVR 0.00149 0.3 
AUTISM 1-palmitoyl-2-palmitoleoyl-GPC(16:0/16:1) 0.00273 0.292 
AUTISM tryptophanbetaine 0.00225 0.307 
AUTISM 1-linoleoyl-GPC(18:2) 0.00132 0.251 
AUTISM X-12007 0.0027 0.272 
AUTISM 1-palmitoyl-2-linoleoyl-GPC(16:0/18:2) 5.11E-05 0.0169 
AUTISM epiandrosteronesulfate 0.000418 0.0833 
AUTISM 5-hydroxyindoleacetate 0.00254 0.307 
AUTISM biliverdin 0.00242 0.312 
AUTISM gamma-glutamyl-epsilon-lysine 0.000681 0.271 
AUTISM beta-alanine 0.00107 0.31 
AUTISM X-15469 0.000691 0.33 
AUTISM alpha-glutamylglycine 9.38E-05 0.0604 
AUTISM 1-methylurate 0.000897 0.332 
AUTISM 2-isopropylmalate 0.00162 0.331 
AUTISM 1-palmitoyl-2-docosahexaenoyl-GPE(16:0/22:6) 0.00159 0.233 
AUTISM C-glycosyltryptophan 0.000396 0.233 
AUTISM 16a-hydroxyDHEA3-sulfate 0.000131 0.028 
AUTISM palmitoylcarnitine 0.001 0.331 
AUTISM eicosapentaenoate(EPA;20:5n3) 0.00339 0.223 
AUTISM 3-aminoisobutyrate 0.00181 0.216 
AUTISM glycerol3-phosphate 0.00149 0.271 
AUTISM pregnenolonesulfate 7.04E-05 0.0454 
AUTISM imidazolelactate 0.00589 0.309 
AUTISM dihomo-linolenate(20:3n3orn6) 0.00153 0.318 
AUTISM 1_2-dimyristoyl-GPC(14:0/14:0) 0.000456 0.294 
AUTISM X-23026 0.000254 0.148 
AUTISM N-acetyl-1-methylhistidine 0.00181 0.307 
AUTISM fumarate 0.0049 0.316 
AUTISM nonanoylcarnitine 0.0012 0.0984 
AUTISM 21-hydroxypregnenolonedisulfate 0.000616 0.13 
AUTISM tryptophan 0.00183 0.242 
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AUTISM X-15503 5.51E-05 0.0355 
AUTISM behenoylsphingomyelin(d18:1/22:0) 0.000133 0.0695 
AUTISM X-21365 0.00207 0.261 
AUTISM X-01911 0.00435 0.248 
AUTISM N-acetylhistidine 0.00286 0.307 
AUTISM 4-androsten-3alpha_17alpha-diolmonosulfate(3) 0.00274 0.176 
AUTISM stearoylsphingomyelin(d18:1/18:0) 0.00279 0.235 
AUTISM 4-androsten-3beta_17beta-diolmonosulfate(2) 0.00115 0.204 
AUTISM xanthine 0.00211 0.296 
AUTISM 10-undecenoate(11:1n1) 0.000843 0.255 
AUTISM X-23639 0.00107 0.303 
BIPOLAR DISORDER 1-palmitoyl-2-meadoyl-GPC(16:0/20:3n9) 0.000406 0.23 
BIPOLAR DISORDER ergothioneine 8.01E-05 0.0484 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
imidazolepropionate 0.00159 0.273 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
X-11880 0.00221 0.284 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
methioninesulfone 0.000244 0.149 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
X-11441 4.34E-05 0.0223 
BODY MASS INDEX trigonelline(N'-methylnicotinate) 0.000235 0.11 
BODY MASS INDEX 2-isopropylmalate 0.00115 0.171 
BODY MASS INDEX 1-myristoylglycerol(14:0) 0.00135 0.171 
BODY MASS INDEX 3-hydroxypyridinesulfate 0.00146 0.171 
BREAST CANCER sulfate 9.21E-05 0.0584 
CHOLESTEROL oleoyl-linoleoyl-glycerol(18:1/18:2)[1] 0.00139 0.14 
CHOLESTEROL 2-linoleoyl-GPE(18:2) 0.000711 0.0799 
CHOLESTEROL X-24061 0.00242 0.18 
CHOLESTEROL X-24278 0.0002 0.0643 
CHOLESTEROL 1-stearoyl-2-linoleoyl-GPI(18:0/18:2) 0.000507 0.0799 
CHOLESTEROL palmitoleoyl-oleoyl-glycerol(16:1/18:1)[2] 0.000745 0.0799 
CHOLESTEROL thyroxine 0.00294 0.21 
CHOLESTEROL 1-palmitoleoyl-2-linoleoyl-GPC(16:1/18:2) 0.00503 0.27 
CHOLESTEROL 2-arachidonoyl-GPE(20:4) 9.36E-05 0.0603 
CHOLESTEROL 1-linolenoylglycerol(18:3) 0.000965 0.148 
CHOLESTEROL 1-methylurate 0.00359 0.21 
CHOLESTEROL 2-linoleoyl-GPC(18:2) 0.00466 0.245 
CHOLESTEROL 1-dihomo-linolenoyl-GPE(20:3n3or6) 0.00107 0.14 
CHOLESTEROL 1-palmitoyl-2-stearoyl-GPC(16:0/18:0) 0.00155 0.111 
CHOLESTEROL 1-stearoyl-2-arachidonoyl-GPI(18:0/20:4) 0.000333 0.138 
CHOLESTEROL 1-linoleoyl-GPE(18:2) 0.000175 0.0563 
CHOLESTEROL 1-oleoylglycerol(18:1) 0.00127 0.148 
CHOLESTEROL X-24241 0.00439 0.257 
CHOLESTEROL 1-palmitoyl-2-oleoyl-GPE(16:0/18:1) 0.00252 0.18 
CHOLESTEROL 1-palmitoyl-2-arachidonoyl-GPI(16:0/20:4) 0.00305 0.196 
CHOLESTEROL 1-palmitoyl-2-dihomo-linolenoyl-GPC(16:0/20:3n3or6) 0.00123 0.111 
CHOLESTEROL dihomo-linolenate(20:3n3orn6) 0.000417 0.0799 
CHRONIC KIDNEY DISEASE pyroglutamine 0.000398 0.0641 
CHRONIC KIDNEY DISEASE quinolinate 0.0022 0.165 
CHRONIC KIDNEY DISEASE 5-hydroxytryptophan 0.00197 0.165 
CHRONIC KIDNEY DISEASE X-21821 0.00476 0.313 
CHRONIC KIDNEY DISEASE hypoxanthine 0.00157 0.165 
CHRONIC KIDNEY DISEASE cyclo(leu-pro) 0.00131 0.165 
CHRONIC KIDNEY DISEASE homocitrulline 4.26E-05 0.00915 
CHRONIC KIDNEY DISEASE gamma-glutamyl-epsilon-lysine 0.00447 0.313 
CHRONIC KIDNEY DISEASE X-11305 0.00114 0.175 
CHRONIC KIDNEY DISEASE 2-aminooctanoate 0.000533 0.165 
CHRONIC KIDNEY DISEASE guanidinoacetate 1.89E-05 0.00609 
CHRONIC KIDNEY DISEASE lactate 0.00243 0.165 
CHRONIC KIDNEY DISEASE 1-(1-enyl-stearoyl)-2-oleoyl-GPC(P-18:0/18:1) 0.0029 0.267 
CHRONIC KIDNEY DISEASE homoarginine 0.000135 0.041 
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CHRONIC KIDNEY DISEASE methioninesulfone 1.50E-05 0.00609 
CHRONIC KIDNEY DISEASE N-acetylhistidine 0.000741 0.165 
CHRONIC KIDNEY DISEASE xanthine 0.000178 0.041 
CONSCIENTIOUSNESS 1-stearoyl-2-oleoyl-GPE(18:0/18:1) 0.000257 0.151 
CONSCIENTIOUSNESS margarate(17:0) 0.00135 0.266 
CONSCIENTIOUSNESS pyridoxate 0.00125 0.266 
CORONARY ARTERY DISEASE 2-hydroxy-3-methylvalerate 0.00253 0.288 
CORONARY ARTERY DISEASE hypoxanthine 0.000273 0.161 
CORONARY ARTERY DISEASE X-12411 0.00251 0.288 
CORONARY ARTERY DISEASE 5-hydroxytryptophan 0.00283 0.288 
CORONARY ARTERY DISEASE X-24125 0.000648 0.191 
CORONARY ARTERY DISEASE xanthine 0.00293 0.288 
CROHN DISEASE carnitine 0.00136 0.284 
CROHN DISEASE 1-stearoyl-2-oleoyl-GPC(18:0/18:1) 0.00143 0.284 
CROHN DISEASE 1-stearoyl-2-docosapentaenoyl-GPC(18:0/22:5n6) 0.000565 0.284 
CROHN DISEASE 1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC(P-16:0/20:4) 0.00253 0.302 
CROHN DISEASE isovalerylcarnitine 0.00289 0.229 
CROHN DISEASE myristoylcarnitine 0.00166 0.229 
CROHN DISEASE alpha-glutamyltyrosine 0.00245 0.229 
CROHN DISEASE 1-stearoyl-2-linoleoyl-GPI(18:0/18:2) 0.00244 0.229 
CROHN DISEASE 1-stearoyl-2-docosapentaenoyl-GPC(18:0/22:5n3) 0.000545 0.151 
CROHN DISEASE stearoylcarnitine 0.00431 0.298 
CROHN DISEASE tryptophanbetaine 0.000528 0.151 
CROHN DISEASE 1-dihomo-linoleoyl-GPC(20:2) 0.0027 0.229 
DIABETES gamma-glutamylalanine 0.00064 0.218 
DIABETES 1-myristoyl-GPC(14:0) 0.00124 0.218 
DIABETES hippurate 0.00155 0.218 
DIABETES pyroglutamylglutamine 0.00117 0.218 
EARLY GROWTH X-18901 0.00145 0.227 
EARLY GROWTH 1-stearoyl-GPI(18:0) 0.00158 0.227 
EARLY GROWTH X-12063 0.00188 0.227 
EARLY GROWTH pseudouridine 0.000235 0.142 
EARLY GROWTH X-23765 0.00058 0.175 
EARLY GROWTH 1-dihomo-linolenoyl-GPC(20:3n3or6) 0.00118 0.289 
EARLY GROWTH 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC(P-16:0/18:2) 0.00269 0.232 
EARLY GROWTH N-acetyltaurine 0.00172 0.289 
EARLY GROWTH 1_2-dimyristoyl-GPC(14:0/14:0) 0.00102 0.289 
EARLY GROWTH X-22147 0.00259 0.232 
EARLY GROWTH oleoyl-linoleoyl-glycerol(18:1/18:2)[2] 0.0018 0.289 
EXTREME_HEIGHT X-11540 0.00332 0.306 
EXTREME_HEIGHT X-11381 0.00198 0.306 
EXTREME_HEIGHT carnitine 0.000708 0.306 
EXTREME_HEIGHT X-12450 0.00262 0.306 
EXTREME_HEIGHT hexanoylcarnitine 0.00297 0.306 
EXTREME_HEIGHT stearoylcarnitine 0.00146 0.306 
EXTREME_HEIGHT octadecanedioate 0.00293 0.306 
FASTING GLUCOSE 1-palmitoyl-2-stearoyl-GPC(16:0/18:0) 0.000809 0.26 
FASTING GLUCOSE 2-arachidonoyl-GPE(20:4) 0.000306 0.197 
FASTING GLUCOSE carnitine 0.000139 0.0757 
GLIOMA X-11787 0.000286 0.14 
GLIOMA X-23026 0.00135 0.282 
GLIOMA imidazolelactate 0.00278 0.282 
GLIOMA 1-methylnicotinamide 0.0018 0.282 
GLIOMA pyroglutamine 0.0028 0.282 
GLIOMA DSGEGDFXAEGGGVR 0.00267 0.282 
GLIOMA X-12729 0.001 0.282 
GLYCATED 
HAEMOGLOBIN(HBA11C) 
lysine 0.000701 0.19 
GLYCATED 
HAEMOGLOBIN(HBA11C) 
1-arachidonoyl-GPI(20:4) 0.00179 0.324 
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GLYCATED 
HAEMOGLOBIN(HBA11C) 
X-17189 0.000222 0.12 
HEIGHT carnitine 0.000366 0.234 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
1-linolenoylglycerol(18:3) 0.00113 0.161 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
1-palmitoyl-GPE(16:0) 0.00288 0.161 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
2-linoleoyl-GPC(18:2) 0.00479 0.315 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
1-palmitoyl-2-oleoyl-GPE(16:0/18:1) 0.00273 0.161 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
2-linoleoyl-GPE(18:2) 0.00144 0.178 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
X-12688 0.0047 0.218 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
1-stearoyl-2-arachidonoyl-GPI(18:0/20:4) 0.0021 0.161 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
1-dihomo-linolenoyl-GPE(20:3n3or6) 0.00118 0.161 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
1-stearoyl-2-linoleoyl-GPC(18:0/18:2) 0.00372 0.189 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
X-24061 0.000629 0.178 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
X-24278 0.0014 0.161 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
2-arachidonoyl-GPE(20:4) 8.41E-05 0.0498 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
1-linoleoyl-GPI(18:2) 0.006 0.257 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
oleoyl-linoleoyl-glycerol(18:1/18:2)[1] 0.00219 0.161 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
1-stearoyl-2-arachidonoyl-GPE(18:0/20:4) 0.00675 0.269 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
xanthine 0.00815 0.303 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
1-palmitoleoyl-2-linoleoyl-GPC(16:1/18:2) 0.00243 0.24 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
1-palmitoyl-2-docosahexaenoyl-GPE(16:0/22:6) 0.00992 0.325 
HIP 2-isopropylmalate 0.000614 0.296 
HIP carnitine 0.00151 0.316 
HIP N6-acetyllysine 0.000603 0.316 
HIP N-acetylputrescine 0.0011 0.296 
HIP N-palmitoylglycine 0.00265 0.332 
HIP 1-methylxanthine 0.00132 0.316 
INSULIN SECRETION X-21341 0.00182 0.321 
INSULIN SECRETION 2-hydroxyglutarate 0.000308 0.185 
INSULIN SECRETION pyroglutamylglutamine 0.00152 0.243 
INSULIN SECRETION ornithine 0.00122 0.321 
INSULIN SECRETION X-21666 0.000799 0.24 
INSULIN SECRETION methioninesulfone 0.00235 0.321 
INSULIN SECRETION X-23644 0.00224 0.321 
INSULIN SECRETION X-12026 0.00417 0.323 
INSULIN SECRETION X-23765 0.00403 0.323 
INSULIN SECRETION mannitol/sorbitol 0.00162 0.243 
JUVENILE ARTHRITIS myristoleoylcarnitine 0.00172 0.3 
JUVENILE ARTHRITIS X-22147 0.00251 0.3 
JUVENILE ARTHRITIS 3-hydroxy-3-methylglutarate 0.00056 0.171 
JUVENILE ARTHRITIS leucylalanine 0.000344 0.171 
JUVENILE ARTHRITIS 3-hydroxyoctanoate 0.00265 0.3 
JUVENILE ARTHRITIS creatinine 0.00295 0.3 
LONGEVITY urea 0.000987 0.212 
LONGEVITY gamma-glutamyltyrosine 0.00164 0.298 
LONGEVITY X-23314 0.000302 0.0973 
LONGEVITY palmitoleoyl-oleoyl-glycerol(16:1/18:1)[2] 0.00111 0.251 
LONGEVITY X-11478 0.000421 0.252 
LONGEVITY cortisol 0.00202 0.261 
LONGEVITY sphingomyelin(d18:1/20:1_d18:2/20:0) 0.0048 0.325 
LONGEVITY glycocholenatesulfate 0.00294 0.251 
LONGEVITY X-24309 8.03E-05 0.0517 
LONGEVITY xanthine 0.00144 0.298 
LONGEVITY X-24242 0.00177 0.251 
LONGEVITY X-11491 0.00311 0.251 
LONGEVITY carnitine 0.000185 0.102 
LONGEVITY 5-hydroxylysine 0.000326 0.17 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
X-24278 0.000172 0.0535 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
1-stearoyl-2-arachidonoyl-GPI(18:0/20:4) 0.000523 0.112 
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LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
1-stearoyl-2-linoleoyl-GPI(18:0/18:2) 0.00137 0.198 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
oleoyl-linoleoyl-glycerol(18:1/18:2)[1] 0.00159 0.198 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
dihomo-linolenate(20:3n3orn6) 0.00328 0.245 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC(P-16:0/20:4) 0.00354 0.245 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
thyroxine 0.00324 0.245 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
1-oleoylglycerol(18:1) 0.000121 0.0535 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
1-palmitoyl-2-stearoyl-GPC(16:0/18:0) 0.000944 0.196 
LUNG CANCER X-21666 0.0003 0.125 
LUNG CANCER gluconate 0.000455 0.149 
METFORMIN 1-stearoyl-2-docosapentaenoyl-GPC(18:0/22:5n6) 0.000237 0.153 
NEUROBLASTOMA p-cresolsulfate 0.000136 0.0849 
NEUROTICISM 5-hydroxylysine 0.00102 0.291 
NEUROTICISM X-11372 0.00117 0.273 
NEUROTICISM 2-aminooctanoate 0.000795 0.291 
NEUROTICISM glycine 0.00119 0.273 
NEUROTICISM 1-(1-enyl-stearoyl)-2-docosahexaenoyl-GPC(P-18:0/22:6) 0.00238 0.302 
NEUROTICISM oleate/vaccenate(18:1) 0.00141 0.273 
NEUROTICISM epiandrosteronesulfate 0.0026 0.302 
OSTEOPOROSIS X-23782 0.00221 0.222 
OSTEOPOROSIS caproate(6:0) 0.0019 0.272 
OSTEOPOROSIS X-21666 0.0013 0.265 
OSTEOPOROSIS N-acetylaspartate(NAA) 0.00165 0.262 
OSTEOPOROSIS 4-androsten-3beta_17beta-dioldisulfate(1) 0.00281 0.272 
OSTEOPOROSIS X-11470 0.000766 0.265 
OSTEOPOROSIS 1-oleoyl-GPI(18:1) 0.00149 0.262 
OSTEOPOROSIS taurolithocholate3-sulfate 0.00391 0.266 
OSTEOPOROSIS 1-palmitoleoyl-2-linoleoyl-GPC(16:1/18:2) 0.00229 0.272 
OSTEOPOROSIS ethylmalonate 0.00143 0.215 
OSTEOPOROSIS 1-palmitoyl-2-dihomo-linolenoyl-GPC(16:0/20:3n3or6) 0.000772 0.262 
OSTEOPOROSIS uridine 0.000345 0.213 
OSTEOPOROSIS X-17327 0.00298 0.266 
OSTEOPOROSIS X-16570 0.00348 0.266 
OSTEOPOROSIS 1-dihomo-linolenoyl-GPC(20:3n3or6) 0.00144 0.232 
OSTEOPOROSIS malonate 0.00112 0.265 
OSTEOPOROSIS tartarate 0.00108 0.232 
OSTEOPOROSIS androsteroidmonosulfate(1) 0.00191 0.298 
OSTEOPOROSIS N-acetyl-beta-alanine 0.00474 0.3 
OSTEOPOROSIS 1-palmitoyl-2-linoleoyl-GPI(16:0/18:2) 0.000471 0.22 
OSTEOPOROSIS N-acetylalanine 0.0011 0.262 
OSTEOPOROSIS 1-palmitoyl-2-oleoyl-GPE(16:0/18:1) 0.00317 0.272 
OSTEOPOROSIS cholate 0.00147 0.298 
OSTEOPOROSIS 1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC(P-16:0/20:4) 0.000876 0.248 
OSTEOPOROSIS X-16935 0.00205 0.266 
OSTEOPOROSIS guanidinoacetate 0.00251 0.272 
OSTEOPOROSIS 4-guanidinobutanoate 0.00345 0.272 
OSTEOPOROSIS 1-oleoyl-2-dihomo-linolenoyl-GPC(18:1/20:3) 0.000792 0.248 
OSTEOPOROSIS X-18899 0.0037 0.266 
OSTEOPOROSIS X-12822 0.000519 0.272 
OSTEOPOROSIS cholinephosphate 0.00198 0.272 
OVERWEIGHT 1-stearoyl-GPE(18:0) 0.00026 0.159 
PANCREATIC CANCER X-17299 8.33E-05 0.0468 
PANCREATIC CANCER glycerate 0.000289 0.163 
PROSTATE CANCER malate 0.000324 0.206 
PROSTATE CANCER X-13529 0.00103 0.314 
PROSTATE CANCER X-23639 0.000621 0.314 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
pyroglutamine 0.00205 0.231 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
1-palmitoyl-2-dihomo-linolenoyl-GPC(16:0/20:3n3or6) 0.000558 0.298 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
X-24435 0.00284 0.262 
 87 
phenotype metabolite p-value Q-value 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
1-oleoyl-2-dihomo-linolenoyl-GPC(18:1/20:3) 0.00163 0.298 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
N-acetylglutamine 0.00281 0.308 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
quinolinate 0.000192 0.123 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
2-hydroxyphenylacetate 0.0024 0.308 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
5alpha-pregnan-3beta_20alpha-dioldisulfate 0.00126 0.231 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
cis-aconitate 0.00147 0.231 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
5-dodecenoate(12:1n7) 0.00215 0.231 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
gamma-glutamylleucine 0.0018 0.231 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
lactate 0.000352 0.208 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
1-dihomo-linolenoyl-GPC(20:3n3or6) 0.00163 0.298 
RHEUMATOID ARTHRITIS X-23997 0.000504 0.324 
RHEUMATOID ARTHRITIS isobutyrylcarnitine 0.000123 0.0681 
SCHIZOPHRENIA X-11372 0.000293 0.177 
SCHIZOPHRENIA methioninesulfone 2.15E-06 0.00139 
SCHIZOPHRENIA X-14838 0.000218 0.14 
SCHIZOPHRENIA 3-methoxytyrosine 0.000972 0.313 
SCHIZOPHRENIA 1_2_3-benzenetriolsulfate(2) 0.000579 0.142 
SCHIZOPHRENIA gamma-glutamylglutamate 3.97E-07 0.000246 
SCHIZOPHRENIA N-methylproline 0.00101 0.314 
SMOKING AGE ONSET epiandrosteronesulfate 0.000158 0.101 
SMOKING AGE ONSET 3-ureidopropionate 0.000981 0.316 
SMOKING CIGAR PER DAY 5-hydroxylysine 0.000385 0.166 
SMOKING CIGAR PER DAY X-22162 0.000581 0.166 
SMOKING EVER SMOKE myristoleate(14:1n5) 0.00032 0.182 
SMOKING FORMER SMOKER X-17179 0.000475 0.271 
TRIGLYCERIDES 2-linoleoyl-GPC(18:2) 0.0111 0.326 
TRIGLYCERIDES dihomo-linolenate(20:3n3orn6) 0.0042 0.18 
TRIGLYCERIDES 1-oleoylglycerol(18:1) 0.00166 0.119 
TRIGLYCERIDES 1-palmitoyl-2-arachidonoyl-GPI(16:0/20:4) 0.000508 0.0979 
TRIGLYCERIDES 1-stearoyl-2-arachidonoyl-GPI(18:0/20:4) 0.000193 0.0979 
TRIGLYCERIDES 1-stearoyl-2-linoleoyl-GPI(18:0/18:2) 0.00113 0.116 
TRIGLYCERIDES 2-linoleoyl-GPE(18:2) 0.00111 0.116 
TRIGLYCERIDES palmitoleoyl-oleoyl-glycerol(16:1/18:1)[2] 0.00299 0.138 
TRIGLYCERIDES 1-palmitoyl-2-oleoyl-GPE(16:0/18:1) 0.00291 0.138 
TRIGLYCERIDES 1-palmitoyl-2-stearoyl-GPC(16:0/18:0) 0.00921 0.298 
TRIGLYCERIDES 1-palmitoleoyl-2-linoleoyl-GPC(16:1/18:2) 0.00479 0.193 
TRIGLYCERIDES X-24278 0.000608 0.0979 
TRIGLYCERIDES 1-dihomo-linolenoyl-GPE(20:3n3or6) 0.00199 0.125 
TRIGLYCERIDES 1-linoleoyl-GPI(18:2) 0.00973 0.298 
TRIGLYCERIDES oleoyl-linoleoyl-glycerol(18:1/18:2)[1] 0.00233 0.125 
TRIGLYCERIDES 2-arachidonoyl-GPE(20:4) 0.000569 0.0979 
TRIGLYCERIDES 1-linoleoyl-GPE(18:2) 0.00126 0.116 
TRIGLYCERIDES theobromine 0.00973 0.298 
TRIGLYCERIDES 1-palmitoyl-2-dihomo-linolenoyl-GPC(16:0/20:3n3or6) 0.00215 0.125 
TRIGLYCERIDES 1-palmitoyl-2-alpha-linolenoyl-GPC(16:0/18:3n3) 0.00564 0.214 
TRIGLYCERIDES 1-linolenoylglycerol(18:3) 0.00144 0.116 
TRIGLYCERIDES X-24061 0.00876 0.298 
ULCERATIVE COLITIS 1-arachidonoyl-GPE(20:4n6) 0.00109 0.33 
ULCERATIVE COLITIS cis-4-decenoylcarnitine 0.00273 0.33 
ULCERATIVE COLITIS X-12688 0.00145 0.33 
ULCERATIVE COLITIS 1-palmitoyl-2-dihomo-linolenoyl-GPC(16:0/20:3n3or6) 0.0026 0.33 
WAIST CIRCUMFERENCE 1-methylxanthine 0.000408 0.262 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
betaine 0.00111 0.216 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
proline 0.00109 0.278 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
myristate(14:0) 0.000566 0.165 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
1-palmitoleoyl-2-linoleoyl-GPC(16:1/18:2) 0.00013 0.0641 
WAIST-HIP RATIO kynurenate 0.0038 0.321 
WAIST-HIP RATIO X-18249 0.00125 0.321 
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WAIST-HIP RATIO beta-alanine 0.00317 0.321 
WAIST-HIP RATIO X-12729 0.00305 0.321 
WAIST-HIP RATIO X-11299 0.00136 0.33 
WAIST-HIP RATIO hexanoylcarnitine 0.00154 0.33 
WAIST-HIP RATIO 1-nonadecanoyl-GPC(19:0) 0.00258 0.321 
WAIST-HIP RATIO X-15492 0.00283 0.322 
WAIST-HIP RATIO X-21411 0.00214 0.322 
WAIST-HIP RATIO sphingomyelin(d18:1/17:0_d17:1/18:0_d19:1/16:0) 0.00171 0.322 
WAIST-HIP RATIO N6-acetyllysine 0.00316 0.321 
WAIST-HIP RATIO trigonelline(N'-methylnicotinate) 0.000186 0.117 
WAIST-HIP RATIO palmitate(16:0) 0.00336 0.321 
WAIST-HIP RATIO 1-palmitoyl-2-arachidonoyl-GPE(16:0/20:4) 0.00141 0.322 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
X-18249 0.00243 0.174 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
palmitoyl-linoleoyl-glycerol(16:0/18:2)[2] 0.00286 0.184 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
N-acetyltaurine 0.00102 0.319 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
1-palmitoleoyl-2-linoleoyl-GPC(16:1/18:2) 0.00176 0.325 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
orotidine 0.0035 0.319 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
X-22816 0.0032 0.319 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
X-18914 0.00167 0.155 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
palmitoleate(16:1n7) 0.00188 0.319 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
1-stearoyl-2-linoleoyl-GPC(18:0/18:2) 0.000541 0.155 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
sphingomyelin(d18:1/17:0_d17:1/18:0_d19:1/16:0) 0.00133 0.155 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
X-11441 0.00119 0.155 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
citrulline 0.00175 0.155 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
N-acetylneuraminate 0.00402 0.321 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
X-23788 0.000295 0.19 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
orotate 0.00179 0.155 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
hexanoylcarnitine 0.00145 0.325 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
X-21286 0.00202 0.325 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
acetylcarnitine 0.00109 0.319 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
gluconate 0.00295 0.319 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
1-nonadecanoyl-GPC(19:0) 0.00463 0.271 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
1-palmitoyl-2-linoleoyl-GPC(16:0/18:2) 0.0015 0.155 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
gamma-glutamylglutamate 0.00192 0.155 
WEIGHT trigonelline(N'-methylnicotinate) 9.26E-05 0.045 
WEIGHT 2-isopropylmalate 0.00122 0.297 
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Gene phenotype associations with Q-value threshold 0.333 
phenotype gene p-value Q-value 
2HR GLUCOSE SHISA4 3.53E-05 0.0648 
2HR GLUCOSE ATF7IP2 0.00198 0.323 
2HR GLUCOSE FKRP 0.0016 0.323 
2HR GLUCOSE CACNG3 0.000476 0.221 
2HR GLUCOSE TECR 9.68E-05 0.101 
2HR GLUCOSE SYT4 4.38E-06 0.0175 
2HR GLUCOSE CCNY 0.00184 0.323 
2HR GLUCOSE SV2A 0.00147 0.323 
2HR GLUCOSE HIGD1B 0.0017 0.323 
2HR GLUCOSE ELMO1 0.000389 0.209 
2HR GLUCOSE MCEE 0.00102 0.323 
2HR GLUCOSE NAA50 0.00245 0.332 
2HR GLUCOSE PYGB 0.00207 0.327 
2HR GLUCOSE STMN4 0.000644 0.265 
2HR GLUCOSE PTDSS2 8.00E-05 0.101 
2HR GLUCOSE NEFL 0.00148 0.323 
2HR GLUCOSE CHRM5 0.000581 0.248 
2HR GLUCOSE TFPI 0.00184 0.323 
2HR GLUCOSE ARSK 0.0022 0.332 
2HR GLUCOSE RPL4 0.000127 0.119 
2HR GLUCOSE MAPK8IP1 0.000108 0.107 
2HR GLUCOSE SDF4 0.000343 0.198 
2HR GLUCOSE ITPK1 3.41E-05 0.0648 
2HR GLUCOSE PCBP2 0.00161 0.323 
2HR GLUCOSE IGSF21 0.00145 0.323 
2HR GLUCOSE PPP1CA 0.000144 0.119 
2HR GLUCOSE ISOC2 0.00151 0.323 
2HR GLUCOSE SV2B 0.00122 0.323 
2HR GLUCOSE TMEM132A 0.00209 0.328 
2HR GLUCOSE INA 0.000781 0.292 
2HR GLUCOSE MOAP1 0.00158 0.323 
2HR GLUCOSE RSL24D1 0.00236 0.332 
2HR GLUCOSE KLHL25 0.00196 0.323 
2HR GLUCOSE APLP1 0.00235 0.332 
2HR GLUCOSE HS3ST2 0.00156 0.323 
2HR GLUCOSE SYNDIG1 0.00151 0.323 
2HR GLUCOSE APEH 0.00122 0.323 
2HR GLUCOSE SSRP1 0.0014 0.323 
2HR GLUCOSE RXRB 0.00173 0.323 
2HR GLUCOSE OLAH 0.00179 0.323 
2HR GLUCOSE SERPINI2 0.0019 0.323 
2HR GLUCOSE CYLC2 0.00155 0.323 
2HR GLUCOSE PDZD4 0.00014 0.119 
2HR GLUCOSE PPP2R5B 0.000858 0.304 
2HR GLUCOSE SENP3 0.000418 0.209 
2HR GLUCOSE VARS2 7.35E-05 0.101 
2HR GLUCOSE PTPN23 9.70E-05 0.101 
2HR GLUCOSE PRDM2 0.000319 0.198 
2HR GLUCOSE LHX2 4.22E-05 0.0672 
2HR GLUCOSE NME3 0.00196 0.323 
2HR GLUCOSE RALYL 0.000217 0.173 
2HR GLUCOSE RPL12 0.00231 0.332 
2HR GLUCOSE CHAC1 0.0017 0.323 
2HR GLUCOSE LRRD1 0.00159 0.323 
2HR GLUCOSE MAP7D1 0.000144 0.119 
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2HR GLUCOSE NOP16 0.00105 0.323 
2HR GLUCOSE ZNF280B 0.00137 0.323 
2HR GLUCOSE TMEM251 0.00133 0.323 
2HR GLUCOSE TLR5 7.17E-05 0.101 
2HR GLUCOSE GABBR2 0.000865 0.304 
2HR GLUCOSE CCND3 0.000482 0.221 
2HR GLUCOSE BAG6 3.94E-05 0.0672 
2HR GLUCOSE MCHR1 0.00176 0.323 
2HR GLUCOSE KRT17 0.00129 0.323 
2HR GLUCOSE JPH4 0.00163 0.323 
2HR GLUCOSE FGF1 0.00166 0.323 
2HR GLUCOSE BLOC1S2 0.000333 0.198 
2HR GLUCOSE SNCB 0.00168 0.323 
2HR GLUCOSE ALKBH7 7.89E-07 0.00629 
2HR GLUCOSE PRPF8 9.48E-05 0.101 
2HR GLUCOSE AATF 0.00229 0.332 
2HR GLUCOSE TNFAIP8L3 0.00158 0.323 
2HR GLUCOSE MAN2C1 0.000768 0.292 
2HR GLUCOSE RASAL1 0.000521 0.231 
2HR GLUCOSE PRPS1L1 0.00118 0.323 
2HR GLUCOSE PPFIA3 0.000552 0.24 
2HR GLUCOSE CDC25B 0.00227 0.332 
2HR GLUCOSE C12orf57 0.000342 0.198 
2HR GLUCOSE INO80E 0.000225 0.174 
2HR GLUCOSE PRPF31 0.00196 0.323 
2HR GLUCOSE NRGN 0.0019 0.323 
2HR GLUCOSE DUS1L 0.000251 0.182 
2HR GLUCOSE RPS6KA4 0.00247 0.332 
2HR GLUCOSE SLC25A43 0.00166 0.323 
2HR GLUCOSE TAGLN3 0.000427 0.209 
2HR GLUCOSE NUDC 2.91E-06 0.0139 
2HR GLUCOSE VAC14 0.00104 0.323 
2HR GLUCOSE EMP2 0.00242 0.332 
2HR GLUCOSE SERF2 0.000975 0.323 
2HR GLUCOSE UBR4 0.000363 0.201 
2HR GLUCOSE ZFAND2A 0.00177 0.323 
2HR GLUCOSE ASIC2 0.00204 0.327 
2HR GLUCOSE SCGB1D2 0.00237 0.332 
2HR GLUCOSE SSR2 3.19E-05 0.0648 
2HR GLUCOSE MAN1B1 0.000341 0.198 
2HR GLUCOSE TPD52L2 0.000348 0.198 
2HR GLUCOSE SAMD8 0.000413 0.209 
2HR GLUCOSE TPT1-AS1 0.0021 0.329 
2HR GLUCOSE LY6E 0.00158 0.323 
2HR GLUCOSE IQSEC3 0.00138 0.323 
2HR GLUCOSE MTFR1L 0.00196 0.323 
2HR GLUCOSE LPCAT4 3.47E-05 0.0648 
2HR GLUCOSE MFSD12 0.00243 0.332 
2HR GLUCOSE ENTPD6 0.00113 0.323 
2HR GLUCOSE DLGAP4 0.00183 0.323 
2HR GLUCOSE FAM3A 0.00145 0.323 
2HR GLUCOSE MAST3 0.00152 0.323 
2HR GLUCOSE EXOC8 0.00124 0.323 
2HR GLUCOSE CHRM1 0.00166 0.323 
2HR GLUCOSE ZNRF4 0.000994 0.323 
2HR GLUCOSE SAMD11 0.00228 0.332 
2HR GLUCOSE RPS19 0.00244 0.332 
2HR GLUCOSE MICAL1 0.00161 0.323 
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2HR GLUCOSE PRKCB 0.000393 0.209 
2HR GLUCOSE HDAC6 0.00247 0.332 
2HR GLUCOSE FTO 0.00213 0.331 
2HR GLUCOSE GANAB 0.000346 0.198 
2HR GLUCOSE ISCA2 0.00226 0.332 
2HR GLUCOSE DDB1 0.00123 0.323 
2HR GLUCOSE TJAP1 0.00183 0.323 
2HR GLUCOSE C7orf26 0.000343 0.198 
2HR GLUCOSE NRSN1 0.000711 0.283 
2HR GLUCOSE GBP4 0.00194 0.323 
2HR GLUCOSE RBM23 0.00162 0.323 
2HR GLUCOSE ZNF777 0.00164 0.323 
2HR GLUCOSE MLF2 0.0016 0.323 
2HR GLUCOSE CST3 0.00122 0.323 
2HR GLUCOSE CKMT1B 1.82E-07 0.00218 
2HR GLUCOSE DYNC2LI1 0.00199 0.323 
2HR GLUCOSE GAA 0.00231 0.332 
2HR GLUCOSE NGEF 0.00135 0.323 
2HR GLUCOSE FUNDC2 0.0022 0.332 
2HR GLUCOSE PPP1R1B 0.00237 0.332 
2HR GLUCOSE GPX4 1.51E-06 0.00904 
2HR GLUCOSE ELMOD3 0.00204 0.327 
2HR GLUCOSE RAP1GAP 0.00215 0.331 
2HR GLUCOSE NR1H2 0.000726 0.284 
2HR GLUCOSE ITGB4 0.00133 0.323 
2HR GLUCOSE CPNE1 0.00241 0.332 
2HR GLUCOSE SIPA1L3 0.00148 0.323 
2HR GLUCOSE WASH2P 0.000639 0.265 
2HR GLUCOSE ZCCHC11 0.000512 0.231 
2HR GLUCOSE CKAP2L 0.00123 0.323 
2HR GLUCOSE TUBB4A 0.000427 0.209 
2HR GLUCOSE SULT4A1 0.00206 0.327 
2HR GLUCOSE C19orf70 0.00174 0.323 
2HR GLUCOSE PPP1R15A 0.00077 0.292 
2HR GLUCOSE DPM2 2.55E-05 0.0648 
2HR GLUCOSE ICAM5 0.00187 0.323 
2HR GLUCOSE LAMB3 2.53E-05 0.0648 
2HR GLUCOSE ROGDI 0.00224 0.332 
2HR GLUCOSE P4HB 8.67E-05 0.101 
2HR GLUCOSE PPP6R1 0.00113 0.323 
ACUTE MYELOID LEUKEMIA LIPI 9.31E-06 0.283 
AGE AT MENARCHE BDNF 0.000137 0.26 
AGE AT MENARCHE SLC16A4 6.31E-05 0.22 
AGE AT MENARCHE EXOSC6 8.71E-05 0.248 
AGE AT MENARCHE RHOA 2.55E-06 0.0133 
AGE AT MENARCHE RBM6 0.000129 0.26 
AGE AT MENARCHE NOB1 0.000104 0.327 
AGE AT MENARCHE WWP2 0.000184 0.32 
AGE AT MENARCHE TMEM38B 8.79E-05 0.306 
AGE AT MENARCHE IP6K1 1.22E-05 0.048 
AGE AT MENARCHE SATB2 5.33E-07 0.00835 
AGE AT MENARCHE RNF123 9.72E-06 0.0436 
AGE AT MENARCHE SMAD3 0.000141 0.26 
AGE AT MENARCHE SERPINA2 7.56E-05 0.296 
AGE AT MENARCHE NFAT5 7.91E-05 0.248 
AGE AT MENARCHE DOCK3 0.000107 0.26 
AGE RELATED MACULAR 
DEGENERATION 
LHX9 2.11E-05 0.0755 
AGE RELATED MACULAR 
DEGENERATION 
TRIM4 0.00012 0.247 
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AGE RELATED MACULAR 
DEGENERATION 
BTBD16 3.97E-05 0.109 
AGE RELATED MACULAR 
DEGENERATION 
PLA2G12A 0.000131 0.247 
AGE RELATED MACULAR 
DEGENERATION 
ZAN 0.000127 0.247 
AGE RELATED MACULAR 
DEGENERATION 
CFHR1 4.75E-07 0.00382 
AGE RELATED MACULAR 
DEGENERATION 
GABRR2 3.86E-05 0.109 
AGE RELATED MACULAR 
DEGENERATION 
CASP6 4.07E-05 0.109 
AGE RELATED MACULAR 
DEGENERATION 
SMU1 6.53E-06 0.0511 
AGE RELATED MACULAR 
DEGENERATION 
CFHR4 1.00E-05 0.043 
AGE RELATED MACULAR 
DEGENERATION 
CLK4 5.33E-05 0.132 
AGE RELATED MACULAR 
DEGENERATION 
CFHR3 7.01E-12 2.25E-07 
AGE RELATED MACULAR 
DEGENERATION 
KCNT2 1.21E-06 0.0189 
AGE RELATED MACULAR 
DEGENERATION 
ZBTB41 7.47E-07 0.0048 
AGE RELATED MACULAR 
DEGENERATION 
CFH 1.74E-07 0.00186 
AGE RELATED MACULAR 
DEGENERATION 
ZNF766 9.67E-05 0.222 
AGE RELATED MACULAR 
DEGENERATION 
PLEKHA1 3.15E-10 5.06E-06 
AGE RELATED MACULAR 
DEGENERATION 
STAG3L5P 1.07E-05 0.043 
ALCOHOLISM EZH2 1.97E-05 0.305 
ALZHEIMER EHD2 0.000189 0.253 
ALZHEIMER CFHR3 6.68E-05 0.247 
ALZHEIMER OPA3 2.24E-06 0.0141 
ALZHEIMER KCTD5 5.49E-05 0.232 
ALZHEIMER FAM151A 2.27E-07 0.00404 
ALZHEIMER DCN 0.000158 0.23 
ALZHEIMER CC2D1A 7.87E-05 0.318 
ALZHEIMER PALM2 2.17E-05 0.214 
ALZHEIMER CR1 2.48E-05 0.0724 
ALZHEIMER L3HYPDH 6.90E-06 0.0681 
ALZHEIMER MARK4 5.12E-07 0.00557 
ALZHEIMER SETD5 8.13E-05 0.157 
ALZHEIMER ADAM23 0.000213 0.264 
ALZHEIMER GGCT 5.07E-05 0.27 
ALZHEIMER CPA5 2.76E-05 0.163 
ALZHEIMER CLASRP 1.24E-05 0.0442 
ALZHEIMER CLPTM1 8.83E-05 0.221 
ALZHEIMER TAS2R60 0.00015 0.229 
ALZHEIMER LINC00639 9.17E-05 0.271 
ALZHEIMER CEACAM19 4.61E-09 0.000149 
ALZHEIMER SV2B 4.85E-08 0.00155 
ALZHEIMER INTU 2.69E-05 0.214 
ALZHEIMER ZNF222 0.000112 0.234 
ALZHEIMER PVRIG 0.000114 0.234 
ALZHEIMER ZNF133 0.000183 0.257 
ALZHEIMER EML2 1.92E-06 0.0124 
ALZHEIMER PCDH19 2.06E-05 0.329 
ALZHEIMER PIGR 0.000103 0.174 
ALZHEIMER PPP1R37 7.16E-06 0.0288 
ALZHEIMER ZNF235 0.000122 0.234 
ALZHEIMER MDK 3.69E-05 0.236 
ALZHEIMER ELMO1 7.09E-05 0.318 
ALZHEIMER NFATC2IP 3.44E-05 0.17 
ALZHEIMER SYT4 3.77E-06 0.0302 
ALZHEIMER RIN1 0.000104 0.28 
ALZHEIMER FOSB 4.77E-05 0.141 
ALZHEIMER APOC1 6.43E-05 0.122 
ALZHEIMER JKAMP 1.52E-05 0.112 
ALZHEIMER ZNF225 2.59E-06 0.0141 
ALZHEIMER APOE 6.20E-09 9.96E-05 
ALZHEIMER ENKD1 8.95E-05 0.318 
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ALZHEIMER PTK2B 3.08E-06 0.0141 
ALZHEIMER MS4A6A 0.000174 0.244 
ALZHEIMER GPR135 2.73E-07 0.00404 
ALZHEIMER ERCC2 4.63E-05 0.0992 
ALZHEIMER EPHA1-AS1 8.25E-05 0.157 
ALZHEIMER ZNF226 4.52E-06 0.021 
ALZHEIMER ZNF417 8.79E-05 0.318 
ALZHEIMER GEMIN7 2.08E-06 0.0141 
ALZHEIMER NKPD1 3.24E-05 0.0771 
ALZHEIMER SEZ6L 3.35E-05 0.214 
ALZHEIMER KLC3 3.36E-05 0.0771 
ALZHEIMER BRMS1L 7.56E-05 0.249 
ALZHEIMER APOC1P1 0.000243 0.289 
ALZHEIMER AKAP2 8.53E-06 0.214 
ANOREXIA NERVOSA PP2D1 1.86E-06 0.0575 
ASTHMA ORMDL3 3.04E-05 0.189 
ASTHMA GSDMB 2.57E-06 0.0398 
ASTHMA CCDC117 4.31E-05 0.199 
ASTHMA PNMT 7.57E-06 0.0781 
ASTHMA CACNB1 2.46E-06 0.0398 
ASTHMA RAPGEFL1 2.72E-05 0.189 
ASTHMA ZPBP2 7.41E-05 0.232 
ASTHMA IKZF3 7.11E-05 0.232 
AUTISM DNM1P46 1.12E-05 0.253 
AUTISM WFDC6 8.77E-06 0.272 
AUTISM MAPT 5.20E-06 0.0805 
AUTISM UBE2H 3.41E-06 0.106 
AUTISM ZNRF2 3.47E-05 0.174 
AUTISM CLDN23 3.85E-05 0.174 
AUTISM IRX1 4.85E-05 0.192 
AUTISM EXTL3-AS1 6.25E-05 0.324 
AUTISM PDCL3 7.71E-05 0.298 
AUTISM INSL3 3.14E-05 0.324 
AUTISM OR5M10 9.25E-06 0.265 
AUTISM LEPR 1.28E-06 0.0398 
AUTISM NF2 0.000107 0.322 
AUTISM PPP1R3B 6.80E-06 0.108 
AUTISM GBP3 2.57E-05 0.265 
AUTISM LIMD2 4.35E-06 0.135 
AUTISM NEIL2 5.46E-05 0.185 
AUTISM SGK1 2.78E-06 0.0863 
AUTISM CITED1 5.85E-05 0.298 
AUTISM BPTF 1.22E-05 0.189 
AUTISM DND1 5.58E-05 0.323 
AUTISM RNF126 2.79E-05 0.324 
AUTISM UBE2Q2P1 2.61E-06 0.0805 
AUTISM SRC 3.79E-05 0.294 
AUTISM ROBO1 8.96E-06 0.278 
AUTISM RNF152 5.63E-05 0.298 
AUTISM FBXW4P1 6.97E-05 0.309 
AUTISM FAM41C 2.10E-05 0.217 
AUTISM ZNF641 4.77E-06 0.148 
AUTISM LRFN4 4.30E-06 0.133 
AUTISM TMEM14A 7.32E-05 0.324 
AUTISM EXOC4 1.44E-05 0.152 
AUTISM SLC35G5 8.82E-05 0.254 
AUTISM USP11 6.26E-05 0.323 
AUTISM AFF1 1.63E-05 0.253 
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AUTISM RIMKLA 4.70E-06 0.146 
AUTISM ZNF713 1.63E-05 0.127 
AUTISM PHTF1 1.18E-05 0.184 
AUTISM CLDN22 9.85E-06 0.305 
AUTISM MTMR9 5.20E-06 0.0825 
AUTISM NSUN7 1.51E-05 0.265 
AUTISM DPH7 8.69E-06 0.27 
AUTISM BNIPL 1.54E-06 0.0476 
AUTISM OR4D5 1.13E-05 0.175 
AUTISM TTBK1 3.07E-05 0.162 
AUTISM BID 9.89E-06 0.153 
AUTISM PPIH 1.61E-05 0.285 
AUTISM ARMC2 9.26E-05 0.324 
AUTISM RBM33 2.57E-05 0.265 
AUTISM GPR141 1.93E-05 0.299 
AUTISM LYAR 5.06E-05 0.324 
AUTISM BPESC1 4.12E-05 0.258 
AUTISM AQR 3.34E-05 0.207 
AUTISM NOXO1 6.02E-05 0.324 
AUTISM TMEM222 1.55E-05 0.127 
AUTISM IL20RB 2.54E-07 0.00789 
AUTISM RAD51 4.21E-05 0.324 
AUTISM DZANK1 2.63E-05 0.285 
AUTISM RRP12 7.43E-06 0.0769 
AUTISM SIGMAR1 1.61E-05 0.324 
AUTISM NPRL2 6.65E-05 0.251 
AUTISM C2orf88 3.19E-05 0.33 
AUTISM ENPP4 4.91E-08 0.00153 
AUTISM MSRA 5.83E-05 0.185 
AUTISM C17orf80 1.18E-05 0.183 
AUTISM RSPO1 8.25E-05 0.324 
AUTISM MTHFR 1.79E-06 0.0557 
AUTISM ACSF2 1.00E-05 0.31 
AUTISM FAM66A 1.62E-05 0.128 
AUTISM UBE2L3 1.08E-05 0.183 
AUTISM PCDHGC5 6.63E-05 0.324 
AUTISM 5-Mar 1.87E-05 0.265 
AUTISM ENPP5 2.39E-05 0.187 
BIPOLAR DISORDER CDAN1 5.22E-06 0.16 
BIPOLAR DISORDER SLC7A6 1.58E-05 0.0992 
BIPOLAR DISORDER LMAN2L 1.00E-05 0.0992 
BIPOLAR DISORDER DDN 1.60E-06 0.0251 
BIPOLAR DISORDER ITIH4 1.37E-05 0.0992 
BIPOLAR DISORDER CACNB3 2.14E-08 0.000671 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
BTN3A2 4.11E-11 1.29E-06 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
NT5C2 6.29E-07 0.00492 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
FRMD7 2.93E-05 0.0918 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
BTN1A1 2.03E-07 0.00212 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
SNF8 0.000101 0.293 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
ARL17A 3.71E-07 0.0116 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
CCDC36 1.95E-05 0.0873 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
CACNB3 2.85E-08 0.000892 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
HIST1H4C 5.60E-06 0.0292 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
SPTBN2 2.75E-05 0.108 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
LPAR3 4.65E-05 0.242 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
ARL3 6.68E-07 0.0104 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
MVP 1.26E-05 0.0873 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
MUSTN1 7.84E-05 0.223 
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BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
RCE1 6.35E-06 0.0663 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
CTSF 1.60E-05 0.0873 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
ITIH4 1.26E-05 0.0656 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
PRKAG1 9.28E-05 0.242 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
C11orf80 4.69E-05 0.133 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
RNPS1 0.000103 0.293 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
PSMD3 9.38E-05 0.293 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
SFXN2 0.000105 0.234 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
MCHR1 2.49E-05 0.0865 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
DDN 5.11E-06 0.0663 
BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
WFDC12 1.93E-05 0.0873 
BIRTH LENGTH GPR6 9.87E-06 0.153 
BIRTH LENGTH ZBTB7B 3.02E-06 0.0937 
BIRTH WEIGHT TIPARP 4.68E-05 0.323 
BIRTH WEIGHT POC1A 5.14E-05 0.323 
BIRTH WEIGHT RBBP9 6.12E-05 0.323 
BIRTH WEIGHT CHADL 6.67E-06 0.211 
BIRTH WEIGHT HMGA2 5.76E-05 0.323 
BLOOD_TEST_INDICATOR CWF19L1 1.33E-06 0.0435 
BLOOD_TEST_INDICATOR ABHD1 1.72E-05 0.282 
BLOOD_TEST_INDICATOR DOCK7 3.04E-06 0.0497 
BLOOD_TEST_INDICATOR OR2AE1 1.35E-05 0.147 
BLOOD_TEST_INDICATOR CNNM3 2.49E-05 0.203 
BLOOD_TEST_INDICATOR ALDH1A2 2.93E-06 0.096 
BLOOD_TEST_INDICATOR GATM 3.93E-05 0.305 
BLOOD_TEST_INDICATOR HFE 5.90E-05 0.305 
BLOOD_TEST_INDICATOR HNF1A 1.98E-06 0.0648 
BLOOD_TEST_INDICATOR MRC1 5.03E-06 0.0822 
BLOOD_TEST_INDICATOR PSTK 5.46E-05 0.305 
BLOOD_TEST_INDICATOR CYP3A7 2.44E-08 0.000586 
BLOOD_TEST_INDICATOR CCDC110 3.66E-05 0.238 
BLOOD_TEST_INDICATOR NR1H3 3.85E-06 0.126 
BLOOD_TEST_INDICATOR CSF3 1.52E-05 0.203 
BLOOD_TEST_INDICATOR MAN2A2 4.55E-06 0.149 
BLOOD_TEST_INDICATOR AP2M1 2.57E-06 0.0822 
BLOOD_TEST_INDICATOR BCAM 2.46E-05 0.269 
BLOOD_TEST_INDICATOR SIM1 1.92E-05 0.305 
BLOOD_TEST_INDICATOR NAP1L2 2.46E-05 0.203 
BLOOD_TEST_INDICATOR SIAH3 6.62E-05 0.308 
BLOOD_TEST_INDICATOR NBPF3 1.10E-05 0.119 
BLOOD_TEST_INDICATOR CDKN2D 1.67E-05 0.203 
BLOOD_TEST_INDICATOR SPATA5L1 2.34E-05 0.305 
BLOOD_TEST_INDICATOR C15orf48 9.13E-05 0.332 
BLOOD_TEST_INDICATOR PSMA5 2.44E-05 0.269 
BLOOD_TEST_INDICATOR ZNF280A 3.30E-05 0.305 
BLOOD_TEST_INDICATOR ANGPTL3 3.84E-07 0.0126 
BODY MASS INDEX FBXL19 2.01E-05 0.0443 
BODY MASS INDEX FAM180B 0.000112 0.187 
BODY MASS INDEX TM6SF2 4.06E-05 0.0709 
BODY MASS INDEX NPIPB9 0.000102 0.269 
BODY MASS INDEX TUFM 6.79E-06 0.0194 
BODY MASS INDEX BDNF 0.000133 0.321 
BODY MASS INDEX ANKDD1B 0.000127 0.181 
BODY MASS INDEX RPS10 9.72E-05 0.153 
BODY MASS INDEX SH3YL1 0.000204 0.246 
BODY MASS INDEX HCN4 3.02E-06 0.0479 
BODY MASS INDEX C1QL2 9.91E-06 0.0619 
BODY MASS INDEX SLC39A13 0.000123 0.193 
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BODY MASS INDEX MTCH2 0.000113 0.187 
BODY MASS INDEX FKBP1B 0.000133 0.182 
BODY MASS INDEX CENPO 7.25E-05 0.256 
BODY MASS INDEX MYBPC3 3.01E-05 0.0727 
BODY MASS INDEX C1QTNF4 5.47E-05 0.244 
BODY MASS INDEX RBL2 3.22E-05 0.0562 
BODY MASS INDEX NDUFS3 5.94E-06 0.0627 
BODY MASS INDEX UHRF1BP1 1.86E-05 0.0419 
BODY MASS INDEX FEM1B 0.000247 0.272 
BODY MASS INDEX ACP1 0.000129 0.283 
BODY MASS INDEX ADCY3 3.20E-06 0.05 
BODY MASS INDEX NPIPB6 7.32E-07 0.00583 
BODY MASS INDEX SH2B1 4.89E-05 0.0959 
BODY MASS INDEX TFAP2B 5.56E-06 0.0194 
BODY MASS INDEX DNAJC27-AS1 8.21E-05 0.256 
BODY MASS INDEX FNBP4 0.000134 0.281 
BODY MASS INDEX NUPR1 4.06E-06 0.0155 
BODY MASS INDEX SNRPC 0.000241 0.261 
BODY MASS INDEX OR14A16 0.000152 0.199 
BODY MASS INDEX FUBP1 2.80E-07 0.00509 
BODY MASS INDEX NFATC2IP 1.08E-05 0.0679 
BODY MASS INDEX BPIFB1 0.000283 0.329 
BODY MASS INDEX NEGR1 1.93E-07 0.00606 
BODY MASS INDEX DNMT3L 0.000257 0.322 
BODY MASS INDEX PMS2P3 2.85E-07 0.00751 
BODY MASS INDEX EIF3CL 2.48E-06 0.0259 
BODY MASS INDEX C18orf54 6.02E-05 0.21 
BODY MASS INDEX LGR4 2.98E-05 0.104 
BREAST CANCER PDE4A 0.00116 0.292 
BREAST CANCER TTYH1 0.000768 0.313 
BREAST CANCER WDR13 0.00273 0.332 
BREAST CANCER AP5M1 0.00108 0.313 
BREAST CANCER BLOC1S2 3.29E-07 0.00829 
BREAST CANCER FCN1 0.000849 0.292 
BREAST CANCER RXRB 0.00125 0.292 
BREAST CANCER ACTG1 0.000905 0.292 
BREAST CANCER CHCHD6 0.00221 0.319 
BREAST CANCER CORO2B 0.00164 0.297 
BREAST CANCER SSR2 0.00124 0.292 
BREAST CANCER GATAD2A 0.000272 0.3 
BREAST CANCER SLC2A1 0.002 0.319 
BREAST CANCER PHC2 0.000221 0.18 
BREAST CANCER SLC8A2 0.00245 0.329 
BREAST CANCER PRKCZ 0.000408 0.245 
BREAST CANCER PSMD6 4.29E-05 0.1 
BREAST CANCER CCDC14 0.0024 0.324 
BREAST CANCER WDR45B 0.00043 0.252 
BREAST CANCER SHISA4 4.80E-06 0.0242 
BREAST CANCER KEAP1 0.00194 0.311 
BREAST CANCER ABHD14A 0.000203 0.171 
BREAST CANCER DHPS 0.00202 0.312 
BREAST CANCER NSUN4 0.000274 0.3 
BREAST CANCER LSM7 0.00142 0.292 
BREAST CANCER RPS19 1.11E-05 0.0312 
BREAST CANCER OGDHL 0.00277 0.332 
BREAST CANCER CNTROB 0.000528 0.267 
BREAST CANCER NCAN 0.00137 0.292 
BREAST CANCER C1orf61 0.00163 0.314 
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BREAST CANCER C1orf35 0.00226 0.321 
BREAST CANCER LRP1 0.00198 0.311 
BREAST CANCER FOXJ2 5.79E-05 0.0841 
BREAST CANCER ZNF347 0.00187 0.314 
BREAST CANCER PI4KAP2 0.00157 0.314 
BREAST CANCER OR4D1 2.49E-05 0.074 
BREAST CANCER LHX6 0.00228 0.321 
BREAST CANCER PTGS2 0.000456 0.254 
BREAST CANCER SLITRK1 0.0019 0.315 
BREAST CANCER PTPN23 0.000127 0.133 
BREAST CANCER CDK16 0.00117 0.313 
BREAST CANCER SUPT16H 0.000641 0.289 
BREAST CANCER CCDC85B 0.0003 0.205 
BREAST CANCER SHARPIN 7.87E-06 0.0312 
BREAST CANCER COPE 0.00201 0.312 
BREAST CANCER ROGDI 5.68E-05 0.0841 
BREAST CANCER EFNB3 0.000825 0.313 
BREAST CANCER DPM2 0.000311 0.207 
BREAST CANCER FAM213B 0.000252 0.181 
BREAST CANCER TMEM237 0.000353 0.316 
BREAST CANCER BRINP2 0.00114 0.313 
BREAST CANCER ZNF777 0.00214 0.318 
BREAST CANCER DND1 0.000292 0.3 
BREAST CANCER C19orf66 0.00121 0.292 
BREAST CANCER SHISA5 8.58E-05 0.108 
BREAST CANCER KCNJ8 0.00176 0.314 
BREAST CANCER KCNN4 7.35E-05 0.136 
BREAST CANCER TESK2 0.000253 0.3 
BREAST CANCER AP2A2 0.00263 0.332 
BREAST CANCER KLHL25 0.000337 0.233 
BREAST CANCER SCGB1D2 0.000264 0.185 
BREAST CANCER HSCB 0.000293 0.3 
BREAST CANCER TNFSF9 0.00107 0.313 
BREAST CANCER GKN1 0.00169 0.299 
BREAST CANCER LYPD5 0.000193 0.263 
BREAST CANCER HCG27 3.20E-05 0.316 
BREAST CANCER LRR1 0.00154 0.297 
BREAST CANCER NSFL1C 0.000877 0.292 
BREAST CANCER TRIM41 0.000906 0.292 
BREAST CANCER CDC37 0.00142 0.292 
BREAST CANCER CCND3 0.00274 0.332 
BREAST CANCER EDF1 8.44E-05 0.0974 
BREAST CANCER HEXA-AS1 0.00136 0.292 
BREAST CANCER ALKBH7 0.000786 0.292 
BREAST CANCER DNM3 0.0012 0.292 
BREAST CANCER HDAC3 0.00186 0.311 
BREAST CANCER TMEM231 0.0022 0.319 
BREAST CANCER MLF2 0.00185 0.311 
BREAST CANCER KLC1 0.00205 0.315 
BREAST CANCER ARPC5 0.0015 0.313 
BREAST CANCER DDN 2.59E-05 0.0592 
BREAST CANCER PPP1CA 5.92E-05 0.0841 
BREAST CANCER PDAP1 0.00173 0.303 
BREAST CANCER EIF5A2 0.00235 0.325 
BREAST CANCER TRIM2 0.00197 0.311 
BREAST CANCER SLC22A17 0.00159 0.297 
BREAST CANCER ACOT11 0.000672 0.313 
BREAST CANCER NUDC 3.64E-06 0.0264 
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BREAST CANCER NOSIP 0.000154 0.155 
BREAST CANCER SSNA1 0.00126 0.292 
BREAST CANCER DLEU2 0.00162 0.314 
BREAST CANCER TTLL1 0.00166 0.297 
BREAST CANCER RPLP1 0.000235 0.181 
BREAST CANCER ASH1L 0.00016 0.228 
BREAST CANCER MAGI2 0.00208 0.319 
BREAST CANCER FAM3A 6.74E-05 0.0894 
BREAST CANCER ENTPD8 0.00248 0.325 
BREAST CANCER VPS4A 8.50E-05 0.0974 
BREAST CANCER MRPL47 0.000112 0.122 
BREAST CANCER TYRO3 0.0015 0.297 
BREAST CANCER AGXT 0.000872 0.292 
BREAST CANCER PYGB 0.00269 0.332 
BREAST CANCER RUVBL1 0.000318 0.308 
BREAST CANCER PNPLA6 0.00218 0.321 
BREAST CANCER NRGN 0.000619 0.313 
BREAST CANCER VBP1 0.000998 0.292 
BREAST CANCER MAGED2 0.00104 0.313 
BREAST CANCER BEAN1 0.00171 0.314 
BREAST CANCER HIST2H2BA 9.69E-08 0.00159 
BREAST CANCER ZNF48 0.000725 0.313 
BREAST CANCER STRN4 0.00123 0.292 
BREAST CANCER TUBGCP2 0.00103 0.292 
BREAST CANCER POLR2A 0.000978 0.292 
BREAST CANCER B4GALNT4 0.000281 0.3 
BREAST CANCER APEH 0.000831 0.292 
BREAST CANCER BAG6 4.13E-05 0.0802 
BREAST CANCER ATG10 0.000358 0.316 
BREAST CANCER AARSD1 0.00123 0.292 
BREAST CANCER TMEM141 0.00242 0.324 
BREAST CANCER PPP6R1 0.000408 0.245 
BREAST CANCER MLC1 0.00178 0.314 
BREAST CANCER RAD51B 3.09E-05 0.0843 
BREAST CANCER FAM200B 0.00116 0.313 
BREAST CANCER SGCE 1.53E-05 0.0557 
BREAST CANCER NUDT5 0.00147 0.297 
BREAST CANCER GPX4 2.15E-05 0.0543 
BREAST CANCER HDGF 0.00149 0.313 
BREAST CANCER BTBD7 0.00177 0.314 
BREAST CANCER FUNDC2 0.00249 0.325 
BREAST CANCER VPS4B 0.00136 0.292 
BREAST CANCER CD83 5.01E-05 0.316 
BREAST CANCER TNFAIP8L3 0.00136 0.313 
BREAST CANCER SEC13 0.00234 0.32 
BREAST CANCER RPS6KB2 0.00255 0.328 
BREAST CANCER MICAL3 0.00225 0.319 
BREAST CANCER C11orf49 0.00232 0.32 
BREAST CANCER MAPK8IP1 2.74E-05 0.0624 
BREAST CANCER ST7 0.00199 0.311 
BREAST CANCER TAOK2 0.000752 0.292 
BREAST CANCER CYP3A5 0.00101 0.292 
BREAST CANCER GAS7 0.00122 0.313 
BREAST CANCER GABARAP 0.000334 0.212 
BREAST CANCER CRHR1 0.000142 0.211 
BREAST CANCER IGSF9B 0.000167 0.158 
BREAST CANCER HEXB 0.0016 0.297 
BREAST CANCER FAM13B 0.00126 0.313 
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BREAST CANCER OPTN 0.0025 0.325 
BREAST CANCER CAPNS1 0.00125 0.313 
BREAST CANCER RPL7A 0.00276 0.332 
BREAST CANCER DDIT3 0.0017 0.314 
BREAST CANCER SUPT5H 0.00198 0.311 
BREAST CANCER MTFR1L 3.72E-06 0.0264 
BREAST CANCER RPL4 0.00192 0.311 
BREAST CANCER ELMO1 0.0013 0.292 
BREAST CANCER ESYT2 0.000753 0.292 
BREAST CANCER KXD1 0.000599 0.285 
BREAST CANCER DUS1L 5.52E-05 0.0841 
BREAST CANCER PDIA3 0.000176 0.158 
BREAST CANCER SLC9A3R1 0.00108 0.292 
BREAST CANCER CRIP2 0.000157 0.152 
BREAST CANCER FDXACB1 1.66E-05 0.0557 
BREAST CANCER LHX2 9.62E-06 0.0346 
BREAST CANCER RPL26L1 0.00148 0.297 
BREAST CANCER GGA3 0.00268 0.332 
BREAST CANCER C7orf26 0.00124 0.292 
BREAST CANCER GANAB 0.00136 0.292 
BREAST CANCER GNG10 0.00203 0.319 
BREAST CANCER RBM23 0.00134 0.292 
BREAST CANCER CRAT 0.000646 0.289 
BREAST CANCER MAP7D1 0.000937 0.292 
BREAST CANCER EIF3G 0.00192 0.311 
BREAST CANCER ARF4 0.00181 0.311 
BREAST CANCER KCNJ4 0.00239 0.327 
BREAST CANCER WBP2 0.00142 0.292 
BREAST CANCER TPD52L2 0.000337 0.212 
BREAST CANCER STIP1 0.000677 0.289 
BREAST CANCER P4HA1 0.00234 0.32 
BREAST CANCER TRAPPC12 0.00106 0.292 
BREAST CANCER YDJC 0.00111 0.292 
BREAST CANCER RNF220 0.00137 0.292 
BREAST CANCER CTNNA3 0.000729 0.292 
BREAST CANCER DLGAP4 0.00211 0.318 
BREAST CANCER SLC4A3 0.00209 0.319 
BREAST CANCER LRRC37A2 0.000292 0.3 
BREAST CANCER TMED9 0.000961 0.292 
BREAST CANCER NR1H2 0.00182 0.311 
BREAST CANCER RIIAD1 0.00241 0.324 
BREAST CANCER FLII 0.000514 0.267 
BREAST CANCER CMC2 7.39E-05 0.0931 
BREAST CANCER UBXN6 0.000896 0.292 
BREAST CANCER SENP3 0.000949 0.292 
BREAST CANCER SDF4 0.00247 0.325 
BREAST CANCER BAD 0.00111 0.292 
BREAST CANCER P4HB 0.000249 0.181 
BREAST CANCER GAA 0.000738 0.292 
BREAST CANCER ENTPD6 6.01E-05 0.0841 
BREAST CANCER LCA5 0.00182 0.311 
BREAST CANCER PSMF1 0.00161 0.297 
BREAST CANCER FAP 0.00195 0.311 
BREAST CANCER ITPK1 0.00122 0.292 
BREAST CANCER TET2-AS1 0.000122 0.19 
BREAST CANCER TUBB2B 0.00204 0.319 
BREAST CANCER TAF15 0.000615 0.287 
BREAST CANCER DDB1 0.00264 0.332 
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BREAST CANCER PHB2 0.000821 0.292 
BREAST CANCER NLGN2 0.00104 0.292 
BREAST CANCER SLC7A4 0.00228 0.319 
BREAST CANCER RDM1 5.81E-05 0.127 
BREAST CANCER PAK1 0.00225 0.321 
BREAST CANCER TMEM132A 0.00155 0.297 
BREAST CANCER PPP2R5B 0.000249 0.181 
BREAST CANCER ADRA2C 0.00205 0.319 
BREAST CANCER NIT2 0.000345 0.316 
BREAST CANCER CST3 0.000859 0.292 
BREAST CANCER FURIN 0.00223 0.319 
BREAST CANCER AKT1 0.000982 0.292 
BREAST CANCER LRRCC1 0.00187 0.314 
BREAST CANCER MAN2C1 0.000882 0.292 
BREAST CANCER 9-Sep 0.00116 0.292 
BREAST CANCER RPS2 0.00243 0.324 
BREAST CANCER PSAP 0.00124 0.292 
BREAST CANCER COX6B1 0.00172 0.303 
CHILDHOOD INTELLIGENCE SDHC 5.36E-06 0.163 
CHOLESTEROL SDC1 9.55E-05 0.131 
CHOLESTEROL RBKS 0.000113 0.127 
CHOLESTEROL MPV17 1.40E-06 0.00507 
CHOLESTEROL FER1L4 5.58E-05 0.0979 
CHOLESTEROL AMIGO1 0.000171 0.175 
CHOLESTEROL TRIP11 0.000372 0.31 
CHOLESTEROL FNDC4 1.62E-05 0.0348 
CHOLESTEROL KIAA1324 0.000316 0.261 
CHOLESTEROL APOB 4.36E-05 0.0957 
CHOLESTEROL TAF6L 0.000224 0.245 
CHOLESTEROL MAFB 0.000156 0.17 
CHOLESTEROL PTPN13 5.41E-05 0.0901 
CHOLESTEROL ANGPTL3 2.15E-06 0.00618 
CHOLESTEROL MAU2 0.000292 0.254 
CHOLESTEROL YIPF2 0.000488 0.325 
CHOLESTEROL NEIL2 1.90E-05 0.0376 
CHOLESTEROL MLEC 1.76E-05 0.0558 
CHOLESTEROL HP 0.000165 0.167 
CHOLESTEROL IFT172 4.96E-08 0.000392 
CHOLESTEROL CGREF1 9.47E-07 0.00499 
CHOLESTEROL GDF5 3.00E-05 0.079 
CHOLESTEROL PLS3 2.31E-05 0.0664 
CHOLESTEROL SLC4A1AP 7.94E-05 0.114 
CHOLESTEROL FKBP7 0.000412 0.301 
CHOLESTEROL RPAP2 0.00046 0.32 
CHOLESTEROL POLK 2.67E-05 0.0597 
CHOLESTEROL WTAP 4.89E-07 0.00766 
CHOLESTEROL BCAM 5.17E-05 0.0979 
CHOLESTEROL AFF1 2.57E-05 0.0463 
CHOLESTEROL ATP13A1 1.99E-06 0.0104 
CHOLESTEROL HS1BP3-IT1 4.54E-05 0.0957 
CHOLESTEROL C6orf106 0.00023 0.218 
CHOLESTEROL KHK 1.61E-05 0.0348 
CHOLESTEROL FADS3 9.65E-05 0.133 
CHOLESTEROL ZNF441 0.000111 0.147 
CHOLESTEROL DOCK7 4.67E-08 0.000392 
CHOLESTEROL VAPA 0.00018 0.211 
CHOLESTEROL ADAL 0.000131 0.166 
CHOLESTEROL ATMIN 1.65E-05 0.0348 
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CHOLESTEROL MLXIPL 1.42E-08 0.000225 
CHOLESTEROL SLC44A2 5.31E-06 0.0177 
CHOLESTEROL LPIN3 0.00013 0.136 
CHOLESTEROL GSTM2 0.000333 0.261 
CHOLESTEROL POC5 4.62E-05 0.0804 
CHOLESTEROL PPP1R3B 0.000258 0.263 
CHOLESTEROL NCAN 0.000413 0.301 
CHOLESTEROL C10orf67 0.00028 0.25 
CHOLESTEROL SIDT2 2.41E-09 7.63E-05 
CHOLESTEROL MKRN2 1.91E-06 0.0104 
CHOLESTEROL PCSK7 0.000208 0.235 
CHOLESTEROL PAFAH1B2 6.18E-05 0.0976 
CHOLESTEROL GSTM4 1.16E-06 0.0123 
CHOLESTEROL CSGALNACT1 2.64E-05 0.0463 
CHOLESTEROL IRF7 0.000452 0.32 
CHOLESTEROL CPNE8 0.000319 0.273 
CHOLESTEROL TMEM258 9.53E-05 0.115 
CHOLESTEROL TAGLN 9.95E-05 0.115 
CHOLESTEROL SORT1 9.26E-05 0.115 
CHOLESTEROL APOE 1.59E-05 0.0558 
CHOLESTEROL TM6SF2 0.000329 0.261 
CHOLESTEROL TMEM31 0.000127 0.166 
CHOLESTEROL PSRC1 5.81E-09 0.000184 
CHOLESTEROL COPZ1 0.000292 0.289 
CHOLESTEROL GSTM2P1 0.000315 0.273 
CHOLESTEROL PSMA5 1.58E-05 0.0558 
CHRONIC KIDNEY DISEASE CXCL11 3.67E-05 0.283 
CHRONIC KIDNEY DISEASE AES 5.74E-05 0.296 
CHRONIC KIDNEY DISEASE FAM47E-STBD1 6.80E-05 0.283 
CHRONIC KIDNEY DISEASE NUPR1 8.39E-05 0.296 
CHRONIC KIDNEY DISEASE PPCS 0.000124 0.303 
CHRONIC KIDNEY DISEASE LPGAT1 0.00012 0.303 
CHRONIC KIDNEY DISEASE SFXN2 0.000116 0.303 
CHRONIC KIDNEY DISEASE RTF1 7.14E-05 0.283 
CHRONIC KIDNEY DISEASE ACBD3 1.45E-05 0.23 
CHRONIC KIDNEY DISEASE RSBN1L 5.63E-05 0.283 
CHRONIC KIDNEY DISEASE SLC30A4 6.04E-05 0.283 
CHRONIC KIDNEY DISEASE SLC28A2 1.88E-05 0.198 
CHRONIC KIDNEY DISEASE NPIPB6 3.34E-05 0.265 
CHRONIC KIDNEY DISEASE SPATA5L1 1.67E-06 0.0265 
CHRONIC KIDNEY DISEASE NLRP2 0.000139 0.314 
COGNITIVE PERFORMANCE BAK1 0.000141 0.239 
COGNITIVE PERFORMANCE ATRIP 4.58E-05 0.125 
COGNITIVE PERFORMANCE DOCK3 0.000121 0.229 
COGNITIVE PERFORMANCE TANK 0.000169 0.243 
COGNITIVE PERFORMANCE PRR22 0.000169 0.243 
COGNITIVE PERFORMANCE DNAJB2 0.000219 0.296 
COGNITIVE PERFORMANCE MST1 2.23E-05 0.0866 
COGNITIVE PERFORMANCE WDR6 0.000115 0.229 
COGNITIVE PERFORMANCE TUFM 6.60E-06 0.0606 
COGNITIVE PERFORMANCE NPIPB6 9.77E-06 0.0606 
COGNITIVE PERFORMANCE KCNIP2 3.79E-05 0.117 
COGNITIVE PERFORMANCE TNKS2 4.83E-05 0.125 
COGNITIVE PERFORMANCE APEH 1.77E-05 0.0866 
COGNITIVE PERFORMANCE RNF123 1.30E-06 0.0404 
COGNITIVE PERFORMANCE IRF2BP2 0.000172 0.243 
COGNITIVE PERFORMANCE KCNIP2-AS1 8.37E-05 0.185 
CORONARY ARTERY DISEASE MTAP 9.06E-06 0.139 
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CORONARY ARTERY DISEASE PSMA5 8.42E-07 0.0258 
CORONARY ARTERY DISEASE PSRC1 1.03E-05 0.323 
CROHN DISEASE AIRE 0.000193 0.242 
CROHN DISEASE ZNF300P1 5.54E-06 0.0566 
CROHN DISEASE NUPR1 1.02E-05 0.0311 
CROHN DISEASE PTGER4 1.07E-07 0.00326 
CROHN DISEASE LIPG 0.000213 0.258 
CROHN DISEASE SPINK4 5.89E-05 0.16 
CROHN DISEASE GSTCD 0.000271 0.306 
CROHN DISEASE SOHLH2 2.09E-05 0.0675 
CROHN DISEASE UBE2L3 0.000362 0.326 
CROHN DISEASE ZNF169 0.000185 0.242 
CROHN DISEASE SCAMP3 0.000241 0.262 
CROHN DISEASE NPIPB6 2.56E-06 0.0156 
CROHN DISEASE UBA7 2.16E-05 0.0506 
CROHN DISEASE CCDC116 0.000362 0.326 
CROHN DISEASE FGFR1OP 6.70E-06 0.0255 
CROHN DISEASE RNF123 1.06E-06 0.0108 
CROHN DISEASE RBM6 3.31E-05 0.0681 
CROHN DISEASE TUFM 0.000168 0.197 
CROHN DISEASE NFATC2IP 4.56E-05 0.0731 
CROHN DISEASE ADAM15 0.000105 0.18 
CROHN DISEASE CAMKV 1.20E-05 0.112 
CROHN DISEASE PRRC1 5.19E-05 0.0833 
CROHN DISEASE CLEC1B 0.000221 0.258 
CROHN DISEASE EIF3C 3.31E-05 0.112 
CROHN DISEASE ZPBP2 2.02E-05 0.0506 
CROHN DISEASE EDC3 7.67E-05 0.117 
CROHN DISEASE GPX1 0.00012 0.197 
CROHN DISEASE SEMA3B-AS1 7.78E-05 0.17 
CROHN DISEASE PKLR 8.47E-06 0.043 
CROHN DISEASE RNASET2 3.37E-05 0.0642 
CROHN DISEASE NKD1 3.70E-05 0.112 
CROHN DISEASE ASH1L 1.55E-05 0.0591 
CROHN DISEASE LYRM7 3.22E-05 0.112 
CROHN DISEASE P4HA2 2.98E-05 0.0681 
CROHN DISEASE IL1RL1 0.000291 0.306 
CROHN DISEASE HNRNPA1L2 0.000149 0.207 
CROHN DISEASE IL18R1 0.000322 0.316 
CROHN DISEASE IRGM 4.45E-05 0.231 
CROHN DISEASE HCN3 3.76E-05 0.0681 
CROHN DISEASE CUL2 9.54E-05 0.18 
CROHN DISEASE AMT 2.51E-05 0.112 
CROHN DISEASE SLC22A5 3.05E-05 0.0681 
CROHN DISEASE EGR2 2.24E-05 0.171 
CROHN DISEASE NPIPB9 0.000216 0.258 
CROHN DISEASE GBA 3.59E-05 0.0681 
CROHN DISEASE FAM69A 0.000338 0.312 
CROHN DISEASE FAM212A 7.25E-07 0.011 
CROHN DISEASE CYLD 5.56E-06 0.0566 
CROHN DISEASE C3orf62 3.13E-05 0.112 
CROHN DISEASE KTN1 0.000291 0.306 
CROHN DISEASE SLC22A4 9.92E-05 0.18 
CROHN DISEASE CARD6 6.31E-05 0.0874 
CROHN DISEASE IP6K1 3.27E-05 0.0642 
CROHN DISEASE DAP3 0.000331 0.312 
DEPRESSIVE TP53 6.93E-06 0.217 
DIABETES PYY2 5.02E-05 0.315 
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DIABETES CDKN2B 4.81E-05 0.315 
DIABETES FCHSD1 2.04E-06 0.0373 
DIABETES NINJ2 2.96E-05 0.31 
DIABETES KIF11 4.42E-06 0.14 
DIASTOLIC BLOOD PRESSURE CLIC4 1.95E-05 0.178 
DIASTOLIC BLOOD PRESSURE CSK 1.80E-05 0.178 
DIASTOLIC BLOOD PRESSURE OXER1 2.27E-05 0.178 
DIASTOLIC BLOOD PRESSURE LMAN1L 1.20E-05 0.178 
EARLY GROWTH NDUFB4 1.50E-05 0.232 
EARLY GROWTH LIN28B 1.34E-05 0.232 
EDUYEARS RNF123 1.83E-05 0.0568 
EDUYEARS MST1 7.11E-05 0.179 
EDUYEARS TANK 0.0002 0.274 
EDUYEARS NPIPB9 0.000104 0.179 
EDUYEARS PRMT5-AS1 0.000323 0.3 
EDUYEARS NPIPB6 1.61E-06 0.0167 
EDUYEARS IL27 0.000321 0.3 
EDUYEARS TUFM 1.32E-06 0.0167 
EDUYEARS CDK2AP1 0.000343 0.305 
EDUYEARS HCG11 0.000128 0.21 
EDUYEARS EPHA2 0.000356 0.307 
EDUYEARS DGUOK 0.000318 0.3 
EDUYEARS TNKS2 1.67E-05 0.0568 
EDUYEARS WDR6 8.58E-05 0.179 
EDUYEARS NUPR1 9.85E-05 0.179 
EDUYEARS DNAJB2 9.51E-05 0.179 
EDUYEARS PRR22 0.000203 0.274 
EDUYEARS SEMA6D 0.000227 0.284 
EDUYEARS IRF2BP2 9.98E-06 0.0443 
EDUYEARS KCNIP2 0.000298 0.3 
EDUYEARS APEH 0.000176 0.26 
EDUYEARS KCNIP2-AS1 0.000228 0.284 
EXTRAVERSION LIMD2 3.87E-05 0.208 
EXTRAVERSION CEP55 1.95E-05 0.208 
EXTREME_BMI ADCY3 4.18E-06 0.0644 
EXTREME_BMI NEGR1 3.20E-06 0.0644 
EXTREME_HEIGHT E2F1 0.00013 0.211 
EXTREME_HEIGHT MYBPC3 5.00E-05 0.13 
EXTREME_HEIGHT ADAMTSL3 0.000167 0.244 
EXTREME_HEIGHT NPR3 0.00021 0.294 
EXTREME_HEIGHT MYH7B 3.67E-05 0.114 
EXTREME_HEIGHT PUS1 0.000275 0.294 
EXTREME_HEIGHT KCTD18 3.20E-05 0.114 
EXTREME_HEIGHT AKTIP 0.000114 0.211 
EXTREME_HEIGHT PLCL1 0.000229 0.294 
EXTREME_HEIGHT VTA1 1.24E-05 0.0838 
EXTREME_HEIGHT RASA2 0.000167 0.244 
EXTREME_HEIGHT MAP3K3 1.34E-05 0.0838 
EXTREME_HEIGHT P4HA2 0.000328 0.296 
EXTREME_HEIGHT ZBTB38 0.000325 0.296 
EXTREME_HEIGHT AMZ1 8.78E-05 0.193 
EXTREME_HEIGHT FER1L4 2.77E-05 0.114 
EXTREME_HEIGHT PROCR 0.000336 0.296 
EXTREME_HEIGHT PXMP4 3.13E-05 0.114 
EXTREME_HEIGHT GDF5 4.21E-06 0.0838 
EXTREME_HEIGHT HIST1H3B 5.07E-05 0.13 
EXTREME_HEIGHT HIST1H2BF 0.000272 0.294 
EXTREME_HEIGHT CDK6 1.33E-05 0.0838 
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EXTREME_HEIGHT ASIP 0.000129 0.211 
EXTREME_HEIGHT DHX16 0.000259 0.294 
EXTREME_HEIGHT CEP250 5.94E-05 0.141 
EXTREME_HEIGHT C6orf106 0.000104 0.211 
EXTREME_HEIGHT HMGA2 0.000121 0.211 
EXTREME_HEIGHT SLC22A5 0.000298 0.296 
FASTING GLUCOSE IFT172 1.64E-07 0.00376 
FASTING GLUCOSE FNDC4 2.63E-06 0.0142 
FASTING GLUCOSE ZSCAN25 0.000124 0.33 
FASTING GLUCOSE RGS8 3.13E-06 0.0142 
FASTING GLUCOSE KHK 3.00E-06 0.0142 
FASTING GLUCOSE CRY2 9.33E-05 0.328 
FASTING GLUCOSE BBIP1 1.56E-05 0.198 
FASTING GLUCOSE G6PC2 5.31E-07 0.00681 
FASTING GLUCOSE P4HA2 2.76E-05 0.217 
FASTING GLUCOSE CGREF1 4.94E-07 0.00681 
FASTING GLUCOSE GPN1 3.03E-05 0.181 
FASTING GLUCOSE KRTCAP3 4.13E-05 0.187 
FASTING GLUCOSE SNX17 8.84E-05 0.302 
FASTING INSULIN STARD9 0.00196 0.318 
FASTING INSULIN NGEF 0.00159 0.318 
FASTING INSULIN NDUFS3 2.09E-07 0.00195 
FASTING INSULIN PCBP2 0.00174 0.318 
FASTING INSULIN NRSN1 0.00115 0.318 
FASTING INSULIN RASAL1 4.90E-05 0.0902 
FASTING INSULIN ZCCHC11 0.000659 0.267 
FASTING INSULIN ZNRF4 0.000993 0.318 
FASTING INSULIN VAC14 0.00115 0.318 
FASTING INSULIN DLGAP4 0.00212 0.327 
FASTING INSULIN CA10 0.00183 0.318 
FASTING INSULIN SYNDIG1 0.00163 0.318 
FASTING INSULIN BRINP2 0.00236 0.327 
FASTING INSULIN CACNG3 0.000652 0.267 
FASTING INSULIN FUNDC2 0.00242 0.331 
FASTING INSULIN SMDT1 0.000138 0.311 
FASTING INSULIN KCNJ4 0.0016 0.318 
FASTING INSULIN COL26A1 1.79E-05 0.281 
FASTING INSULIN PDZD4 0.000121 0.131 
FASTING INSULIN CDC25B 0.00231 0.327 
FASTING INSULIN FKRP 0.00164 0.318 
FASTING INSULIN TPT1-AS1 0.00233 0.327 
FASTING INSULIN URM1 0.00167 0.318 
FASTING INSULIN ITGB4 0.00146 0.318 
FASTING INSULIN UBR4 0.000519 0.253 
FASTING INSULIN CLPTM1 0.00144 0.318 
FASTING INSULIN LPCAT4 7.36E-05 0.126 
FASTING INSULIN TLR5 0.000176 0.15 
FASTING INSULIN DDB1 0.00196 0.318 
FASTING INSULIN EXOC8 0.00125 0.318 
FASTING INSULIN CELF6 0.00158 0.318 
FASTING INSULIN FAM180B 1.98E-07 0.00195 
FASTING INSULIN HS3ST2 0.00155 0.318 
FASTING INSULIN SERPINH1 0.00207 0.324 
FASTING INSULIN DUS1L 0.000317 0.181 
FASTING INSULIN ASIC2 0.00235 0.327 
FASTING INSULIN PPP6R1 0.00184 0.318 
FASTING INSULIN C7orf26 0.000495 0.247 
FASTING INSULIN NUDC 2.59E-06 0.0124 
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FASTING INSULIN PRPF8 0.000233 0.154 
FASTING INSULIN MTFR1L 0.00217 0.327 
FASTING INSULIN PTDSS2 0.000198 0.154 
FASTING INSULIN SNCB 0.00157 0.318 
FASTING INSULIN ALKBH7 1.15E-06 0.00811 
FASTING INSULIN TUBB4A 0.000992 0.318 
FASTING INSULIN CDC37 0.00185 0.318 
FASTING INSULIN DYNC2LI1 0.00232 0.327 
FASTING INSULIN GAA 0.00237 0.327 
FASTING INSULIN TMEM132A 0.00228 0.327 
FASTING INSULIN WBP2 0.00158 0.318 
FASTING INSULIN PPP1R15A 0.00127 0.318 
FASTING INSULIN SSRP1 0.00171 0.318 
FASTING INSULIN IGSF21 0.00244 0.332 
FASTING INSULIN C1QTNF4 4.05E-05 0.128 
FASTING INSULIN DPM2 8.02E-05 0.128 
FASTING INSULIN ATP6V0B 0.00219 0.327 
FASTING INSULIN GPX4 1.36E-06 0.00811 
FASTING INSULIN CHRM1 0.00135 0.318 
FASTING INSULIN ICAM5 0.000229 0.154 
FASTING INSULIN SHISA4 2.94E-05 0.0704 
FASTING INSULIN NR1H2 0.000822 0.296 
FASTING INSULIN SIPA1L3 0.00154 0.318 
FASTING INSULIN C19orf70 0.00187 0.318 
FASTING INSULIN PRKCB 0.000621 0.267 
FASTING INSULIN STAT1 0.00122 0.318 
FASTING INSULIN WASH2P 0.00131 0.318 
FASTING INSULIN SULT4A1 0.00216 0.327 
FASTING INSULIN TFPI 0.00186 0.318 
FASTING INSULIN FNBP4 5.09E-07 0.00229 
FASTING INSULIN SLC25A43 0.00189 0.318 
FASTING INSULIN MYBPC3 0.000102 0.247 
FASTING INSULIN FGF1 0.00166 0.318 
FASTING INSULIN ARHGAP1 2.96E-07 0.00195 
FASTING INSULIN AGBL2 6.83E-05 0.179 
FASTING INSULIN SV2A 0.00153 0.318 
FASTING INSULIN CKMT1B 6.21E-07 0.00743 
FASTING INSULIN IQSEC3 0.00142 0.318 
FASTING INSULIN MAN1B1 0.000279 0.167 
FASTING INSULIN CDK16 0.00015 0.139 
FASTING INSULIN KRT17 0.00179 0.318 
FASTING INSULIN SCGB1D2 0.00196 0.318 
FASTING INSULIN BAG6 9.40E-06 0.0363 
FASTING INSULIN MOAP1 0.00193 0.318 
FASTING INSULIN SGTA 0.00234 0.327 
FASTING INSULIN RPL12 0.00236 0.327 
FASTING INSULIN HIGD1B 0.00175 0.318 
FASTING INSULIN P4HB 0.000119 0.131 
FASTING INSULIN MICAL1 0.00204 0.32 
FASTING INSULIN IFT172 1.06E-05 0.152 
FASTING INSULIN SENP3 0.000745 0.282 
FASTING INSULIN ARAP1 3.17E-05 0.111 
FASTING INSULIN SDF4 0.000712 0.279 
FASTING INSULIN ADAMTS19 0.000361 0.196 
FASTING INSULIN GBP4 7.12E-07 0.0225 
FASTING INSULIN SLC39A13 2.89E-07 0.00195 
FASTING INSULIN TNFAIP8L3 0.00026 0.16 
FASTING INSULIN ISOC2 0.00107 0.318 
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FASTING INSULIN MLF2 0.00185 0.318 
FASTING INSULIN CST3 0.00149 0.318 
FASTING INSULIN TECR 0.000245 0.154 
FASTING INSULIN JPH4 0.00223 0.327 
FASTING INSULIN TUBGCP2 0.00107 0.318 
FASTING INSULIN LAMB3 3.25E-05 0.0708 
FASTING INSULIN PTPN23 0.000116 0.131 
FASTING INSULIN CHRM5 0.000581 0.263 
FASTING INSULIN NOP16 0.00135 0.318 
FASTING INSULIN TXNL4B 0.00191 0.318 
FASTING INSULIN ARSK 0.0023 0.327 
FASTING INSULIN MAN2C1 0.000583 0.263 
FASTING INSULIN TMEM251 0.00149 0.318 
FASTING INSULIN PRPS1L1 0.00135 0.318 
FASTING INSULIN PYGB 0.00165 0.318 
FASTING INSULIN RBM23 0.00166 0.318 
FASTING INSULIN PPP1CA 0.00013 0.131 
FASTING INSULIN OLAH 0.00202 0.32 
FASTING INSULIN GABBR2 9.64E-05 0.128 
FASTING INSULIN VARS2 0.000142 0.136 
FASTING INSULIN CKAP2L 0.00123 0.318 
FASTING INSULIN LHX2 1.21E-05 0.0363 
FASTING INSULIN MAPK8IP1 9.25E-05 0.128 
FASTING INSULIN POLR2A 0.0011 0.318 
FASTING INSULIN NEFL 0.00198 0.318 
FASTING INSULIN ZNF280B 0.00187 0.318 
FASTING INSULIN INA 0.00172 0.318 
FASTING INSULIN RALYL 0.000446 0.227 
FASTING INSULIN CHAC1 0.00177 0.318 
FASTING INSULIN SAMD8 0.000411 0.214 
FASTING INSULIN SERPINI2 0.00209 0.325 
FASTING INSULIN PPP2R5B 0.000568 0.263 
FASTING INSULIN STMN4 0.00144 0.318 
FASTING INSULIN INO80E 0.000243 0.154 
FASTING INSULIN CCNY 0.00221 0.327 
FASTING INSULIN PRDM2 0.000671 0.268 
FASTING INSULIN RPL4 0.000192 0.154 
FASTING INSULIN SYT4 1.16E-05 0.0363 
FASTING INSULIN MTCH2 3.71E-07 0.00195 
FASTING INSULIN ITPK1 9.58E-05 0.128 
FASTING INSULIN NRGN 0.000216 0.154 
FASTING INSULIN TPD52L2 0.000888 0.313 
FASTING INSULIN CYLC2 0.00175 0.318 
FASTING INSULIN CCND3 0.00064 0.267 
FASTING INSULIN LY6E 0.00177 0.318 
FASTING INSULIN BLOC1S2 0.000131 0.131 
FASTING INSULIN ELMO1 0.000412 0.214 
FASTING INSULIN SOD1 0.0019 0.318 
FASTING INSULIN DDN 0.000747 0.282 
FASTING INSULIN RXRB 0.00126 0.318 
FASTING INSULIN MAST3 0.00162 0.318 
FASTING INSULIN C12orf57 0.000548 0.262 
FASTING INSULIN SSR2 3.66E-05 0.073 
FASTING INSULIN ASXL3 0.00139 0.318 
FASTING INSULIN GANAB 0.000753 0.282 
FASTING INSULIN MFSD12 0.000346 0.193 
FASTING INSULIN MCEE 0.00102 0.318 
FASTING INSULIN TAF15 0.00142 0.318 
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FASTING INSULIN LRRD1 0.00159 0.318 
FASTING INSULIN FOXS1 1.27E-05 0.152 
FASTING INSULIN PDE2A 3.34E-07 0.00195 
FASTING INSULIN TAGLN3 0.000992 0.318 
FASTING INSULIN MCHR1 0.00144 0.318 
FASTING INSULIN PPFIA3 0.000108 0.131 
FASTING INSULIN MON1A 3.14E-06 0.0986 
FASTING INSULIN SERF2 0.00135 0.318 
FASTING INSULIN MAP7D1 0.000158 0.14 
FASTING INSULIN APEH 0.00128 0.318 
FIVE PSYCHIATRIC DISEASES ITIH4 3.16E-07 0.00338 
FIVE PSYCHIATRIC DISEASES MUSTN1 0.000157 0.289 
FIVE PSYCHIATRIC DISEASES GNL3 0.000194 0.294 
FIVE PSYCHIATRIC DISEASES PBRM1 2.02E-05 0.0703 
FIVE PSYCHIATRIC DISEASES FAM219A 0.000145 0.284 
FIVE PSYCHIATRIC DISEASES SFXN2 1.62E-05 0.0703 
FIVE PSYCHIATRIC DISEASES NEK4 0.00017 0.294 
FIVE PSYCHIATRIC DISEASES ARL3 4.49E-06 0.0351 
FIVE PSYCHIATRIC DISEASES GLT8D1 7.02E-05 0.165 
FIVE PSYCHIATRIC DISEASES BCAP29 3.07E-05 0.0873 
FIVE PSYCHIATRIC DISEASES NT5C2 3.24E-07 0.00338 
FIVE PSYCHIATRIC DISEASES SPCS1 2.42E-05 0.0756 
HEAD CIRCUMFERENCE SBNO1 1.88E-05 0.0738 
HEAD CIRCUMFERENCE OGFOD2 2.22E-06 0.0348 
HEAD CIRCUMFERENCE DCAKD 1.55E-05 0.0738 
HEAD CIRCUMFERENCE PXMP4 1.34E-05 0.0738 
HEAD CIRCUMFERENCE CDK2AP1 0.000104 0.272 
HEAD CIRCUMFERENCE ADORA3 1.65E-05 0.0738 
HEAD CIRCUMFERENCE ZNFX1 3.07E-07 0.00963 
HEAD CIRCUMFERENCE SLC45A3 5.43E-06 0.0568 
HEAD CIRCUMFERENCE ZNF32 1.80E-05 0.0738 
HEIGHT ANKRD24 0.00214 0.292 
HEIGHT ST3GAL6-AS1 0.00132 0.26 
HEIGHT S100A3 0.000938 0.281 
HEIGHT NCOA6 0.0025 0.3 
HEIGHT USP12 0.00206 0.29 
HEIGHT ERVK13-1 9.28E-05 0.122 
HEIGHT CBFA2T2 0.000612 0.226 
HEIGHT HEMK1 0.000204 0.137 
HEIGHT ARHGAP35 0.00213 0.292 
HEIGHT ZNF277 0.0033 0.329 
HEIGHT PXDN 0.000382 0.177 
HEIGHT MEOX1 0.00261 0.301 
HEIGHT MAP3K3 3.66E-05 0.104 
HEIGHT DCDC5 0.00197 0.289 
HEIGHT NFATC4 0.00107 0.281 
HEIGHT ADCY4 0.00211 0.291 
HEIGHT RAB24 0.00248 0.3 
HEIGHT PTPRJ 0.000241 0.139 
HEIGHT PIEZO1 0.00327 0.328 
HEIGHT OGFOD2 0.00204 0.29 
HEIGHT OMG 0.000313 0.154 
HEIGHT ASB3 0.00305 0.317 
HEIGHT CDC40 0.000934 0.281 
HEIGHT TACO1 0.000376 0.176 
HEIGHT USP25 0.00151 0.289 
HEIGHT P4HA2 0.00111 0.281 
HEIGHT SLC11A1 0.000411 0.185 
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HEIGHT HIST1H2BD 0.000257 0.139 
HEIGHT PCTP 0.00156 0.294 
HEIGHT NME6 0.00196 0.289 
HEIGHT TMX4 0.00298 0.317 
HEIGHT HHIP-AS1 0.000326 0.168 
HEIGHT OMP 0.00145 0.263 
HEIGHT RPL23 0.0017 0.271 
HEIGHT LGALS4 0.00104 0.281 
HEIGHT RASA2 6.53E-05 0.143 
HEIGHT CENPO 9.82E-05 0.148 
HEIGHT C14orf39 0.0021 0.291 
HEIGHT TBX2 0.00214 0.324 
HEIGHT SPATA3-AS1 0.000846 0.279 
HEIGHT CA11 0.00186 0.31 
HEIGHT FCER2 0.000888 0.281 
HEIGHT LINC00928 0.00109 0.281 
HEIGHT ZBTB4 0.00231 0.295 
HEIGHT OR2T29 0.000841 0.23 
HEIGHT CAMSAP2 0.00154 0.263 
HEIGHT TTLL6 0.00121 0.258 
HEIGHT IHH 0.000186 0.137 
HEIGHT MAP1LC3A 2.66E-05 0.0928 
HEIGHT CDH16 0.0003 0.157 
HEIGHT CDK6 2.32E-05 0.0669 
HEIGHT PLCL1 0.000173 0.21 
HEIGHT CD99L2 0.000107 0.282 
HEIGHT PNPLA1 0.000869 0.232 
HEIGHT BCKDHB 0.002 0.29 
HEIGHT EFEMP1 0.0018 0.308 
HEIGHT C6orf106 1.11E-06 0.0133 
HEIGHT PNPLA8 0.00236 0.296 
HEIGHT PPARD 1.73E-05 0.0907 
HEIGHT C1QTNF4 0.00162 0.267 
HEIGHT AMZ1 0.000148 0.113 
HEIGHT DHX16 0.00121 0.258 
HEIGHT NPR3 4.72E-05 0.104 
HEIGHT EBPL 0.000926 0.239 
HEIGHT DDX19A 0.00238 0.298 
HEIGHT E2F1 1.18E-05 0.0489 
HEIGHT PTPMT1 0.00296 0.317 
HEIGHT APOBEC3C 0.001 0.281 
HEIGHT PIGU 0.000223 0.138 
HEIGHT IGHMBP2 0.00319 0.321 
HEIGHT GPR182 0.00301 0.317 
HEIGHT HMGA2 9.32E-05 0.148 
HEIGHT FRYL 0.00222 0.294 
HEIGHT ZBTB24 0.00095 0.241 
HEIGHT DNAJC27-AS1 0.00163 0.297 
HEIGHT ITIH4 0.000396 0.181 
HEIGHT TSEN15 8.07E-05 0.148 
HEIGHT SMG9 0.00289 0.315 
HEIGHT GRINA 0.00071 0.217 
HEIGHT KIR3DX1 0.00168 0.301 
HEIGHT CALCOCO1 0.00245 0.3 
HEIGHT ACTL10 0.00196 0.289 
HEIGHT SUGP2 0.00231 0.295 
HEIGHT PFN4 0.000305 0.293 
HEIGHT RSPH9 0.00233 0.295 
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HEIGHT MST1P2 0.00139 0.289 
HEIGHT FAM180B 9.26E-05 0.122 
HEIGHT SNORA75 0.000542 0.196 
HEIGHT U2AF1L4 0.00165 0.297 
HEIGHT TTTY13 0.000493 0.192 
HEIGHT KCNH2 0.00048 0.192 
HEIGHT IDH3A 0.00159 0.267 
HEIGHT MED28 0.000338 0.296 
HEIGHT BAG2 0.00136 0.261 
HEIGHT ATAD1 0.000793 0.226 
HEIGHT GFER 0.00248 0.3 
HEIGHT TRPC4AP 0.000367 0.298 
HEIGHT SNX32 0.000169 0.137 
HEIGHT CEP250 8.68E-05 0.102 
HEIGHT KCNK9 0.000405 0.3 
HEIGHT DENND6A 4.90E-05 0.104 
HEIGHT OR7E156P 0.00267 0.304 
HEIGHT PRRC1 0.000296 0.153 
HEIGHT GDF5 4.39E-07 0.0139 
HEIGHT NPY2R 0.000633 0.213 
HEIGHT SBNO1 0.00152 0.263 
HEIGHT JKAMP 0.00115 0.281 
HEIGHT SOCS5 0.00154 0.263 
HEIGHT CCDC126 0.000438 0.189 
HEIGHT HIST1H2BF 5.64E-05 0.224 
HEIGHT LINC00471 0.00118 0.257 
HEIGHT PGP 0.000534 0.196 
HEIGHT MAFF 0.00139 0.261 
HEIGHT ASIP 0.000351 0.172 
HEIGHT KCNG1 0.00137 0.289 
HEIGHT CDK2AP1 0.000701 0.241 
HEIGHT NEK3 0.00181 0.308 
HEIGHT C2orf69 0.00118 0.281 
HEIGHT WDR6 0.000447 0.192 
HEIGHT ATRNL1 0.003 0.317 
HEIGHT SMIM23 0.0016 0.294 
HEIGHT TTC23 0.00142 0.263 
HEIGHT PEX1 0.000818 0.226 
HEIGHT RAPSN 0.00119 0.283 
HEIGHT VTA1 1.40E-05 0.0492 
HEIGHT CD8B 0.00113 0.257 
HEIGHT STAG2 0.00257 0.301 
HEIGHT SERAC1 0.00294 0.317 
HEIGHT AP5B1 0.000489 0.192 
HEIGHT RIOK3 0.00292 0.315 
HEIGHT PXMP4 0.00015 0.113 
HEIGHT FASTKD1 0.00155 0.293 
HEIGHT ITIH4-AS1 0.00225 0.294 
HEIGHT SLC25A45 0.00195 0.31 
HEIGHT SLC39A13 0.000704 0.217 
HEIGHT SCUBE3 0.000146 0.186 
HEIGHT BAAT 0.00226 0.294 
HEIGHT CCDC91 8.71E-05 0.148 
HEIGHT HAPLN4 0.00244 0.3 
HEIGHT KPNA6 0.000809 0.226 
HEIGHT NCF2 0.00221 0.294 
HEIGHT ITPR3 0.000456 0.193 
HEIGHT PCDH19 0.00138 0.261 
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HEIGHT BIN2 0.00262 0.301 
HEIGHT LOXL1-AS1 0.00148 0.263 
HEIGHT CDKN1A 0.0014 0.289 
HEIGHT RNASE4 0.00114 0.281 
HEIGHT SERPINF2 0.00206 0.29 
HEIGHT GGT7 0.000908 0.281 
HEIGHT KRT6C 0.000134 0.112 
HEIGHT LGALS8 1.14E-06 0.0357 
HEIGHT PCIF1 0.00231 0.295 
HEIGHT THUMPD1 0.000232 0.139 
HEIGHT TM7SF3 0.00159 0.267 
HEIGHT LGALS3 0.00222 0.294 
HEIGHT CNNM2 0.00098 0.244 
HEIGHT HAS2 0.00335 0.332 
HEIGHT LYSMD1 0.000871 0.232 
HEIGHT GNA12 0.00127 0.289 
HEIGHT BCS1L 0.00193 0.289 
HEIGHT SLC9A3R2 0.000214 0.137 
HEIGHT FER1L4 5.79E-07 0.0182 
HEIGHT ZNFX1 0.000199 0.13 
HEIGHT STAG1 0.00136 0.261 
HEIGHT TCP11 7.76E-05 0.102 
HEIGHT AGBL2 0.00188 0.286 
HEIGHT LHFPL3-AS1 0.00147 0.289 
HEIGHT ZNF688 0.000864 0.232 
HEIGHT STXBP3 0.000251 0.266 
HEIGHT FUT4 0.00108 0.281 
HEIGHT DVL3 0.00172 0.271 
HEIGHT FRRS1 0.00271 0.304 
HEIGHT CHRNB1 0.000752 0.222 
HEIGHT RGS11 0.00111 0.257 
HEIGHT DMRTA2 0.00108 0.281 
HEIGHT RDH8 0.00112 0.281 
HEIGHT CLPSL1 0.00197 0.289 
HEIGHT ABCE1 2.91E-05 0.148 
HEIGHT C17orf53 0.00127 0.26 
HEIGHT SMOC2 0.00259 0.301 
HEIGHT KCTD18 8.77E-05 0.102 
HEIGHT NCL 0.00258 0.301 
HEIGHT HIST1H3B 9.01E-05 0.148 
HEIGHT PNKD 0.000816 0.226 
HEIGHT G6PC3 0.000104 0.127 
HEIGHT ADCY3 1.66E-06 0.0181 
HEIGHT CAMKMT 0.000649 0.213 
HEIGHT PIGV 0.00139 0.261 
HEIGHT ZCCHC24 0.00162 0.267 
HEIGHT USP26 0.00136 0.289 
HEIGHT ACTR1A 0.00206 0.29 
HEIGHT TTTY5 0.00075 0.253 
HEIGHT ARFGEF2 0.0018 0.282 
HEIGHT NDUFAF1 0.00284 0.312 
HEIGHT DPAGT1 0.00226 0.294 
HEIGHT PROCR 1.23E-05 0.13 
HEIGHT TRPM7 0.00135 0.261 
HEIGHT CRNN 0.000636 0.232 
HEIGHT AKTIP 0.000334 0.162 
HEIGHT GABRR1 0.00216 0.292 
HEIGHT LINC00933 0.000289 0.286 
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HEIGHT GPR152 1.03E-05 0.0489 
HEIGHT CA5BP1 0.0017 0.302 
HEIGHT UBQLN2 0.000202 0.137 
HEIGHT TRIM8 0.000251 0.139 
HEIGHT PHF20 0.000517 0.201 
HEIGHT NCOA1 0.00149 0.289 
HEIGHT NDUFS3 0.00127 0.26 
HEIGHT GOLGA6L5P 0.00194 0.31 
HEIGHT RAB9A 0.00191 0.31 
HEIGHT ZFAS1 6.63E-05 0.11 
HEIGHT SNX12 0.00241 0.299 
HEIGHT NFAT5 0.0011 0.257 
HEIGHT BTN2A2 9.12E-05 0.122 
HEIGHT HCN2 0.00305 0.317 
HEIGHT CCDC177 0.00107 0.256 
HEIGHT HIST1H4E 0.000255 0.149 
HEIGHT OR1N2 0.000405 0.3 
HEIGHT CDC42SE2 0.000214 0.137 
HEIGHT DCPS 0.00107 0.256 
HEIGHT CPNE1 2.62E-05 0.0928 
HEIGHT RAPGEF6 0.000512 0.196 
HEIGHT ARF6 0.0015 0.263 
HEIGHT ANG 0.00192 0.31 
HEIGHT DCAF16 0.00027 0.151 
HEIGHT NKAIN1 0.00152 0.289 
HEIGHT OXCT1 0.00136 0.261 
HEIGHT PLEC 0.00301 0.317 
HEIGHT RAB33A 0.00215 0.292 
HEIGHT PADI2 0.00132 0.26 
HEIGHT MYBPC3 0.000242 0.148 
HEIGHT SNF8 0.00152 0.263 
HEIGHT UBL5 0.0021 0.291 
HEIGHT PPM1M 0.00303 0.317 
HEIGHT RBMXL1 0.000527 0.196 
HEIGHT SLC22A4 5.03E-05 0.104 
HEIGHT ZBTB38 2.11E-05 0.148 
HEIGHT RABEP1 0.00283 0.312 
HEIGHT SURF4 0.00159 0.267 
HEIGHT PRRT3 2.34E-05 0.0928 
HEIGHT ERGIC3 1.27E-06 0.0133 
HEIGHT CNRIP1 0.00149 0.263 
HEIGHT HIST1H2AC 5.57E-05 0.104 
HEIGHT RAD9A 0.000201 0.137 
HEIGHT ZNF76 0.00149 0.289 
HEIGHT DLEU1 0.000163 0.137 
HEIGHT C12orf65 0.000896 0.281 
HEIGHT PSMC5 0.00149 0.289 
HEIGHT MS4A12 0.00133 0.289 
HEIGHT KRTAP19-3 0.00201 0.29 
HEIGHT RCBTB1 0.00266 0.304 
HEIGHT SPIN1 0.00226 0.294 
HEIGHT FUBP1 5.63E-05 0.104 
HEIGHT HCG11 0.00149 0.263 
HEIGHT DBF4B 0.000126 0.111 
HEIGHT FAM208A 0.000755 0.222 
HEIGHT PUS1 0.000258 0.149 
HEIGHT MYH7B 2.68E-06 0.0425 
HEIGHT MOB4 0.00207 0.29 
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HEIGHT ADAMTSL3 2.85E-06 0.0181 
HEIGHT NMT1 0.000648 0.213 
HEIGHT HIST1H4B 1.37E-05 0.086 
HEIGHT CWH43 0.00208 0.29 
HEIGHT FASLG 0.00212 0.323 
HEIGHT ZRANB1 0.00291 0.315 
HEIGHT LRBA 0.00248 0.3 
HEIGHT GOLGA2P7 0.000993 0.244 
HEIGHT RASA3 0.00139 0.289 
HEIGHT UHRF1BP1 0.00112 0.257 
HEIGHT IL20RB 0.00302 0.317 
HEIGHT JMJD4 6.82E-05 0.143 
HEIGHT EIF1AD 0.000222 0.138 
HEIGHT EIF6 1.87E-05 0.0585 
HEIGHT KATNBL1 0.000526 0.201 
HEIGHT CYSTM1 0.00318 0.321 
HEIGHT RNF25 0.00195 0.289 
HEIGHT HIST1H1C 0.000329 0.296 
HEIGHT SPAG4 0.00171 0.302 
HEIGHT BICD2 0.00143 0.289 
HEIGHT PRLH 0.00151 0.289 
HEIGHT DEF6 6.36E-05 0.101 
HEIGHT RYBP 0.000628 0.213 
HEIGHT INE1 0.000261 0.149 
HEIGHT ARL6IP4 0.00126 0.26 
HEIGHT KCND2 4.89E-05 0.104 
HEIGHT SLC35G6 0.00187 0.286 
HEIGHT HHIP 6.79E-05 0.101 
HEIGHT SLC22A5 0.000734 0.22 
HEIGHT PRKAG3 0.00318 0.321 
HEIGHT RAB40A 0.00164 0.297 
HEIGHT CTPS2 0.00299 0.317 
HEIGHT PRKXP1 0.00118 0.257 
HEIGHT KDM1A 0.000886 0.232 
HEIGHT FANCE 0.00281 0.311 
HEIGHT TMEM82 0.00208 0.323 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
AFF1 0.000177 0.18 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
MYBPC3 4.39E-07 0.0029 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
CSGALNACT1 0.000203 0.163 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
IRF7 4.40E-05 0.0696 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
SLC39A13 5.78E-05 0.0695 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
MT1X 0.000372 0.259 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
CTCF 0.000427 0.284 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
MEP1A 0.000118 0.156 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
PSKH1 6.14E-06 0.0388 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
ERBB2 1.28E-05 0.0463 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
REEP1 0.00013 0.158 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
PCSK7 0.000183 0.154 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
LRP4 3.13E-05 0.0466 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
CETP 1.71E-05 0.0539 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
PTPMT1 5.85E-06 0.0166 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
C1QTNF4 4.69E-07 0.0029 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
APH1B 0.000269 0.239 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
RPL17 0.00017 0.148 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
RAPSN 3.78E-05 0.0513 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
SPIB 0.000154 0.18 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
GFOD2 5.84E-06 0.0166 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
UBE3B 0.000184 0.182 
 113 
phenotype gene p-value Q-value 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
PARD6A 1.96E-05 0.0361 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
DUS2 3.08E-05 0.0628 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
SSH1 0.000331 0.261 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
DPEP3 1.66E-06 0.0263 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
NDUFS3 1.56E-06 0.00696 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
ZNF408 1.78E-05 0.0361 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
C10orf67 0.000191 0.157 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
NR1H3 9.31E-08 0.0029 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
RNF214 0.000105 0.0968 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
ACP2 1.62E-07 0.00512 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
CACNB1 2.39E-05 0.0404 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
LCAT 2.91E-06 0.0307 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
TSNAXIP1 8.04E-05 0.084 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
TCEANC2 2.15E-05 0.0567 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
CCDC92 2.01E-05 0.0567 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
PSMA5 8.06E-05 0.084 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
NFATC3 0.000212 0.163 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
WDR17 6.87E-05 0.0795 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
ESRP2 5.21E-07 0.0029 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
CKAP5 4.98E-07 0.0029 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
PRKAR1B 0.000167 0.18 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
PSMD3 0.000452 0.293 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
C11orf49 1.11E-05 0.0289 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
HPS3 0.000284 0.239 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
DMRTC1 3.21E-05 0.0628 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
TAGLN 0.000208 0.194 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
FAM180B 4.67E-06 0.0369 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
C6orf106 9.75E-05 0.0923 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
ACD 1.21E-05 0.0463 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
AGBL2 2.90E-05 0.0454 
HIGH-DENSITY LIPOPROTEIN 
CHOLESTEROL 
RBM6 0.000223 0.166 
HIP NEGR1 3.31E-06 0.0116 
HIP FTO 7.56E-05 0.234 
HIP KCNJ13 0.000165 0.261 
HIP C6orf106 4.86E-05 0.0848 
HIP TMEM219 9.19E-05 0.144 
HIP GDF5 1.56E-05 0.0967 
HIP BPIFB1 0.00022 0.288 
HIP RBL2 8.24E-06 0.0199 
HIP SH2B1 3.13E-05 0.161 
HIP VWA7 0.000202 0.253 
HIP HCN4 4.39E-05 0.298 
HIP FER1L4 6.69E-07 0.00517 
HIP SPN 6.52E-05 0.136 
HIP SBK1 0.000161 0.282 
HIP HIST1H2BF 4.72E-05 0.0848 
HIP LRP8 0.000131 0.211 
HIP FUBP1 1.06E-08 0.000334 
HIP NPIPB9 0.000107 0.255 
HIP IL27 2.43E-05 0.0586 
HIP NFATC2IP 4.48E-06 0.0156 
HIP ACP1 0.000237 0.306 
HIP HIST1H4B 0.000143 0.204 
HIP TFAP2B 4.46E-06 0.0127 
HIP NPIPB8 0.000159 0.211 
HIP LGR4 1.53E-05 0.0344 
HIP NPIPB6 6.28E-08 0.000648 
HIP EIF3CL 1.43E-06 0.00697 
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HIP RABEP2 1.42E-05 0.039 
HIP ZBTB38 6.28E-05 0.298 
HIP RYBP 6.84E-06 0.0214 
HIP TUFM 3.17E-06 0.0111 
HIP PSG7 0.00025 0.328 
HIP FKBP1B 0.000207 0.269 
HIP NUPR1 5.93E-08 0.000648 
HIP ADJUSTED BMI ABCB9 1.75E-05 0.0685 
HIP ADJUSTED BMI KRT6C 0.000305 0.239 
HIP ADJUSTED BMI ADAMTSL3 1.22E-05 0.0579 
HIP ADJUSTED BMI EPB41L1 2.50E-05 0.117 
HIP ADJUSTED BMI CRNN 0.000591 0.284 
HIP ADJUSTED BMI CROCC 3.53E-05 0.0993 
HIP ADJUSTED BMI AKTIP 0.000373 0.268 
HIP ADJUSTED BMI SLC38A2 0.000172 0.279 
HIP ADJUSTED BMI RAB43 0.000449 0.281 
HIP ADJUSTED BMI CDK6 1.53E-05 0.0776 
HIP ADJUSTED BMI SNX32 7.24E-05 0.121 
HIP ADJUSTED BMI HIST1H2AC 5.37E-06 0.0389 
HIP ADJUSTED BMI THRA 0.000375 0.268 
HIP ADJUSTED BMI SUGP2 0.000112 0.153 
HIP ADJUSTED BMI FBXL13 1.02E-05 0.287 
HIP ADJUSTED BMI MAP3K3 0.000115 0.158 
HIP ADJUSTED BMI BRI3 0.000718 0.293 
HIP ADJUSTED BMI HIST1H4E 0.000676 0.29 
HIP ADJUSTED BMI PROCR 0.00014 0.175 
HIP ADJUSTED BMI ORMDL3 4.99E-05 0.105 
HIP ADJUSTED BMI SLC25A45 0.000232 0.316 
HIP ADJUSTED BMI PLCL1 8.93E-05 0.155 
HIP ADJUSTED BMI CDH16 0.00038 0.27 
HIP ADJUSTED BMI HHIP 2.58E-05 0.0841 
HIP ADJUSTED BMI AP5B1 0.000682 0.29 
HIP ADJUSTED BMI GPR152 3.50E-06 0.0315 
HIP ADJUSTED BMI HIST1H4B 7.24E-06 0.0379 
HIP ADJUSTED BMI CDK2AP1 0.000142 0.247 
HIP ADJUSTED BMI HHIP-AS1 4.75E-05 0.0994 
HIP ADJUSTED BMI GDF5 2.77E-06 0.0286 
HIP ADJUSTED BMI KLF14 0.000206 0.281 
HIP ADJUSTED BMI ABCE1 0.000248 0.226 
HIP ADJUSTED BMI LGI4 9.40E-05 0.155 
HIP ADJUSTED BMI FAM208A 2.09E-05 0.0688 
HIP ADJUSTED BMI VPS53 1.40E-05 0.0776 
HIP ADJUSTED BMI TRIM38 0.000199 0.254 
HIP ADJUSTED BMI ALDH1L1 0.000162 0.26 
HIP ADJUSTED BMI BTN2A2 2.07E-05 0.0651 
HIP ADJUSTED BMI SSBP2 0.000153 0.279 
HIP ADJUSTED BMI MST1P2 0.0007 0.292 
HIP ADJUSTED BMI HMGA2 2.17E-05 0.0809 
HIP ADJUSTED BMI THUMPD1 0.000153 0.172 
HIP ADJUSTED BMI RIOK3 0.000671 0.29 
HIP ADJUSTED BMI C1orf54 0.000423 0.281 
HIP ADJUSTED BMI BTN3A3 0.000176 0.273 
HIP ADJUSTED BMI ITPR3 0.000687 0.297 
HIP ADJUSTED BMI EIF2B1 6.61E-05 0.147 
HIP ADJUSTED BMI VTA1 3.10E-05 0.0809 
HIP ADJUSTED BMI MGARP 0.000622 0.284 
HIP ADJUSTED BMI SPIN1 0.000575 0.284 
HIP ADJUSTED BMI ZBTB38 3.91E-05 0.309 
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HIP ADJUSTED BMI HIST1H2BD 9.43E-06 0.0382 
HIP ADJUSTED BMI BHLHE41 0.000223 0.213 
HIP ADJUSTED BMI EBPL 4.80E-05 0.116 
HIP ADJUSTED BMI ESPNP 0.000178 0.279 
HIP ADJUSTED BMI HIST1H1C 2.51E-05 0.0718 
HIP ADJUSTED BMI GOLGA6L5P 0.000114 0.21 
HIP ADJUSTED BMI GKN2 0.000451 0.281 
HIP ADJUSTED BMI EHBP1L1 0.000257 0.231 
HIP ADJUSTED BMI BVES 0.000136 0.251 
HIP ADJUSTED BMI DBF4B 0.00035 0.262 
HIP ADJUSTED BMI TMEM117 0.000264 0.316 
HIP ADJUSTED BMI RASA2 0.000272 0.228 
HIP ADJUSTED BMI AMZ1 7.24E-05 0.172 
HIP ADJUSTED BMI OTUD4 1.89E-05 0.287 
HIP ADJUSTED BMI TMCC1-AS1 0.000182 0.26 
HIP ADJUSTED BMI MYH7B 0.000775 0.312 
HIP ADJUSTED BMI CEP250 0.000335 0.256 
HIP ADJUSTED BMI HIST1H3B 5.73E-06 0.036 
HIP ADJUSTED BMI FER1L4 7.95E-07 0.0222 
HIP ADJUSTED BMI HIST1H2BF 5.80E-05 0.122 
HIP ADJUSTED BMI EFEMP1 0.000237 0.225 
INFLAMMATORY BOWEL DISEASE BCAS3 0.000218 0.224 
INFLAMMATORY BOWEL DISEASE ADAM15 0.000114 0.163 
INFLAMMATORY BOWEL DISEASE NRN1 0.000474 0.308 
INFLAMMATORY BOWEL DISEASE TREX1 0.000186 0.218 
INFLAMMATORY BOWEL DISEASE CYLD 3.78E-05 0.138 
INFLAMMATORY BOWEL DISEASE USP4 0.000129 0.177 
INFLAMMATORY BOWEL DISEASE SLC26A6 0.000691 0.324 
INFLAMMATORY BOWEL DISEASE USP19 8.69E-05 0.142 
INFLAMMATORY BOWEL DISEASE KRTAP22-2 0.000578 0.308 
INFLAMMATORY BOWEL DISEASE CACNB1 8.36E-05 0.142 
INFLAMMATORY BOWEL DISEASE PDLIM4 0.00063 0.313 
INFLAMMATORY BOWEL DISEASE SALL4 0.000501 0.308 
INFLAMMATORY BOWEL DISEASE MEIS2 3.93E-05 0.138 
INFLAMMATORY BOWEL DISEASE NDUFS2 5.88E-05 0.138 
INFLAMMATORY BOWEL DISEASE TNFSF15 0.000439 0.308 
INFLAMMATORY BOWEL DISEASE PMPCA 9.07E-05 0.142 
INFLAMMATORY BOWEL DISEASE SLC22A5 6.42E-05 0.138 
INFLAMMATORY BOWEL DISEASE PRRC1 0.000412 0.308 
INFLAMMATORY BOWEL DISEASE DLD 0.000637 0.313 
INFLAMMATORY BOWEL DISEASE IP6K1 0.000238 0.237 
INFLAMMATORY BOWEL DISEASE NPIPB6 0.000557 0.308 
INFLAMMATORY BOWEL DISEASE GSDMB 0.000161 0.196 
INFLAMMATORY BOWEL DISEASE SPINK4 0.000302 0.276 
INFLAMMATORY BOWEL DISEASE RBM6 6.51E-05 0.138 
INFLAMMATORY BOWEL DISEASE KIF25 0.000475 0.308 
INFLAMMATORY BOWEL DISEASE LIPG 4.85E-05 0.138 
INFLAMMATORY BOWEL DISEASE GPX1 9.67E-05 0.144 
INFLAMMATORY BOWEL DISEASE UBE2L3 0.0006 0.313 
INFLAMMATORY BOWEL DISEASE IP6K2 0.000524 0.308 
INFLAMMATORY BOWEL DISEASE ORMDL3 0.000438 0.308 
INFLAMMATORY BOWEL DISEASE MST1 0.000298 0.276 
INFLAMMATORY BOWEL DISEASE RNF123 6.06E-05 0.138 
INFLAMMATORY BOWEL DISEASE SPANXN2 0.000706 0.326 
INFLAMMATORY BOWEL DISEASE CUL2 1.14E-05 0.0939 
INFLAMMATORY BOWEL DISEASE AMT 1.98E-06 0.0487 
INFLAMMATORY BOWEL DISEASE ETS2 0.000733 0.331 
INFLAMMATORY BOWEL DISEASE EIF3C 7.13E-05 0.138 
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INFLAMMATORY BOWEL DISEASE ERBB2 8.12E-05 0.142 
INFLAMMATORY BOWEL DISEASE MED13L 0.000566 0.308 
INFLAMMATORY BOWEL DISEASE ZPBP2 8.00E-06 0.0875 
INFLAMMATORY BOWEL DISEASE INSL6 0.000213 0.224 
INFLAMMATORY BOWEL DISEASE TRAIP 3.43E-05 0.138 
INFLAMMATORY BOWEL DISEASE SEMA3B-AS1 0.000136 0.178 
INFLAMMATORY BOWEL DISEASE P4HA2 0.000648 0.313 
INFLAMMATORY BOWEL DISEASE LYRM7 0.000256 0.248 
INFLAMMATORY BOWEL DISEASE CAMKV 2.97E-06 0.0487 
INFLAMMATORY BOWEL DISEASE SOHLH2 1.81E-05 0.103 
INSULIN SECRETION HNF4A 8.39E-06 0.132 
INSULIN SECRETION MARK2P9 1.38E-05 0.144 
INSULIN SECRETION SRSF10 7.42E-05 0.303 
INSULIN SECRETION SYMPK 4.00E-07 0.0125 
INSULIN SECRETION NRP2 3.86E-05 0.303 
INSULIN SECRETION KIF11 6.27E-06 0.112 
INSULIN SECRETION KPNA1 6.74E-05 0.303 
INSULIN SECRETION LRRC15 2.48E-05 0.302 
INSULIN SECRETION CCDC150 3.85E-05 0.302 
INSULIN SECRETION SLC36A4 3.26E-05 0.255 
INSULIN SECRETION PNRC2 5.04E-05 0.303 
INSULIN SECRETION HSPA6 9.87E-07 0.031 
INSULIN SECRETION MEP1B 2.50E-05 0.2 
INSULIN SECRETION CNKSR2 6.68E-05 0.303 
INSULIN SECRETION HHEX 1.98E-06 0.0622 
INSULIN SECRETION FAM131A 5.98E-05 0.303 
INSULIN SECRETION LPXN 2.47E-05 0.194 
LONGEVITY ZNF649 3.79E-06 0.117 
LONGEVITY PSMA5 9.71E-07 0.0264 
LONGEVITY PSRC1 1.64E-06 0.0264 
LONGEVITY SORT1 9.71E-06 0.0675 
LONGEVITY CRIP1 6.29E-05 0.254 
LONGEVITY LCAT 3.39E-05 0.267 
LONGEVITY FPR3 1.72E-05 0.266 
LONGEVITY CD81 1.63E-05 0.331 
LONGEVITY CELSR2 7.94E-05 0.271 
LONGEVITY SLC22A3 5.07E-05 0.254 
LONGEVITY MGA 2.28E-05 0.267 
LONGEVITY PSMA4 5.91E-06 0.0636 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
GSTM2 2.40E-05 0.0499 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
TMEM258 7.30E-05 0.104 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
RHD 7.00E-05 0.104 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
SLC24A4 0.000173 0.248 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
WTAP 5.56E-07 0.00435 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
GTF3C4 9.19E-05 0.12 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
BCAM 3.09E-05 0.0751 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
POLK 1.63E-05 0.0464 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
GDF7 7.85E-05 0.138 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
MKRN2 5.21E-05 0.096 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
KIAA1324 8.91E-05 0.12 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
SORT1 6.08E-05 0.0986 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
HS1BP3-IT1 0.000302 0.317 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
CEACAM19 0.000181 0.196 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
MAU2 0.000172 0.193 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
RHCE 0.000199 0.262 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
ST3GAL4 0.000319 0.317 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
SMARCA4 0.000159 0.185 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
ANGPTL3 1.92E-06 0.0141 
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LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
ATP13A1 2.48E-05 0.0499 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
TMEM50A 2.05E-05 0.0495 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
PSMA5 2.67E-06 0.0141 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
MAFB 0.000331 0.317 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
ATXN7L2 0.000305 0.299 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
MLEC 9.35E-06 0.0369 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
POC5 2.55E-05 0.0499 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
ABCG5 0.000198 0.262 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
DOCK7 8.85E-07 0.00554 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
SLC44A2 1.04E-07 0.00133 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
TMEM25 0.000294 0.317 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
GSTM4 9.53E-08 0.00133 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
APOE 1.19E-05 0.0374 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
APOB 5.63E-05 0.111 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
AMIGO1 5.95E-05 0.111 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
HNF1A 0.000126 0.199 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
PSRC1 3.18E-09 0.0001 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
ZNF441 4.54E-05 0.0956 
LOW-DENSITY LIPOPROTEIN 
CHOLESTEROL 
SYPL2 0.000237 0.288 
LUNG CANCER SOCS1 3.88E-06 0.054 
LUNG CANCER MICAL1 6.53E-06 0.054 
LUNG CANCER TERT 1.43E-06 0.0244 
MULTIPLE SCLEROSIS HLA-DRB5 1.21E-05 0.132 
MULTIPLE SCLEROSIS WDR46 4.65E-05 0.202 
MULTIPLE SCLEROSIS GPR65 3.64E-06 0.0277 
MULTIPLE SCLEROSIS RNFT1 2.20E-05 0.112 
MULTIPLE SCLEROSIS PSMB9 1.58E-06 0.016 
MULTIPLE SCLEROSIS HLA-DOA 1.61E-07 0.00491 
MULTIPLE SCLEROSIS TAP2 4.22E-07 0.00643 
MULTIPLE SCLEROSIS GOLGB1 5.52E-05 0.324 
MULTIPLE SCLEROSIS SP110 1.40E-05 0.0854 
MULTIPLE SCLEROSIS RAD21L1 8.32E-06 0.255 
NEUROBLASTOMA MTFMT 2.23E-05 0.257 
NEUROBLASTOMA SHOX2 3.65E-05 0.257 
NEUROBLASTOMA OPRM1 4.23E-05 0.257 
NEUROMYELITIS OPTICA MIR3150A 9.12E-06 0.295 
NEUROMYELITIS OPTICA BTN3A2 1.82E-07 0.00294 
NEUROMYELITIS OPTICA ZCWPW1 2.73E-05 0.293 
NEUROMYELITIS OPTICA TRIM26 8.27E-06 0.133 
NEUROMYELITIS OPTICA FAM187B 9.84E-07 0.0317 
NEUROTICISM KANSL1 9.50E-05 0.0804 
NEUROTICISM FAM66D 1.65E-06 0.00332 
NEUROTICISM NMT1 0.000477 0.229 
NEUROTICISM FAM86B3P 1.31E-05 0.0156 
NEUROTICISM DEFB134 0.000752 0.295 
NEUROTICISM FAM167A 2.12E-05 0.0235 
NEUROTICISM SLC35G5 3.63E-08 0.00013 
NEUROTICISM ABCB6 0.000406 0.205 
NEUROTICISM LRRC37A 0.00015 0.103 
NEUROTICISM MSRA 3.92E-12 2.10E-08 
NEUROTICISM SERTAD1 0.000519 0.239 
NEUROTICISM PPP1R3B 1.90E-14 6.09E-10 
NEUROTICISM HCG18 4.66E-06 0.145 
NEUROTICISM BOLA2 3.24E-05 0.0347 
NEUROTICISM CCDC178 0.000585 0.258 
NEUROTICISM PLEKHM1 0.000577 0.258 
NEUROTICISM CLDN23 2.83E-12 1.82E-08 
NEUROTICISM LGALS3 0.00052 0.239 
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NEUROTICISM XKR6 1.90E-07 0.000554 
NEUROTICISM OR8B2 1.90E-06 0.00358 
NEUROTICISM CTSB 2.55E-07 0.000684 
NEUROTICISM LINC00208 0.000704 0.284 
NEUROTICISM CYSTM1 0.000392 0.205 
NEUROTICISM THAP2 0.000102 0.0837 
NEUROTICISM TNP2 1.13E-05 0.014 
NEUROTICISM ACVR2A 0.000193 0.126 
NEUROTICISM ACSL4 4.19E-05 0.0414 
NEUROTICISM BLK 4.25E-05 0.0414 
NEUROTICISM ZNF502 0.000614 0.267 
NEUROTICISM PARP8 0.000147 0.103 
NEUROTICISM ZNF671 0.000149 0.103 
NEUROTICISM ERI1 3.45E-06 0.00528 
NEUROTICISM DND1 2.18E-06 0.00389 
NEUROTICISM MFHAS1 3.41E-11 1.37E-07 
NEUROTICISM ARHGAP27 0.000113 0.0887 
NEUROTICISM ADM 0.000109 0.0879 
NEUROTICISM FAM66A 0.00044 0.216 
NEUROTICISM NSFP1 0.000777 0.301 
NEUROTICISM FDFT1 4.91E-14 7.90E-10 
NEUROTICISM TESC 0.000681 0.284 
NEUROTICISM DSC2 0.000223 0.135 
NEUROTICISM ARL17B 0.000693 0.284 
NEUROTICISM MTMR9 1.31E-13 1.28E-09 
NEUROTICISM SOX7 0.000816 0.312 
NEUROTICISM TDH 5.75E-05 0.0544 
NEUROTICISM NEIL2 1.60E-13 1.28E-09 
NEUROTICISM SLC25A23 0.000127 0.097 
OBESITY C1QL2 8.48E-05 0.276 
OBESITY LGR4 8.96E-05 0.276 
OBESITY BPIFB1 0.000189 0.306 
OBESITY FBXL19 0.000225 0.306 
OBESITY TUFM 0.000196 0.306 
OBESITY ADCY3 0.000133 0.276 
OBESITY EIF3CL 1.63E-05 0.17 
OBESITY SMAD3 0.000129 0.276 
OBESITY NEGR1 1.35E-06 0.0421 
OBESITY BDNF 8.24E-05 0.276 
OBESITY FTO 0.000138 0.276 
OBESITY ACP1 7.43E-05 0.276 
OBESITY RBL2 4.83E-05 0.276 
OBESITY FUBP1 2.51E-06 0.0392 
OBESITY NFATC2IP 3.51E-05 0.274 
OBESITY NPIPB9 0.000224 0.306 
OSTEOPOROSIS HOXC9 1.03E-06 0.0322 
OSTEOPOROSIS SEC11A 6.50E-06 0.212 
OSTEOPOROSIS NUDT11 6.65E-07 0.0209 
OSTEOPOROSIS GRN 8.29E-06 0.152 
OSTEOPOROSIS HTR1D 1.00E-05 0.152 
OVERWEIGHT C1QL2 5.35E-05 0.304 
OVERWEIGHT BDNF 5.82E-05 0.304 
OVERWEIGHT GALNT1 3.19E-05 0.304 
OVERWEIGHT EIF3CL 4.39E-05 0.304 
OVERWEIGHT NEGR1 5.98E-07 0.0187 
PANCREATIC CANCER COMMD5 2.80E-05 0.286 
PANCREATIC CANCER TSPYL2 4.22E-06 0.129 
PARKINSON PANX1 8.55E-05 0.162 
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PARKINSON PLEKHM1 2.61E-05 0.0879 
PARKINSON BRD8 0.000261 0.234 
PARKINSON MAPT-AS1 5.39E-05 0.119 
PARKINSON FAM83F 5.68E-06 0.161 
PARKINSON RDM1 7.69E-07 0.00583 
PARKINSON PIGG 0.00028 0.236 
PARKINSON ARL17B 1.76E-09 5.32E-05 
PARKINSON LUM 0.000233 0.228 
PARKINSON FUT3 0.000262 0.234 
PARKINSON MAPK8IP1 0.000393 0.298 
PARKINSON SLC2A13 0.000273 0.236 
PARKINSON BPTF 0.000114 0.169 
PARKINSON MAT2A 0.000113 0.169 
PARKINSON NMT1 0.000251 0.234 
PARKINSON ITGAL 4.17E-05 0.115 
PARKINSON MMRN1 0.000215 0.228 
PARKINSON KANSL1-AS1 3.51E-09 5.32E-05 
PARKINSON BCAP29 0.00011 0.169 
PARKINSON DND1 3.44E-07 0.00347 
PARKINSON MAPT 0.000125 0.173 
PARKINSON LRRC37A2 0.00016 0.194 
PARKINSON PDCD11 0.000317 0.253 
PROSTATE CANCER GIMAP5 8.83E-06 0.268 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
AMZ1 1.74E-05 0.214 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
ADAMTSL3 5.00E-05 0.274 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
FER1L4 2.76E-05 0.214 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
LRMP 5.30E-05 0.274 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
PFN4 1.85E-05 0.197 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
NDOR1 3.55E-05 0.296 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
NDUFAF1 1.66E-05 0.214 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
RPRD1A 1.35E-05 0.197 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
WDYHV1 8.48E-05 0.329 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
ZBTB38 1.10E-06 0.0341 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
ZW10 2.52E-05 0.197 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
DNAJC27-AS1 6.04E-05 0.314 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
GPR152 1.17E-05 0.168 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
AVPI1 7.20E-06 0.225 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
EFEMP1 1.62E-05 0.168 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
GNA12 8.15E-05 0.329 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
LIN28B 1.29E-05 0.201 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
ADCY3 7.97E-07 0.0249 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
LCE2C 2.11E-05 0.214 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
CENPO 1.33E-05 0.138 
PUBERTAL GROWTH LATE 
ADOLESCENCE 
USP27X 4.20E-05 0.225 
RHEUMATOID ARTHRITIS TUT1 0.000229 0.247 
RHEUMATOID ARTHRITIS HLA-DPA1 3.42E-12 5.37E-08 
RHEUMATOID ARTHRITIS COL11A2 3.99E-05 0.0893 
RHEUMATOID ARTHRITIS HLA-DPB2 2.68E-14 8.43E-10 
RHEUMATOID ARTHRITIS SUOX 0.00017 0.118 
RHEUMATOID ARTHRITIS HSD17B8 5.95E-05 0.0655 
RHEUMATOID ARTHRITIS RSBN1 0.000134 0.119 
RHEUMATOID ARTHRITIS CUL5 1.56E-05 0.0246 
RHEUMATOID ARTHRITIS TMEM38B 0.000257 0.252 
RHEUMATOID ARTHRITIS BTN3A1 0.000176 0.239 
RHEUMATOID ARTHRITIS PPARD 0.000281 0.283 
RHEUMATOID ARTHRITIS TRIM9 5.59E-05 0.109 
RHEUMATOID ARTHRITIS TNFSF11 2.09E-06 0.00393 
RHEUMATOID ARTHRITIS TSFM 0.00012 0.0895 
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RHEUMATOID ARTHRITIS HSPA12B 7.24E-05 0.0723 
RHEUMATOID ARTHRITIS WDR86 0.000238 0.277 
RHEUMATOID ARTHRITIS ZBTB22 1.44E-06 0.00308 
RHEUMATOID ARTHRITIS RXRB 3.36E-07 0.00132 
RHEUMATOID ARTHRITIS HIST1H4B 0.000193 0.252 
RHEUMATOID ARTHRITIS ERBB2 7.33E-05 0.0711 
RHEUMATOID ARTHRITIS GGNBP1 0.00036 0.29 
RHEUMATOID ARTHRITIS RPS18 0.000111 0.0895 
RHEUMATOID ARTHRITIS RGL2 3.87E-07 0.00124 
RHEUMATOID ARTHRITIS TAP2 2.59E-06 0.0046 
RHEUMATOID ARTHRITIS DCLRE1B 1.96E-05 0.0294 
RHEUMATOID ARTHRITIS HIST1H2BD 1.21E-07 0.00175 
RHEUMATOID ARTHRITIS HMGN4 5.50E-06 0.0251 
RHEUMATOID ARTHRITIS HLA-DQA1 8.68E-10 5.61E-06 
RHEUMATOID ARTHRITIS PSMB9 1.27E-06 0.00304 
RHEUMATOID ARTHRITIS SMAD3 0.000154 0.128 
RHEUMATOID ARTHRITIS VPS52 0.000118 0.0895 
RHEUMATOID ARTHRITIS TBC1D22B 1.96E-05 0.0294 
RHEUMATOID ARTHRITIS BAK1 1.80E-08 6.39E-05 
RHEUMATOID ARTHRITIS HLA-DRB1 0.000125 0.152 
RHEUMATOID ARTHRITIS TUBB6 0.000415 0.246 
RHEUMATOID ARTHRITIS CACNB1 5.82E-05 0.0621 
RHEUMATOID ARTHRITIS BLK 0.000342 0.219 
RHEUMATOID ARTHRITIS IP6K3 7.21E-06 0.0251 
RHEUMATOID ARTHRITIS MEGF8 6.94E-05 0.0719 
RHEUMATOID ARTHRITIS CLEC16A 0.000379 0.233 
RHEUMATOID ARTHRITIS DAXX 4.47E-09 1.92E-05 
RHEUMATOID ARTHRITIS HIPK1 1.04E-05 0.0193 
RHEUMATOID ARTHRITIS HLA-DRB5 8.77E-12 2.80E-07 
RHEUMATOID ARTHRITIS ZNF322 4.52E-05 0.0944 
RHEUMATOID ARTHRITIS GSDMB 1.71E-05 0.0246 
RHEUMATOID ARTHRITIS MAGI3 1.41E-05 0.0246 
RHEUMATOID ARTHRITIS HIST1H4A 0.000164 0.234 
RHEUMATOID ARTHRITIS HLA-DOA 2.16E-07 0.000972 
RHEUMATOID ARTHRITIS HIST1H2AC 3.74E-05 0.0893 
RHEUMATOID ARTHRITIS WDR46 9.17E-06 0.018 
RHEUMATOID ARTHRITIS TAPBP 4.81E-09 1.92E-05 
RHEUMATOID ARTHRITIS H1FX 0.000106 0.0992 
RHEUMATOID ARTHRITIS HLA-DMA 7.22E-06 0.0251 
RHEUMATOID ARTHRITIS MFAP2 5.41E-05 0.0598 
RHEUMATOID ARTHRITIS HLA-DQB2 2.21E-05 0.0272 
RHEUMATOID ARTHRITIS HLA-DOB 1.21E-06 0.00759 
RHEUMATOID ARTHRITIS PHF1 7.64E-07 0.00267 
RHEUMATOID ARTHRITIS AP4B1-AS1 0.000307 0.261 
RHEUMATOID ARTHRITIS MLN 0.000126 0.152 
RHEUMATOID ARTHRITIS COCH 0.000203 0.236 
RHEUMATOID ARTHRITIS HMGA1 1.64E-05 0.0246 
RHEUMATOID ARTHRITIS CUTA 2.50E-06 0.00535 
RHEUMATOID ARTHRITIS ITPR3 2.27E-11 3.62E-07 
RHEUMATOID ARTHRITIS RNASET2 6.78E-07 0.00531 
RHEUMATOID ARTHRITIS HLA-DPB1 8.78E-10 5.61E-06 
RHEUMATOID ARTHRITIS PHF19 0.00034 0.281 
RHEUMATOID ARTHRITIS HCG24 1.30E-06 0.00304 
RHEUMATOID ARTHRITIS HLA-DQB1 4.84E-05 0.0552 
SCHIZOPHRENIA TRPC4 0.000175 0.196 
SCHIZOPHRENIA NT5C2 9.75E-09 0.000152 
SCHIZOPHRENIA BCAP29 5.34E-05 0.159 
SCHIZOPHRENIA HLA-DPB1 0.000358 0.29 
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SCHIZOPHRENIA TNKS 0.000266 0.269 
SCHIZOPHRENIA BTN3A1 0.000145 0.267 
SCHIZOPHRENIA MCHR1 1.54E-05 0.0536 
SCHIZOPHRENIA CSH2 0.000173 0.3 
SCHIZOPHRENIA KCNJ13 0.000102 0.137 
SCHIZOPHRENIA CREB1 9.38E-05 0.209 
SCHIZOPHRENIA ASAH1 0.00013 0.282 
SCHIZOPHRENIA GNL1 8.94E-05 0.208 
SCHIZOPHRENIA C16orf96 0.000198 0.31 
SCHIZOPHRENIA SFXN2 0.000129 0.235 
SCHIZOPHRENIA BTN3A2 1.60E-11 5.01E-07 
SCHIZOPHRENIA ZSCAN16 0.000147 0.282 
SCHIZOPHRENIA VPS29 0.000351 0.29 
SCHIZOPHRENIA MPHOSPH9 0.000226 0.244 
SCHIZOPHRENIA ZFP57 0.00014 0.235 
SCHIZOPHRENIA CHRNB4 4.41E-05 0.11 
SCHIZOPHRENIA HLA-DQA1 9.78E-06 0.0528 
SCHIZOPHRENIA DPYD 0.000177 0.247 
SCHIZOPHRENIA KLC1 7.72E-05 0.131 
SCHIZOPHRENIA TM9SF1 0.000157 0.237 
SCHIZOPHRENIA SLC17A4 7.86E-05 0.205 
SCHIZOPHRENIA HCG11 7.64E-05 0.131 
SCHIZOPHRENIA FRMD7 0.000129 0.282 
SCHIZOPHRENIA BTN3A3 0.00014 0.167 
SCHIZOPHRENIA LEMD2 1.74E-05 0.0564 
SCHIZOPHRENIA C11orf24 8.23E-08 0.000858 
SCHIZOPHRENIA CNNM2 2.20E-05 0.0762 
SCHIZOPHRENIA PDCD11 0.000339 0.321 
SCHIZOPHRENIA AK2 3.96E-05 0.103 
SCHIZOPHRENIA GTF2A1L 2.72E-05 0.0852 
SCHIZOPHRENIA PSMB9 0.000355 0.29 
SCHIZOPHRENIA HIST1H2AC 0.000503 0.33 
SCHIZOPHRENIA ZKSCAN4 3.27E-05 0.0928 
SCHIZOPHRENIA HLA-DPB2 0.00051 0.33 
SCHIZOPHRENIA UPB1 0.000455 0.307 
SCHIZOPHRENIA WDR82 1.71E-05 0.0762 
SCHIZOPHRENIA BTN1A1 1.64E-07 0.00128 
SCHIZOPHRENIA HFE 1.56E-05 0.061 
SCHIZOPHRENIA HIST1H4C 3.34E-06 0.0261 
SCHIZOPHRENIA CCDC107 5.38E-05 0.168 
SCHIZOPHRENIA ANKRD44 0.000157 0.181 
SCHIZOPHRENIA PPP1R3B 1.29E-05 0.0541 
SCHIZOPHRENIA ABCB9 2.97E-05 0.0875 
SCHIZOPHRENIA HLA-DQA2 3.82E-06 0.0268 
SCHIZOPHRENIA GATAD2A 0.000346 0.29 
SCHIZOPHRENIA TAP2 0.000318 0.29 
SCHIZOPHRENIA WBP1L 1.24E-05 0.0578 
SCHIZOPHRENIA ARL3 9.56E-07 0.00886 
SCHIZOPHRENIA HIST1H4B 0.000248 0.258 
SMOKING CIGAR PER DAY ZNF665 3.99E-06 0.125 
SMOKING EVER SMOKE RTEL1 2.00E-05 0.314 
SMOKING EVER SMOKE TXN 4.41E-06 0.138 
STOKE ICA1L 7.34E-05 0.302 
STOKE LRRC18 3.98E-05 0.253 
STOKE RTKN 3.81E-05 0.326 
STOKE PIGA 5.04E-05 0.267 
STOKE ACLY 2.50E-06 0.0809 
STOKE CRIP1 4.02E-05 0.326 
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STOKE NPEPPS 9.49E-05 0.302 
STOKE ALDH2 1.44E-07 0.00456 
STOKE AMT 0.000113 0.302 
STOKE CDC42EP5 9.87E-05 0.302 
STOKE CENPQ 8.99E-05 0.302 
STOKE LRCH1 3.08E-05 0.326 
STOKE AS3MT 3.36E-05 0.253 
STOKE KRTAP19-7 1.86E-06 0.0296 
SUBJECTIVE WELL BEING ZFAS1 3.09E-08 0.000917 
SUBJECTIVE WELL BEING ZNFX1 1.62E-06 0.024 
SYSTOLIC BLOOD PRESSURE AGO1 0.000115 0.328 
SYSTOLIC BLOOD PRESSURE LMAN1L 4.49E-05 0.235 
SYSTOLIC BLOOD PRESSURE OXER1 5.62E-05 0.252 
SYSTOLIC BLOOD PRESSURE SFXN2 6.31E-06 0.198 
SYSTOLIC BLOOD PRESSURE SLC39A12-AS1 9.77E-05 0.328 
SYSTOLIC BLOOD PRESSURE ITGA3 2.91E-05 0.229 
SYSTOLIC BLOOD PRESSURE CSK 1.97E-05 0.207 
SYSTOLIC BLOOD PRESSURE ADM 4.41E-05 0.235 
TRIGLYCERIDES DOCK7 1.60E-08 0.000167 
TRIGLYCERIDES OR8B2 8.57E-05 0.112 
TRIGLYCERIDES LINC00599 0.000272 0.251 
TRIGLYCERIDES FNDC4 1.86E-06 0.00973 
TRIGLYCERIDES ANGPTL3 4.13E-06 0.0144 
TRIGLYCERIDES ADAL 5.42E-05 0.0772 
TRIGLYCERIDES SLC5A6 5.74E-05 0.0782 
TRIGLYCERIDES KHK 2.88E-05 0.0477 
TRIGLYCERIDES GCKR 2.19E-05 0.0412 
TRIGLYCERIDES FADS3 0.000155 0.173 
TRIGLYCERIDES PPP1R3B 0.000249 0.245 
TRIGLYCERIDES MPV17 1.25E-05 0.0308 
TRIGLYCERIDES ATP13A1 4.73E-05 0.0706 
TRIGLYCERIDES RNF214 0.00025 0.245 
TRIGLYCERIDES TAGLN 1.45E-09 3.07E-05 
TRIGLYCERIDES MLXIPL 3.18E-08 0.000199 
TRIGLYCERIDES SNX17 2.89E-05 0.0477 
TRIGLYCERIDES AFF1 9.94E-05 0.125 
TRIGLYCERIDES TMEM31 0.000211 0.228 
TRIGLYCERIDES OST4 0.000245 0.245 
TRIGLYCERIDES CGREF1 6.10E-06 0.0191 
TRIGLYCERIDES CSGALNACT1 3.90E-05 0.061 
TRIGLYCERIDES RBKS 1.49E-05 0.0332 
TRIGLYCERIDES BLK 0.000126 0.146 
TRIGLYCERIDES PCSK7 1.28E-05 0.0308 
TRIGLYCERIDES SIDT2 1.96E-09 3.07E-05 
TRIGLYCERIDES IFT172 0.000108 0.13 
TRIGLYCERIDES NEIL2 1.95E-05 0.0407 
TYPE 2 DIABETES ZNF239 9.79E-06 0.145 
ULCERATIVE COLITIS GALNT9 1.98E-05 0.0328 
ULCERATIVE COLITIS MED24 0.000799 0.294 
ULCERATIVE COLITIS ZGLP1 0.00105 0.32 
ULCERATIVE COLITIS ZPBP2 3.22E-05 0.214 
ULCERATIVE COLITIS CYTH1 0.000601 0.242 
ULCERATIVE COLITIS ACAP1 1.75E-05 0.0319 
ULCERATIVE COLITIS CDH18 2.98E-05 0.0408 
ULCERATIVE COLITIS DGCR9 0.000302 0.173 
ULCERATIVE COLITIS ELAVL4 7.89E-05 0.0709 
ULCERATIVE COLITIS CPNE9 7.80E-05 0.0709 
ULCERATIVE COLITIS ISG15 0.000443 0.208 
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ULCERATIVE COLITIS GPR88 4.56E-05 0.0548 
ULCERATIVE COLITIS ST8SIA5 6.06E-06 0.0176 
ULCERATIVE COLITIS LRMP 0.00101 0.32 
ULCERATIVE COLITIS CASQ1 0.000205 0.134 
ULCERATIVE COLITIS DLD 6.75E-06 0.0177 
ULCERATIVE COLITIS CDHR4 0.000923 0.312 
ULCERATIVE COLITIS S100G 9.26E-06 0.0208 
ULCERATIVE COLITIS BSPRY 0.000287 0.167 
ULCERATIVE COLITIS ADORA2A 0.000119 0.0947 
ULCERATIVE COLITIS WRB 3.88E-06 0.0153 
ULCERATIVE COLITIS USP4 2.22E-05 0.0333 
ULCERATIVE COLITIS TCERG1L 1.82E-05 0.0319 
ULCERATIVE COLITIS IGSF1 4.51E-06 0.0158 
ULCERATIVE COLITIS UBA7 0.000121 0.0947 
ULCERATIVE COLITIS CAMKV 1.02E-05 0.214 
ULCERATIVE COLITIS C20orf27 9.07E-06 0.0208 
ULCERATIVE COLITIS TGM6 0.00022 0.27 
ULCERATIVE COLITIS IP6K1 1.30E-05 0.0269 
ULCERATIVE COLITIS DAG1 5.47E-05 0.0573 
ULCERATIVE COLITIS KRTAP22-2 0.000402 0.198 
ULCERATIVE COLITIS DOCK3 0.000127 0.247 
ULCERATIVE COLITIS STX1A 6.14E-06 0.0176 
ULCERATIVE COLITIS RGS14 2.39E-13 7.51E-09 
ULCERATIVE COLITIS MEIS2 4.00E-05 0.214 
ULCERATIVE COLITIS SLC30A3 0.00054 0.235 
ULCERATIVE COLITIS NKX2-3 6.60E-05 0.214 
ULCERATIVE COLITIS TNFRSF14 0.000624 0.248 
ULCERATIVE COLITIS RHOA 1.37E-05 0.0269 
ULCERATIVE COLITIS CCDC88C 2.21E-05 0.0333 
ULCERATIVE COLITIS CBWD1 0.000875 0.309 
ULCERATIVE COLITIS NEUROD2 3.24E-05 0.0424 
ULCERATIVE COLITIS NXPE1 7.17E-05 0.214 
ULCERATIVE COLITIS HERC2 0.000194 0.27 
ULCERATIVE COLITIS OLAH 6.06E-05 0.0615 
ULCERATIVE COLITIS RTN4R 0.000146 0.112 
ULCERATIVE COLITIS C1orf194 0.000324 0.182 
ULCERATIVE COLITIS SOHLH2 0.00102 0.32 
ULCERATIVE COLITIS HTR4 0.000203 0.134 
ULCERATIVE COLITIS ARHGEF25 0.000443 0.208 
ULCERATIVE COLITIS GSDMB 0.000217 0.27 
ULCERATIVE COLITIS KCNJ6 0.000221 0.14 
ULCERATIVE COLITIS PASK 2.46E-06 0.0111 
ULCERATIVE COLITIS PCDHGC3 0.000797 0.294 
ULCERATIVE COLITIS ERBB2 0.000423 0.205 
ULCERATIVE COLITIS APEH 0.000114 0.247 
ULCERATIVE COLITIS TMA7 0.000151 0.247 
ULCERATIVE COLITIS RNF123 6.11E-07 0.0048 
ULCERATIVE COLITIS IFIT3 0.000164 0.123 
ULCERATIVE COLITIS MST1 0.000105 0.247 
ULCERATIVE COLITIS CACNB1 8.74E-05 0.0743 
ULCERATIVE COLITIS FAM212A 0.000587 0.24 
ULCERATIVE COLITIS ORMDL3 4.70E-05 0.0548 
ULCERATIVE COLITIS NPTX1 0.000222 0.14 
ULCERATIVE COLITIS CHRM3 4.10E-07 0.0043 
ULCERATIVE COLITIS GSDMA 0.000819 0.296 
ULCERATIVE COLITIS RBM6 1.45E-06 0.00762 
ULCERATIVE COLITIS HPCAL1 2.62E-05 0.0374 
ULCERATIVE COLITIS AMT 7.74E-05 0.0709 
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ULCERATIVE COLITIS RAPGEFL1 5.16E-05 0.0565 
ULCERATIVE COLITIS ETS2 0.000222 0.27 
ULCERATIVE COLITIS WDR66 1.20E-06 0.00752 
ULCERATIVE COLITIS PSMD3 0.000373 0.192 
ULCERATIVE COLITIS SLC7A6OS 0.000514 0.229 
ULCERATIVE COLITIS FCER1G 9.59E-05 0.247 
ULCERATIVE COLITIS ZMYND10 3.81E-05 0.0479 
ULCERATIVE COLITIS CAMSAP2 7.21E-05 0.0709 
UPPER GASTROINTESTINAL 
CANCER 
SEMG2 1.89E-06 0.0286 
UPPER GASTROINTESTINAL 
CANCER 
PLCE1 1.83E-06 0.0286 
UPPER GASTROINTESTINAL 
CANCER 
PLCE1-AS1 2.40E-05 0.182 
WAIST CIRCUMFERENCE SBK1 9.80E-05 0.209 
WAIST CIRCUMFERENCE RAG1 4.31E-05 0.149 
WAIST CIRCUMFERENCE ANKDD1B 8.74E-05 0.209 
WAIST CIRCUMFERENCE NFATC2IP 4.79E-06 0.0419 
WAIST CIRCUMFERENCE HCN4 4.35E-06 0.0419 
WAIST CIRCUMFERENCE TMEM219 1.76E-05 0.0426 
WAIST CIRCUMFERENCE EIF3CL 1.97E-06 0.0137 
WAIST CIRCUMFERENCE FTO 9.40E-05 0.265 
WAIST CIRCUMFERENCE IL27 2.53E-05 0.0874 
WAIST CIRCUMFERENCE LGR4 5.34E-05 0.112 
WAIST CIRCUMFERENCE CRY1 0.000186 0.253 
WAIST CIRCUMFERENCE TUFM 6.58E-07 0.00414 
WAIST CIRCUMFERENCE RBL2 1.60E-05 0.062 
WAIST CIRCUMFERENCE VWA7 0.000195 0.255 
WAIST CIRCUMFERENCE OTX1 5.91E-05 0.154 
WAIST CIRCUMFERENCE NPIPB9 0.000118 0.311 
WAIST CIRCUMFERENCE NEGR1 3.88E-07 0.00305 
WAIST CIRCUMFERENCE NPIPB6 2.19E-07 0.00279 
WAIST CIRCUMFERENCE OAZ1 0.000106 0.277 
WAIST CIRCUMFERENCE RABEP2 0.000144 0.325 
WAIST CIRCUMFERENCE UPP1 0.000231 0.289 
WAIST CIRCUMFERENCE TFAP2B 1.01E-06 0.00452 
WAIST CIRCUMFERENCE NUPR1 1.08E-06 0.00422 
WAIST CIRCUMFERENCE FUBP1 2.30E-06 0.00804 
WAIST CIRCUMFERENCE DNMT3L 0.000159 0.324 
WAIST CIRCUMFERENCE EIF3C 7.31E-05 0.232 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
GOLGA6L5P 0.000181 0.33 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
HIST1H2BK 0.000124 0.313 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
KRT6C 0.000159 0.329 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
DYNLT1 0.000159 0.331 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
CTCF 6.12E-05 0.274 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
CEP63 2.08E-05 0.147 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
ANAPC13 1.11E-05 0.117 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
AMZ1 0.000102 0.288 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
SLC38A11 3.52E-06 0.0716 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
CCDC92 1.41E-06 0.0442 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
ZNF606 0.000139 0.328 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
C5orf47 5.21E-05 0.233 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
STXBP3 9.14E-05 0.284 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
HIST1H3B 6.86E-06 0.106 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
ZNF385D 2.37E-05 0.151 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
LOXL1-AS1 1.03E-05 0.151 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
TRIM8 3.42E-05 0.241 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
FOXS1 4.62E-05 0.241 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
GPR152 4.68E-06 0.101 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
KCTD19 0.000143 0.324 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
ADAMTSL3 4.52E-06 0.0716 
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WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
CPAMD8 0.000179 0.331 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
CROCC 3.29E-05 0.17 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
HAS2 2.63E-05 0.147 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
HIST1H2AC 9.80E-06 0.101 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
RIOK3 0.000155 0.324 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
HIST1H2BD 3.63E-05 0.182 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
WDR82 9.89E-05 0.31 
WAIST CIRCUMFERENCE ADJUSTED 
FOR BMI 
TUBD1 2.78E-05 0.147 
WAIST-HIP RATIO SLC38A11 6.83E-06 0.217 
WAIST-HIP RATIO HCN4 9.00E-06 0.143 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
CCDC92 5.34E-07 0.0168 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
GDF5 2.66E-06 0.0827 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
RAF1 1.90E-05 0.199 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
SEMA3G 6.57E-06 0.103 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
ZBTB7B 4.20E-05 0.33 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
CAPNS1 2.36E-05 0.243 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
CTCF 6.29E-05 0.268 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
MKRN2 1.12E-05 0.176 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
FER1L4 1.03E-05 0.159 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
MYH7B 2.36E-05 0.249 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
SLC38A11 1.88E-05 0.228 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
ADAM15 4.20E-05 0.33 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
SCN2A 2.16E-05 0.228 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
KRT28 2.02E-05 0.249 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
FAM110B 9.44E-06 0.228 
WAIST-HIP RATIO ADJUSTED FOR 
BMI 
CHKB 2.91E-05 0.228 
WEIGHT NEGR1 7.77E-07 0.0123 
WEIGHT FUBP1 7.63E-07 0.0123 
WEIGHT HCN4 2.32E-06 0.0245 
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